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Abstract 
 
Infection by the parasitic nematode Nippostrongylus brasiliensis involves migration 
through the lungs, causing significant damage and generating chronic lung pathology. 
The resolution of N. brasiliensis infection and also the induction of pulmonary 
pathology, including goblet cell hyperplasia and acute airway inflammation, depend 
on IL-4Rα signalling. A key feature of IL-4Rα signalling is the induction of a strong 
TH2 response which induces the development of alternatively activated macrophages 
(AAMs). AAMs are associated with tissue remodelling and the control of exacerbated 
inflammation. In order to investigate potential roles for IL-4Rα in N. brasiliensis–
induced lung pathology, we infected mice deficient for IL-4Rα on macrophages and 
neutrophils (LysMCreIL-4Rα-/lox), IL-4Rα-/- and control mice (IL-4Rα-/lox) with N. 
brasiliensis and examined lung pathology at days 5, 42 and 180 post infection (p.i.). 
All three mice strains showed similar emphysemic-like pathology (alveolar dilatation) 
and airway hyperresponsiveness (AHR) which was well developed by day 42 p.i. and 
remained chronic. However, LysMCreIL-4Rα-/lox mice consistently demonstrated 
earlier and increased pulmonary inflammation when compared to IL-4Rα-/lox control 
mice and IL-4Rα-/- mice. Immunological studies at day 5 p.i. revealed that there were 
increased CD4+ and CD8+ T-cell numbers and increased CD4+ IL-4 and IL-13 
production in the lungs of LysMCreIL-4Rα-/lox mice when compared to control and IL-
4Rα-/- mice. LysMCreIL-4Rα-/lox mice also showed decreased pulmonary arginase 
activity, indicative of a reduction of AAMs. RNA transcript analysis of isolated 
alveolar macrophages showed a strong association with promoting inflammation in 
LysMCreIL-4Rα-/lox mice. Together these data demonstrate that IL-4Rα-responsive 
macrophages control pulmonary inflammation and play an important protective role 
in the lung following N. brasiliensis infection.  
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1. INTRODUCTION 
 
 
1.1 Project rationale 
In this study, we used the parasitic worm N. brasiliensis as a model of chronic lung 
disease in order to uncover the immunological events that drive related medical 
conditions. N. brasiliensis has a brief obligatory phase in the host lung during its life 
cycle, which results in chronic lung disease that continues to develop even after the 
actual infection has been resolved 1, 2. This pathology has similarities with asthma in 
the acute phase 3, 4 and emphysema in the chronic phase 1. At the molecular level, it is 
apparent that cytokine signalling via receptors containing the alpha subunit of the 
interleukin-4 receptor (IL-4Rα) plays an important role in the development of this 
pathology 4-6. These diseases has been associat d with IL-4Rα-dependent 
development of alternative activation of macrophages in the lung 1, 7. In this study we 
investigated in detail how macrophage expression of IL-4Rα modulates the 
development of both acute and chronic immuno-pathology in the lung following N. 
brasiliensis infection.  
 
1.2 The Immune System 
The immune system consists of an array of organs, cells and soluble mediators, which 
co-ordinate together to recognise and protect the host from potentially harmful non-
self factors 8. Upon specific recognition of a pathogen or its antigens, an immune 
response is generated. Immune responses can be general to the challenge (innate). or 
highly specific following a secondary exposure to the challenge (adaptive), or consist 
of both innate and adaptive elements 8. 
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Innate immune responses are typically associated with the first line of defence against 
an invading pathogen. Innate immune components include neutrophils, macrophages, 
dendritic cells (DCs), Natural Killer (NK) cells, eosinophils, basophils, mast cells, 
platelets and the complement system 8. Innate immune responses are frequently 
initiated through host cellular recognition of common structural moieties from 
pathogens or pathogen-associated molecular patterns (PAMPs), which rapidly activate 
the mediators of an innate response 9-11. Recognition of PAMPs is mediated through a 
range of host receptors, including pattern recognition receptors (PRR) such as toll-like 
receptors (TLR), mannose receptors and C-type lectins 9-11. Expression of these 
receptors are found on immune cells, such as phagocytic neutrophils and 
macrophages, B cells, DCs and certain types of T cells, and on non-immune cells 
lining the organs exposed to the environment such as epithelial, endothelial and 
smooth muscle cells in the skin, respiratory and gastrointestinal tracts 10, 12. The 
receptors enable a degree of specific recognition of a PAMP that can be associated 
with certain types of immune challenge, e.g. TLR3 recognising double-stranded 
(viral) RNA 9, 13. Typically, though not exclusively, this interaction results in the 
binding and phagocytosis of these microbes. In addition to phagocytic responses, cells 
can control immunological challenges through other innate mechanisms. For example, 
neutrophils and eosinophils can secrete microbiocidal or cytotoxic molecules such as 
myeloperoxidase (MPO) from neutrophils, or eosinophil peroxidise (EPO), which 
attack pathogens that are too large for phagocytosis (e.g. parasitic worms) 14.  
 
 An adaptive immune response takes longer to launch, however it is usually highly 
specific against its target antigen or pathogen. It is responsible for the development of 
an immunological “memory response” for immediate recognition and responses to 
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future re-infections 8. The adaptive immune response is co-ordinated by antigen 
recognition by randomly generated antigen receptors on T- and B- cells, which 
enables these lymphocytes to recognise nearly all antigens and pathogens 8. The 
antigens are presented to T- and B-cells by antigen presenting cells (APCs) such as 
macrophages and dendritic cells, which form the interface between innate and 
adaptive immunity 11. APCs process and typically present antigens on MHC-II 
molecules to B- or T-cells inducing lymphocytic maturation, activation or 
differentiation 8. T-cells differentiate into T-helper cells, which mainly function to 
produce cytokines. B-cells can develop into memory B-cells or plasma cells and 
depending on the cytokine and co-stimulatory signals, produce several different types 
of antigen-specific antibodies such as IgM, IgG, IgE, IgA or IgD 8. Furthermore, B-
cells can function as APCs as they can process and present antigens on MHC-II 
molecules to CD4+ T-cells and possess APC co-stimulatory molecules, which induce 
the same lymphocytic functions as above 15. Memory B-cells, together with memory 
T-cells provide an immunological memory that is able to launch a rapid response 
upon secondary exposure to the antigen 8. 
 
1.2.1 Cytokines 
Cytokines are essential in the communication and regulation of the cells of both innate 
and adaptive immune responses 8. Cytokines are small protein ligands produced by a 
variety of cells. They bind to specific cell surface receptors and alter gene expression 
in the recipient cell via a signal transduction cascade. Cytokine-mediated responses 
can be autocrine, where the cytokine binds to the receptor on the same cell secreting 
it, or paracrine, where the cytokine binds to receptors of other cells in close proximity 
16. Cytokines include interleukins (IL) and interferons (IFN) and can be pleiotropic, 
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whereby a particular cytokine can have multiple effects on various different cells. 
Cytokine production is transient and its effects include cell differentiation, 
proliferation, activation, release of effector molecules or cell recruitment 16, 17. The 
magnitude and variety of cytokines produced determines whether the host’s immune 
response is protective, ineffective or detrimental and therefore cytokine levels are 
used as indicators of disease progression in patients 16. Furthermore, cytokines can 
indicate the type of adaptive immune response involved based on the type of 
cytokines secreted by CD4+ T-helper cells 16.  
 
1.2.2. Differentiation of T-helper (TH) subsets 
Differentiation of naïve CD4+ T-cells into distinct T-helper subsets is dependent on 
the nature of the antigen presented by the APC and the cytokine environment 8. These 
cytokines play a key role in the differentiation, proliferation and, in certain cases, the 
suppression of TH subset development 17. Undifferentiated CD4+ T-helper cells can 
differentiate into one of the following mutually exclusive cell lineages: the classical 
T-helper 1 (TH1) or TH2 lineages, and the more recently identified, TH17 and 
regulatory T-cell (Treg) lineages. Additional effector T-cell subsets may include IL-5-
producing TH5 and IL-9-producing “reprogrammed” TH9 subsets 18, 19. Each lineage 
is identified by its profile of intracellular transcription factors, extracellular markers 
(receptors), and their cytokine spectrum produced and are each involved in different 
processes (Figure 1) 17.  
 
1.2.3. TH1 vs. TH2  
The TH1 and TH2 subsets were first described by the different cytokine profiles they 
expressed after in vitro antigenic stimulation of CD4+ T-cells 20. Typically, IL-12 
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triggers undifferentiated CD4+ T-cells, which induces TH1 differentiation via the 
STAT-4 pathway to activate the T-box expressed in T-cells (T-bet) transcription 
factor. These TH1 cells are primarily classified by the production of the TH1 hallmark 
cytokine, IFN-gamma (IFN-γ) 21, 22. TH1 immunity is associated with the control of 
protozoan, bacterial and other single-cell pathogens. Conversely, the cytokine IL-4 
triggers undifferentiated CD4+ T-cells to activate the transcription factor GATA3 
through the signal transduction and activator of transcription (STAT)-6 pathway to 
drive TH2 differentiation. GATA-3 activation then promotes IL-4, IL-13 and IL-5 
production, amongst other TH2 cytokines 23. Although it is generally accepted that IL-
4 drives TH2 differentiation 24-26, evidence does exist that IL-4 is not essential for 
initiating TH2 responses 27, 28. TH2 immunity is associated with the control of 
multicellular or metazoan parasitic infections and with the onset of allergic diseases. 
The development of TH1 and TH2 subsets can also be negatively regulated by the 
cytokines IFN-γ and IL-4, which suppress differentiation of TH2 and TH1 subsets, 
respectively. The differences between TH1 and TH2 cells and their properties are 
listed in Table 1 below.  
 
Table 1: Major differences between TH1 and TH2 immune responses. 
 TH1 TH2 
Response to: Microbial and intracellular pathogens 
Extracellular parasites and 
allergic reactions 
Initiating Cytokines: IL-12, IL-18 IL-4 
Antibodies (secreted by 
plasma cells): 
IgG2a  
IgG2b 
IgE  
IgG1 
Transcription factors: T-bet , STAT-4 GATA3, STAT-6 
Cytokines produced: IFN-γ (IL-2)  IL-4 (IL-2), IL-13, IL-5. 
Inhibited by cytokines: IL-4, IL-10, TGF-Β IFN-γ, TGF-Β 
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1.2.4. TH17 and Treg pathways: 
The novel pathways involved in the differentiation of TH17 and Treg cells are not yet 
clearly defined. Although their development is mutually exclusive, Transforming 
growth factor (TGF)-β1 is required for the development of both TH17 and Treg cells 
29. IL-6 also appears to play an important role in either inhibiting Treg or inducing 
TH17 development while IL-23 promotes TH17 development 30. The crucial 
transcription factors for TH17 and Treg cells are orphan nuclear receptor (RORγt) 31 
and forkhead box P3 (Foxp3) 23, 32 respectively, and their key cytokines are IL-17 and 
TGF-β1 respectively (Figure 1). TH17 cells are associated with certain asthmatic 
symptoms 33, autoimmunity 34 and with clearing extracellular microbes 35, while Tregs 
are essential for controlling self tolerance and inflammatory immune responses 36.  
 
 
Figure 1: T-helper subset differentiation. Upon activation by antigens and 
cytokines, naïve CD4+ T-cells can differentiate into T-helper 2 (TH2), TH1, TH17 or 
regulatory T-cells (Tregs). Their determining cytokines (left-most green arrows) 
induce key transcription factors (centre of cells), which induce post-maturation 
cytokine production (on right), resulting in their different cell lineages, which are 
involved in the processes on the right (boxed). Diagram taken from Tato & O’Shea 
(2006) 17. 
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1.3. IL-4 Receptor alpha (IL-4Rα) 
1.3.1. Type I and Type II IL-4 Receptors  
IL-4 and IL-13 are the fundamental cytokines in the TH2 immune response 16 and 
share certain functions, which is partly due to a shared common receptor 
transmembrane subunit, interleukin-4-receptor alpha (IL-4Rα) 37, in their receptor 
complexes. The IL-4Rα subunit is widely expressed on haematopoietic, epithelial, 
muscle, fibroblast, endothelial and hepatocyte cells and brain tissues 38. IL-4Rα 
containing heterodimeric receptors can either associate with the γc subunit, forming a 
type I receptor, or recruit the IL-13 Receptor alpha1 (IL-13Rα1) subunit, forming a 
type II receptor 39, 40. Type I receptors, found in most cells of the haematopoietic 
lineage 41, bind only to IL-4 42, 43, while Type 2 receptors expressed by non-
haematopoietic and myeloid-derived haematopoietic cells bind to both IL-4 and IL-13 
42, 44, accounting for the overlap in biological effects of IL-4 and IL-13 45. However, 
IL-4 and IL-13 have different affinities for the Type II receptor, which results in 
differences in downstream events in the signal transduction cascades, which could 
also explain their differences in effects 43. Recent studies on IL-13Rα1 revealed some 
differences between the Type I and Type II receptor components in TH2 responses to 
helminth (parasite) infections and allergy 46.  
  
Both Type I and Type II receptors signal through the Janus kinase family (Jak) and 
phosphoinositide 3-kinase (PI3K) pathways to activate the TH2 associated 
transcription factors STAT6 (signal transducer and activator of transcription 6) and 
GATA3, to further activate or sustain TH2 gene targets 23, 47. Recently, it was 
discovered that IL-4Rα could also signal through Syk kinase to enhance phagocytosis 
and cell adhesion 48 (Figure 2) 
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Additionally, IL-13 can bind solely to IL-13Rα2 16, which was previously thought to 
be a decoy receptor as it did not induce typical IL-13-mediated activation 49. 
However, IL-13Rα2 has been discovered to play a different role in fibrosis, via AP-1 
and TGF-B signalling 16, 50, and has also recently been suggested to modulate IL-4 
signalling 51 and to play a role in IL-13 regulation during N. brasiliensis infection 52.  
 
 
Figure 2: IL-4 and IL-13 cytokines, their receptor complexes and general 
signalling pathways. The IL-4 (red) cytokine can bind to (black arrows) a type I 
(left) or Type II (middle) receptor, while IL-13 (olive) can bind to the Type II (middle) 
heterodimeric receptor or IL-13Rα2 (right). The IL-4Rα subunit (purple) is shared in 
both receptor types and associates with either JAK which activates STAT6 upon 
binding, or with Syk to induce intracellular signalling (blue arrows).  
 
1.3.2. Significance of IL-4Rα−dependent responses  
IL-4Rα is a critical component of the TH2 immune response responsible for TH2 cell 
differentiation and IgE class switching via STAT-6 activation 53. These cellular events 
result in physiological changes such as airway mucus hypersecretion, airway 
hyperresponsiveness and airway inflammation 54-56. Additionally, IL-4Rα plays a 
central role in TH2 responses to a variety of helminth infection models 37, 57-59. Germ 
line IL-4Rα-deficient mice have been instrumental in elucidating several functions of 
this receptor in vivo 4, 5, 37, 59-63. For example, IL-4Rα-deficient (IL-4Rα-/-) mice 
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showed an impaired IL-4 and IL-13 response in vitro 62 and these mice were more 
resistant during the acute stages of L. major infection62. Conversely, during N. 
brasiliensis infection, IL-4Rα was crucial for parasite expulsion 5, 60, 61. Other 
helminth infections, such as S. mansoni-infected IL-4Rα-/- mice are susceptible to 
infection 59, while Trichinella spiralis-infected IL-4Rα-/- mice showed a reduced 
intestinal pathology and worm expulsion 58. Furthermore, a recent study has 
investigated the conservative region of IL-4Rα in human susceptibility to allergic 
asthma 64, highlighting the importance of IL-4Rα studies in allergic asthma.  
 
1.3.3. Cell type-specific studies 
The development of the Cre recombinase-loxP (Cre-loxP) system has allowed for the 
in vivo study of gene function in a single cell type 65, 66. The transgenic mouse 
contains the Cre-recombinase gene under the control of the promoter of the type of 
cell or tissue of interest and loxP sites flanking the specified gene 67. The promoter 
induces Cre-recombinase expression, which targets loxP sites and induces 
homologous recombination, thus excising the gene or exons of interest within those 
cell lineages 67. This technique has been used to generate cell-specific exon deletions 
(exon 7-9) of IL-4Rα exclusively on either CD4+ T-cells 4, 68, 69, lung (Clara) cells 70, 
smooth muscle cells 5 or macrophages and neutrophils (LysMCreIL-4Rα-/lox) 59, 68; 
while all other cells maintained functional IL-4Rα expression and signalling. These 
cell-specific IL-4Rα-deficient mice have been used to study intracellular parasite 69 
and helminth infections 4, 5, 59, asthma 70 and anaphylaxis 68, to further uncover the 
importance of TH2 and hence IL-4Rα-dependent mechanisms in these cell lineages. 
Genes under the macrophage- and neutrophil-specific lysozyme M (LysM) promoter 
71 have been used to investigate Arginase1 (Arg1-/flox;LysMCre) 72 or IL-
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4Rα (LysMCreIL-4Rα-/lox) function in macrophage/neutrophil lineages in helminth 
infections 4, 5, 59, as well as in anaphylaxis 68, arthritis 73 and colon carcinoma tumour 
studies 74. The LysMCreIL-4Rα-/lox mouse was used in this study to investigate effects 
of N. brasiliensis-induced pulmonary pathology. The details of the generation and 
characterization of LysMCreIL-4Rα-/lox mice were carried out by Herbert and 
colleagues (2004) 59 and are summarised in Figure 3 below.  
 
 
Figure 3: Generation of LysMCreIL-4Rα-/lox mice. IL-4Rα-/- mice 62 were mated 
with transgenic mice possessing a Lysozyme M promoter driving Cre recombinase, 
resulting in LysMCreIL-4Rα-/- offspring. These offspring were mated with mice 
containing IL-4Rα flanked by loxP sites (IL-4Rαlox/lox) to produce mice with LysM 
driven cre-mediated deletion of IL-4Rα (LysMCreIL-4Rα-/lox) 59. Grey arrows: loxP 
flanked IL-4Rα allele; black arrows: deleted allele. Figure adapted from Radwanska 
et al. (2007) 69.  
 
 
1.4 Parasitic Helminths, Nematodes and N. brasiliensis 
1.4.1. Helminths 
The term helminth refers to worm and worm-like parasites and refers to most 
members of the Phyla Nematoda (roundworms), Cestoda (tapeworms) and Trematoda 
(flukes) 75. In this study the murine parasitic nematode N. brasiliensis (discussed in 
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detail later) was used, which is analogous to the human parasite hookworms such as 
Necator americanus and Ancylostoma duodenale 76, 77. Hookworm, along with 
roundworm (Ascaris lumbricoides) and whipworm (Trichuris trichuria) infections, 
are the most prevalent of human parasites and account for approximately 570 million, 
800 million and 600 million human infections, respectively, mostly affecting the 
developing regions of Asia, Africa and Latin America 77.  
 
1.4.2. Significance of parasitic nematode infections 
Parasitic nematode infections cause serious morbidity including chronic inflammatory 
pathology, anaemia, malnutrition and cognitive disorders and can be fatal in extreme 
cases 76, 77. In addition to causing serious morbidity, nematodes can also alter the 
host’s immune response to challenges by other pathogens, environmental antigens and 
vaccines 2, 78, 79. For example, chronic nematode infections appear to negatively affect 
the host’s response to Tuberculosis (TB) vaccines 80.  
 
However the effects of nematode infections on the host are not always negative. 
Central to this school of thought is the “hygiene hypothesis”, which proposes that 
reduced exposure to infections during childhood due to increased human hygiene, 
results in insufficient stimulation of TH1 cells, which cannot counterbalance TH2 
expansion and therefore could give a predisposition to allergy 81. In support of this, a 
number of studies have shown that nematode infections can also decrease allergic 
symptoms 2, 81-84. Additionally, the regulatory cytokines produced in response to 
nematode infections offer a potential treatment method for TH1 auto-immune diseases 
and TH2-driven immune dysfunction such as Crohn’s disease and allergic asthma, 
respectively 2, 81, 85, 86. Together, the high infection rates, debilitating pathology and 
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immuno-modulatory effects of these parasites illustrate the relevance of studying and 
understanding the immunological mechanisms that are induced by nematode 
infections.  
 
1.4.3. Immune responses to parasitic nematodes  
Nematode parasites have been well established as models for studying the 
development of TH2 immune responses and parasite-host interactions 6, 59, 87-96. 
Nematode infections induce a robust TH2 immune response in the host, characterised 
by the secretion of the cytokines IL-4, IL-5, IL-9 and IL-13, as well as the production 
of type 2 antibodies (e.g. IgE) and recruitment of eosinophils, basophils and mast cells 
97, 98. Control of nematode infection is associated with smooth muscle cell, epithelial 
cell, B-cell, T-cell, macrophage, eosinophil, mast and goblet cell responses 5, 91, 97-100. 
Human 101 and mouse 61, 89 studies have shown that the production of IL-4 and/or IL-
13 cytokines generally correlates with protective immunity; namely reduced worm 
burdens and effective worm expulsion. However, this strong TH2 response is also 
associated with immuno-pathology in organs unrelated to the definitive stages of the 
parasitic infection, such as the liver, lung airways, and peritoneal cavity 6, 59, 98, 102-107.  
 
1.4.4 N. brasiliensis life cycle and pathology  
The murine nematode N. brasiliensis was used in this study in an infectious disease 
model to examine the effects of this parasite on pulmonary pathology. N. brasiliensis 
is a medically relevant model to use as the lung pathology arising from larval 
migration bears important similarities to that of analogous hookworm parasites 76, 88, 
108. The murine parasitic nematode N. brasiliensis infects the host through the skin, 
migrating via the blood system to the lungs 60, 108. Here the worms move from the 
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blood vessels to pulmonary airways resulting in considerable lung damage and 
antigen deposition 104. The latter induces a strong TH2 response, causing pulmonary 
inflammation, disruption of alveolar air spaces, haemorrhaging, eosinophilia and the 
development of airway hyperresponsiveness (AHR) 1-3, 88, 109, 110. This results in both 
acute and chronic lung pathology 3, 4. The acute pathology is strikingly similar to 
allergic airway disease 109, considered to be induced by the products from the worm 
(N. brasiliensis excretory and secretory products; NES). The chronic pathology can be 
likened to emphysemic symptoms, due the alveolar damage caused by migration of 
the worm through the lung 1. N. brasiliensis is not retained in the lung, but exits the 
lung via the bronchii, where it is coughed up and swallowed resulting in the 
establishment of a definitive stage in the intestinal tract 3-4 days after initial infection 
110. N. brasiliensis (L4 larvae) mature into adults (L5) and produce eggs by 6 days post 
infection (p.i.) and are usually expelled in immunocompetent BALB/c mice by 9-11 
days p.i. 60, 61, 110 (Figure 4). In contrast, the human analogues Necator americanus 
and Ancylostoma duodenale may reside in the human intestine for up to 5 years 76.  
 
1.4.5. Immune response to N. brasiliensis. 
An infection with N. brasiliensis induces an IL-4/IL-13-dependent 24, polarised TH2 
cytokine and cellular response in the host lung and intestine, including type 2 
antibody (e.g. IgE) and TH2 cytokine production (IL-4, IL-5, IL-9 and IL-13), as well 
as the recruitment of eosinophils, basophils and mast cells 4, 5, 91, 92, 97, 98, 111. This 
results in an IL-4Rα-mediated TH2-dependent parasite expulsion as well as immuno-
pathology in the lung and intestines 4, 5, 60, 92, 112. Specifically, expulsion of N. 
brasiliensis, is dependent on IL-13 113 and the TH2 responses driven by IL-4Rα-
responsive non-haematopoietic cells such as epithelial, intestinal smooth muscle and 
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goblet cells, but is independent of IL-4Rα expression on haematopoietic cells 4-6, 61, 91, 
114. This TH2 response also creates a TH2 polarised inflammatory response in the 
lung, characterised by IL-4Rα-responsive pulmonary CD4+ T-cells 4, which persists 
after expulsion of N. brasiliensis from the mouse 2. 
 
 
Figure 4: Life cycle of N. brasiliensis. Illustration adapted from the University of 
Cambridge 115. 
 
 
1.4.6 N. brasiliensis-induced pulmonary immuno-pathology  
During its development, the obligatory migratory phase of N. brasiliensis through the 
lungs of mice causes considerable pulmonary tissue damage (or lesions) and 
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associated cellular infiltration, airway goblet cell hyperplasia and mucus production 2, 
4, 88, 116. N. brasiliensis-induced pulmonary tissue damage consists of three distinct 
histological pathology: (i) rupturing of blood vessels, or haemorrhaging; (ii) the 
destruction of the alveolar architecture of the lung, known as alveolar dilatation and 
(iii) inflammatory lesions caused by cellular infiltration around blood vessels and 
bronchioles due to the migration of the parasite 88. This is pathological evidence of the 
worm’s migratory pathway, which involves rupturing through the pulmonary blood 
vessels, active migration through the lungs, disrupting alveolar architecture and 
migrating via the bronchioles to be coughed up and swallowed for its definitive stages 
in the intestine.  
 
Although it was initially thought that these inflammatory lesions were only associated 
with the vascular system 117, later studies found granulomas around the parasite in 
secondary infections and inflammatory lesions around the bronchioles 2, 88, thus 
confirming the pathological evidence of worm migration. However, in chronic studies 
the pulmonary lesions continued to develop 36 days after the worm had been expelled 
from the mouse 2, suggesting that the lesions were due to a persistent immunological 
response rather than a direct response to the migrating parasite 2, 104, 118. Recent studies 
have shown that this inflammatory response is predominantly due to IL-4Rα-
responsive CD4+ T-cells 4 and is driven by TH2 cytokines 92, 104. Although the precise 
mechanism of this pulmonary immuno-pathology is unknown, it has been shown that 
N. brasiliensis excretory/secretory (NES) antigens can act as TH2-enhancing 
adjuvants and cause TH2 inflammation and asthmatic symptoms in the lung 3. This 
could be a cause of the gross pathology seen in the lungs of the host.  
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A recent study by Marsland and colleagues (2008) 1 showed that in the chronic stages 
of infection, N. brasiliensis could cause symptoms of emphysema, even though the 
parasite was cleared from the host long before disease development. This was an 
important find as N. brasiliensis infections are not usually considered as a murine 
model of emphysema. Indeed, models of emphysema are usually induced by an 
imbalance of lung remodelling proteins such as matrix metalloproteinases (MMPs), 
cathepsins and other elastases 119-121. These mechanisms and the immunology of 
chronic lung pathology will be covered in the following section.  
 
1.5. Chronic Lung Diseases  
N. brasiliensis migration through the lung causes substantial and chronic lung 
pathology, even after the worms have been expelled 2. The lung pathology is similar 
to the pulmonary inflammation in allergic asthma 3 and the disruption of alveolar 
architecture seen in emphysema 1. The following section highlights the importance of 
chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and 
emphysema. N. brasiliensis infection of mice can be used as a model to study aspects 
of these chronic lung diseases 1, 2.  
 
1.5.1. Chronic obstructive pulmonary disease (COPD) 
There are a broad range of chronic lung diseases, some of which are grouped under 
the Chronic obstructive pulmonary disease (COPD) classification  122, 123. COPD is a 
general term and classification of a group of diseases, defined by the irreversible and 
progressive pathological limitation or obstruction of airflow in the airways and the 
deterioration in lung function. COPD includes the diseases chronic bronchitis (CB) 
and emphysema under its classification. Chronic bronchitis refers to pathology or 
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inflammation in the upper respiratory tract, while emphysema is defined as the 
permanent enlargement, rupture or dilatation of the airways distal to the terminal 
bronchioles, which includes the respiratory bronchioles, alveolar ducts and alveolar 
sacs 122, 124, 125. Therefore, emphysema and CB usually co-exist in the same individual, 
especially in severe cases 123. Since COPD is an encompassing term, it is therefore 
used interchangeably with the terms emphysema and chronic bronchitis 125 . 
 
1.5.2. Significance of COPD  
COPD (and therefore emphysema and chronic bronchitis) is the fourth leading cause 
of death in the world, affecting 16 million people in the United States alone 121, 126. It 
is predicted to be the third most common cause of death and fifth most debilitating 
disease in the world by 2030 127. COPD is such a major worldwide health problem 
primarily due to a poor understanding of its underlying cellular and molecular 
mechanisms and difficulty in early diagnosis, compounded with limited therapeutic 
treatment 124, 128, 129. 
 
1.5.3. Symptoms and pathology 
Being a relatively diverse group of diseases, the clinical syndrome of COPD includes 
a range of pulmonary manifestations 125, 130. Patients with COPD have symptoms of a 
chronic cough and increased sputum production with dyspnoea (breathlessness) in the 
severe stages 125. These are the pulmonary manifestations caused by the definitive 
airflow obstruction due to airway inflammation and lung parenchyma or alveolar 
destruction 131. The diagnostic differences between emphysema and chronic bronchitis 
are almost indistinguishable, which is why they are grouped under COPD. However, 
their differences in lung pathology are clear. The pathological hallmarks of COPD are 
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alveolar dilatation or the destruction of the lung parenchyma seen in emphysema 
patients (Figure 5), and chronic inflammation of peripheral and central airways, 
characteristic of chronic bronchitis (CB) 122, 125. The treatment for chronic bronchitis 
(COPD syndrome) involves daily administration of inhalant bronchodilators, with 
steroids and oxygen supplementation in the severe stages. However, there is 
unfortunately no specific treatment yet available for emphysema 132.  
 
 
Figure 5: Lung pathology in emphysema patients. Healthy adult lungs (left) 
compared with lungs from a patient with emphysema (right). Magnification: 25X. 
Figure adapted from Taraseviciene-Stewart & Voelkel (2008) 125.  
 
 
1.5.4. Causes of COPD/Emphysema  
Causes of COPD/emphysema include the inhalation of noxious particles or gases. 
Genetic predisposition, such as alpha1-antitrypsin deficiency, which is an anti-
protease that protects the lung against protease degradation, can also underlie the 
onset of COPD 119, 125, 133, 134. Major causes of COPD are associated with long-term 
tobacco smoke exposure or smoking cigarettes and this constitutes 90% of COPD 
patients in developed countries 122, 126. However, this may be a biased view as most 
studies are performed using smokers and non-smokers as control groups or on lung 
parenchyma obtained from lung volume reduction surgery (LVRS) 122, 124, 135. 
Additionally, COPD can still progress in COPD patients who are non-smokers or who 
have stopped smoking for a number of years 122, 136. Recent studies also indicate an 
immune or autoimmune component, 122-124, 136, 137 which could explain the continuous 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
29 
exacerbations of both the structural (emphysema) 138 and inflammatory pathology 
(chronic bronchitis) of COPD in patients 129, 135, 139. In addition to these causes of 
COPD, there is a well established “proteolytic hypothesis”, which describes the 
molecular pathogenesis of protease-induced emphysema 119, 140.  
 
1.5.5. Proteases and Emphysema 
Since the discovery in 1964 that patients with severe alpha1-antitrypsin deficiency 
exhibited early emphysema, and that the administration of papain to rats also caused 
emphysema, a “proteolytic hypothesis” of the mechanisms in emphysema was 
formulated 119, 140. This hypothesis describes how emphysema can be induced by an 
imbalance of the proteases, such as collagenases and elastases, and their anti-protease 
counterparts in the lung 119, 134, 141. According to this hypothesis, this imbalance is 
provoked by external stimuli such as tobacco smoke that causes an infiltration of 
inflammatory cells (such as macrophages and neutrophils) which release their 
proteases, thus causing the protease-antiprotease imbalance. These factors lead to the 
proteolysis of lung connective tissue or elastin, and eventually emphysema 142. 
Alternatively, the major pulmonary antiprotease, alpha1-antitrypsin, could be 
inactivated by oxidation induced by the free radicals in tobacco smoke, thereby 
decreasing its protective anti-proteolytic activity and thus causing the imbalance 119.  
 
Since the birth of this hypothesis, there have been several mouse and human studies to 
further elucidate the molecular mechanisms of emphysema 119, 121, 122, 124, 125, 135, 136, 138-
140. Neutrophils and their protease, neutrophil elastase, can play a key role in the 
induction of emphysema, since neutrophil and macrophage numbers increase in the 
lungs of smokers and COPD patients. Therefore this potential release of neutrophil 
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elastase and MMP12 (or macrophage elastase) is also increased, as demonstrated by 
numerous MMP12 and neutrophil elastase murine and human studies 119, 125, 140, 143, 144. 
It is hypothesized that the endogenous protease inhibitors are not induced enough to 
counteract the increased protease levels induced by smoking 119, 125, 140. These 
endogenous protease inhibitors include cystatin C, which inhibits macrophage 
cathepsins, while the tissue inhibitors of metalloproteases (TIMPs) inhibit MMPs 140.  
 
Interestingly, murine models of over-expression of TH1- and TH2-associated 
cytokines IFN-γ, TNF-α and IL-13, show an induction of chronic inflammatory 
conditions and alveolar dilatation associated with COPD 121, 138, 143. The only 
infectious murine models of COPD used involved mice infected with either the 
murine-specific parainfluenza respiratory virus, the Sendai virus (SeV), or with the 
nematode N. brasiliensis 1, 145. Since these studies, numerous different theories and 
classifications of COPD have been proposed from murine and human studies 119, 121, 
122, 124, 125, 135, 136, 138-140. 
 
1.5.6. Immunology of chronic pulmonary inflammation: COPD vs. asthma 
Asthma and COPD, both characterized by airway obstruction, are common disorders 
with similar prevalence and global distribution, predominantly affecting the 
developed countries 123. The strikingly similar characteristics of these disorders and 
their physiological overlap have resulted in the formation of two different schools of 
thought – both with convincing evidence. The Dutch hypothesis states that asthma and 
COPD are different forms of the same disease 146, while its counter argument, the 
British hypothesis states that these disorders are separate entities 147. The similarities 
and differences in asthma and COPD immunology are outlined below.  
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The pulmonary pathology induced by N. brasiliensis and its antigens has similarities 
with asthma 3, 148 and COPD 1. Asthma and COPD are both chronic inflammatory 
disorders of the airways 123 with several similarities and differences (Figure 6). 
Inflammation is mediated in both asthma and COPD by T lymphocytes, granulocytes 
and macrophages 137, 149. Although B lymphocytes can play an important role in 
COPD, their function and mechanistic involvement are not fully understood 123. In 
asthma, the disease-associated T lymphocytes are predominantly CD4+ and the 
associated granulocyte populations are predominantly eosinophilic 150. Asthmatic 
pathology is mediated via CD4+ T lymphocytes and their TH2-associated cytokines 
(e.g. IL-4, IL-5, IL-13). These mediators induce asthmatic pathophysiology such as 
airway hyperresponsiveness, airway inflammation and excessive airway mucus 
production, leading to reversible airway obstruction 151. Unlike asthma, the airway 
obstruction in COPD is irreversible, and the T lymphocyte populations appear to be 
predominantly CD8+ 152 and are associated with a TH1 or TH17 response119, 139, while 
neutrophils constitute the majority of the granulocyte populations 153. The precise 
mechanism by which these TH responses exert their influences and physiological 
responses in asthma and COPD remains to be fully elucidated 123. 
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Figure 6: Similarities and differences between Asthma and COPD. Figure taken 
from Barnes, P.J. (2008) 123. 
 
 
1.5.7. Autoimmune component of COPD 
Besides the classic paradigm that the pulmonary matrix protease-antiprotease 
imbalance causes alveoli destruction and inflammation in COPD, there is a recent 
perception that there could be an autoimmune component of COPD that could be an 
underlying cause of the chronic disease 129, 139.  
 
The lungs of COPD patients show an increase in macrophages, neutrophils, DCs and 
T and B lymphocytes due to cellular recruitment in response to tobacco smoke 123. 
The increase in macrophage and neutrophil numbers present in the lungs of COPD 
patients has been directly implicated in alveolar pathogenesis through secretions of 
proteases such as MMP12 154 and neutrophil elastase, respectively 155, 156. Indeed, 
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alveolar macrophages are central to the inflammatory response as there has been a 
strong correlation between increases in alveolar macrophages and COPD 
inflammatory progression, particularly at the sites of tissue damage, since they are 
known to express pro-inflammatory mediators 156, 157. These mediators are increased 
in the sputum of COPD patients and include chemokines such as IL-8 to attract more 
neutrophils, thus further amplifying the elastin destruction by increased pulmonary 
matrix proteases and TH1-specific chemokines including CXCL9, CXCL10 and 
CXCL11 139, 158. This destructive process is further amplified by the increased 
expression of CXCR3 on the surfaces of alveolar macrophages that respond to 
CXCL9, CXCL10 and CXCL11 and result in the further increased production of 
MMP12 159.  
 
Additional strong evidence of autoimmunity include T-cells reactive to elastin and 
increased IFN-γ and elastin-specific antibody levels in the blood from COPD patients 
138. Further evidence includes increased levels of IL-17 in airways of mice exposed to 
long-term tobacco smoke 160, and increased numbers of effector cytotoxic CD8+ T-
cells and apoptosis-related tissue damage in the emphysematous lung 161.  
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1.6. Alternatively activated Macrophages (AAMs)  
Of particular interest in this study is the role played by macrophages, specifically 
alternatively activated macrophage (AAM) populations, in the lung. N. brasiliensis 
elicits a TH2 response in the lung associated with the TH2 cytokines IL-4 and IL-13 
and infiltration of Type 2 cells 4, which together induce macrophages to become 
alternatively activated 1, 7. Therefore, it is IL-4Rα-responsive macrophages which are 
able to develop into the alternatively activated phenotype which has been associated 
with being protective against a range of pathology 59, 72, 162, 163. Alternatively activated 
macrophages, or M2 macrophages, have been associated with the control of 
inflammation 59, 72, down-regulation of TH2 responses, enhanced wound healing 162, 
and tissue damage 1 in the lung. Additionally, AAMs have been shown to control 
viral-induced lung damage in a IL-4Rα-dependent way 164. As such this population of 
macrophages may be capable of protecting the lung from COPD.  
 
Since their identification 165, AAMs have been defined 166 as macrophages induced by 
the TH2 cytokines IL-4/IL-13, resulting in up-regulation of mannose receptor (MR) 
165. In contrast to their TH1 associated pro-inflammatory classically activated 
macrophage (caM) counterparts, AAMs elicit immunity against multicellular 
pathogens, anti-inflammatory, wound healing and pro-fibrotic effects 166, 167.  
 
AAMs have been characterised by IL-4Rα-driven increased arginase-1 expression 72, 
166-170, induction of chitinase and FIZZ family members (ChaFFs) 171 and chitinase-
like molecules 171-173, along with other biomarkers such as peroxisome proliferator-
activated receptor γ (PPARγ) and mannose receptor (MR). Arginase-1 is associated 
with repression of NO production, suppression of TH2 cytokine activity 72 and 
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production of proline 169, 174. Together these effects of arginase-1 activity constitute an 
array of anti-inflammatory, tissue repair and pro-fibrotic-associated responses 175. MR 
is a C-type lectin involved in endocytosis 170, while PPARγ is a component of 
transcriptional regulation, mainly involved in regulating glucose and lipid 
metabolism, but has recently been suggested to be involved in inflammation and 
atherosclerosis 176.  
 
Helminth infections have been central to AAM-associated studies due to their strong 
induction of TH2 responses. The up-regulation of AAMs has been associated with a 
range of helminth infections (Table 2). AAMs have been associated with the 
expulsion of helminths such as N. brasiliensis 177 and H. Polygyrus 93. Using 
LysMCreIL-4Rα-/lox mice, which do not have IL-4Rα-responsive macrophages, mice 
infected with S. mansoni died from enhanced liver and intestinal pathology and septic 
shock 59. Interestingly, the increased mortality rate of mice deficient for macrophage-
specific Arginase1 was not due to septic shock but from exacerbated inflammation, 
which was associated with uncontrolled CD4+ T-cell proliferation, and liver fibrosis 
72. Additionally, S. mansoni–induced AAMs controlled CD4+ proliferation by 
depletion of the arginine source, since addition of arginine restored CD4+ T-cell 
proliferation in co-culture studies 72. Other helminth infection studies, such as that of 
Brugia malayi, have shown that isolated AAMs from B. malayi–infected mice 
suppress CD4+ T-cell proliferation in vitro 178. Additional B. malayi studies have 
shown that IL-4-dependent alternative activation of macrophages can occur without 
adaptive immunity and that these macrophages are involved in wound healing 162. 
Despite the fact that the macrophages portray the same AAM biomarkers (Table 2), 
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these diverse studies on an even more diverse variety of parasites begs the question of 
whether or not the macrophages are identical in form.  
 
Table 2 Common helminth-associated AAM biomarker molecules. Adapted from 
Reyes & Terrazas (2007) 179. 
 
Parasite AAM biomarker Suppressive activity Role in disease Ref 
Nematodes 
Brugia Malayi Fizz1, Ym1, Arg1 Yes (contact 
dependent/TGF-β-
partially dependent) 
Unknown 178, 
180-182 
Litomosoides 
sigmodontis 
Fizz1, Ym1, Arg1 Yes (contact 
dependent/TGF-β-
partially dependent) 
Unknown 183 
Nippostrongylus 
brasiliensis 
Fizz1, Fizz2, 
Yml, Arg-1, 
MMR AMCase 
IL-21R 
Unknown Lung homeostasis after acute injury 171, 172, 
184 
Heligmosomoides 
polygyrus 
Fizz1, Ym1,MR 
AMCase, IL-4R 
Unknown Host protection, arginase-mediated 
parasite clearance 
93 
Trematodes 
Schistosoma 
mansoni 
Fizz1, Ym1, Arg1 
AMCase, MR, 
IL-21R 
Yes (PD1-PDL 
pathway dependent) 
Divergent role: Host protection 
down-modulate TH1-mediated 
immuno-pathology and progressive 
lung pathology and liver granuloma 
formation 
59, 185 
Fasciola hepatica Fizz1, Ym1, Arg1 Unknown Unknown 186, 187 
Cestodes 
Taenia crassiceps Fizz1, Ym1, 
Arg1, MR, 
mMGL, CD23, 
CCR5, TREM2 
Yes (PD1-PDL 
pathway dependent 
and ROS partially 
dependent) 
 May favour parasite installation 188-191 
Fizz 1, found in inflammatory zone 1; AMCase, acidic mammalian chitinase; LOX, lipoxygenase; MR, 
macrophage mannose receptor; Arg-1, arginase-1; PD, programmed death receptor; PDL, programmed 
death ligand; CCR5, CC chemokine receptor 5; mMGL, mouse macrophage galactose-type-C-type 
lectin; TREM, triggering receptor expressed on myeloid cells, ND, not determined.  
 
 
It has been suggested that since macrophages are both innate and adaptive immune 
cells, they are the first to respond to pathogens and thus initiate the type of response 
by differentiating into classically or alternatively activated macrophages 192. 
Therefore, the macrophages could produce distinct chemokine and chemokine 
receptor spectrums to initiate and to stabilise classical and alternative activation 193. 
Mantovani and colleagues 192 have classified these chemokines and associated them 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
37 
with macrophage activation or TH subset differentiation. For example, the 
chemokines CCL24, CCL22 and CCL17 are induced by the cytokines IL-4 and IL-13 
and have been implicated as AAM biomarkers 166. However, instead of one 
classification of AAMs, three classifications of AAMs have been proposed: M2a, 
M2b and M2c 167, 193. M2a macrophages are considered to be IL-4/IL-13-induced 
macrophages, M2b are macrophages exposed to agonists of TLRs and immune cells 
and the M2c classification refers to IL-10 and glucocorticoid hormone induction of 
macrophages167, 193. For the sake of simplicity, macrophage activation will be 
classified as either classically or alternatively activated, unless stated otherwise.  
 
From the above evidence, AAMs show a down-modulated inflammatory response 
associated with a healing phenotype. Although a good body of knowledge has been 
gained from helminth infection models to further elucidate the functions of AAMs, 
much needs to be elucidated with respect to N. brasiliensis-induced pulmonary 
infections. 
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1.7. Aims, Hypothesis and Objectives 
The aim of the present study was to investigate the development of pulmonary 
pathology following acute (5 days p.i.) and chronic (42 and 180 days p.i.) N. 
brasiliensis infection, with focus on IL-4Rα-responsiveness by macrophages. 
 
It has been recently established by Mearns (MSc. Dissertation, 2007) 57, that mice, 
which lack IL-4Rα specifically on macrophages and neutrophils (LysMCreIL-4Rα-/lox) 
show exacerbated inflammatory lesions at 42 days p.i. (unpublished results) when 
compared to control littermate mice (IL-4Rα-/lox) and IL-4Rα-deficient (IL-4Rα-/-) 
mice. As it is known that AAMs down-modulate inflammation during a TH2-
polarized nematode infection 59, 72 and that LysMCreIL-4Rα-/lox mice lack functional 
AAMs 59, we hypothesized that IL-4Rα-responsive macrophages are alternatively 
activated in the lung and that they may control inflammation.  
 
To test this hypothesis we performed comparative N. brasiliensis infectious studies in 
global or macrophage/neutrophil-specific IL-4Rα-deficient mice and their littermate 
controls and investigated pathological, histological, immunological and molecular 
parameters. Thus the results section of this thesis is divided into three main chapters: 
1) Lung Pathology; 2) Immune responses; and 3) Alveolar macrophage 
characterization.  
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2. MATERIALS AND METHODS 
 
2.1 Mice  
Male mice (6 to 10 weeks old and 4-5 per group) were housed in individually 
ventilated cages in specific-pathogen-free conditions in the Animal Unit at the 
University of Cape Town (UCT). IL-4Rα-deficient (IL-4Rα-/-) mice 62 and 
macrophage/neutrophil cell-specific IL-4Rα-deficient (LysMCreIL-4Rα-/lox) mice 59 
were previously described, generated and characterized. Littermate control mice 
hemizygous for IL-4Rα (IL-4Rα-/lox) were considered as wild type (WT) mice and 
used as controls in all experiments. All mice were backcrossed on a BALB/c 
background to at least the F9 generation and were genotyped prior to experiments to 
confirm their genotype using gene-specific primers (carried out by laboratory staff). 
Mice were euthanized at days 5, 42 and 180 p.i. by CO2 asphyxiation. All animal 
procedures were carried out in an Animal Biosafety Level 2 Laboratory (Animal Unit, 
UCT) and all experiments were conducted in accordance with and approved by the 
Research Animal Ethics Committee of UCT. 
 
2.2. Maintenance of N. brasiliensis life cycle  
N. brasiliensis worms were passaged routinely in Wirstar rats. Live third-stage (L3) 
larvae were prepared in 0.65% NaCl at 10 000 worms/ml. Six to eight rats were 
injected subcutaneously in the flank of the leg with 500 μl of the worm solution using 
20G needles (Braun, Melsungen, Germany). At 5 days p.i., rats were transferred to 
gridded cages for faecal collection, the bottom of which were lined with damp paper 
to keep faecal pellets moist. Faecal pellets from infected rats were collected daily 
from day 6 to day 8 p.i. and soaked each day in ddH2O water containing Fungizone 
(Gibco Life Technologies). Pellets were mixed into a paste-like consistency and 
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spread onto prepared culture dishes consisting of a large petri dish containing a filter 
paper and a piece of square gauze, both moistened in Fungizone (Gibco Life 
Technologies), to act as reservoir. The dishes were incubated in humidified containers 
at 25ºC for at least 5 days to allow L3 larvae to migrate to the edge of the damp filter 
paper. The outer layers of filter paper containing the worms were removed and 
transferred to fresh culture dishes for further incubation and to keep the worms moist 
until they were used for infection.  
 
2.2.1 Preparation of N. brasiliensis worms and infection 
Pieces of filter paper containing fresh L3 larvae were placed in 0.65% NaCl and 
counted in a petri dish on a dissecting microscope to prepare a solution of 3750 
worms/ml in 0.65% NaCl. The infection of mice was carried out in an Animal 
Biosafety Level 2 Laboratory (Animal Unit, UCT). Mice were injected 
subcutaneously with 750 worms in a total volume of 200 u1 0.65% NaC1 using a 21G 
needle (Braun). Naïve control mice were WT (IL-4Rα-/lox) and were injected with 200 
μl of 0.65% NaCl (without N. brasiliensis L3 larvae).  
 
2.3. Measurement of airway hyperresponsiveness (AHR) 
Similar to Marsland et al. (2008) 1, airway hyperresponsiveness (AHR) was measured 
using 1X PBS (control) and increasing concentrations of β-metacholine (MCh) 
(Sigma-Aldrich, Munich, Germany) (5, 10, 20 mg/ml) in whole-body 
plethysmographs (Emka Technologies, Paris, France) and analysed using Iox2 
Software (Emka Technologies, Paris, France). Briefly, individual, unrestrained, 
conscious mice were placed in a whole-body plethysmograph (Emka Technologies) 
and baseline measurements were taken for 5 minutes. Mice were then subjected to 
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aerosolised 1X PBS (control), and exposed to increasing MCh (Sigma-Aldrich) 
concentrations of 5, 10, 20 mg/ml for 1 minute. Mice were then monitored and 
measurements were taken for 15 minutes, using Iox2 Software. Enhanced Pause 
(PenH), a dimensionless parameter, was calculated using the following equation from 
Hamelman et al., (1997) 194: PenH = (Te/Tr - 1) x (PEP/PIP) (Te: expiratory time; Tr: 
relaxation time; PEP: peak expiratory pressure, PIP: peak inspiratory pressure).  
Averages of PenH for the first 5 minutes were subtracted by the individual average 
baseline readings to give a final PenH value for each individual mouse. Maximum 
PenH values were observed at 10mg/ml MCh and these results were used throughout 
the study. 
 
2.4. Histology and Scoring of pathology 
At each time point, mice were killed by CO2 asphyxiation and the lungs were 
carefully removed and fixed in 4% formalin (in 1X PBS) for a minimum of 24 hours. 
All histology sections were prepared by the Department of Histology, Groote Schuur 
Hospital. The lungs were mounted in paraffin blocks for sectioning and the tissue 
sections were then fixed and stained with haematoxylin and eosin (H&E) by 
laboratory staff (Groote Schuur Hospital). All pathological scoring and analysis was 
carried out by viewing multiple sections of whole lungs on a light microscope by the 
researcher and an independent observer (clinical pathologist). In order to distinguish 
any differences between the groups, each section of tissue was evaluated using a 
scoring system for intra- and inter-group statistical analysis. Pulmonary pathological 
scoring was based on severity and quantity (for inflammation and alveolar dilatation), 
using a relative scale (0-3; 0: none, 1: mild, 2: moderate, 3: severe or more than 50% 
of lung area). This was carried out objectively in accordance with accepted clinical 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
42 
and pathologist guidelines and adapted from Radosevic et al (2007) 195. Inflammation 
severity scores were defined as any focal cell infiltrate and based on the density and 
relative size of the area occupied of the most affected lung or lobe. Similarly, alveolar 
dilatation scores were based on the most or worst amount of alveolar damage, and 
scored using the same relative scale.  
 
2.5. Preparation of lung single-cell suspensions 
Single-cell suspensions from processed lung digests were used for re-stimulation 
assays, flow cytometry analysis or cell sorting of alveolar macrophages. Briefly, lung 
lobes were perfused (1mM EDTA in 1X PBS) and individually removed, minced into 
fine pieces and digested in Digestion Buffer (Appendix A) for 90 minutes at 37º C. 
Digested lung tissue were then pushed through 70 μm nylon cell strainers (Becton-
Dickson, New Jersey) and subjected to red cell lysis for 2 minutes in Red Cell Lysis 
Buffer (Appendix A). Remaining cells were collected by centrifugation (1200rpm, 
4ºC, 5 minutes) and re-suspended in 1ml DMEM. Aliquots of the suspension (10 μl) 
were diluted in trypan blue (1 in 10 dilution) to determine cell viability and the cell 
concentrations was determined using a Neubauer haemocytometer. Cell volumes were 
adjusted to attain cell concentrations of 4x106 cells/ml. The media was changed to 
either IMDM (supplemented with 10% FCS, 100U/ml penicillin G, 100μg/ml 
streptomycin) for lung re-stimulations, or to FACS buffer (1X PBS supplemented 
with 0.1% BSA and 0.05% NaN3) for flow cytometry analysis or FACS cell sorting.  
 
2.5.1. Lung Re-stimulations 
The above single-cell suspensions of individual lung digests in IMDM (supplemented 
with 10% FCS, 100 U/ml penicillin G, 100 μg/ml streptomycin) were separately 
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seeded in triplicate into a flat-bottomed 96-well plate (Nunc Maxisorp; Thermo Fisher 
Scientifica, Roskilde, Denmark) at 4x105 cells per well. The cells for each individual 
mouse lung were re-stimulated either with anti-CD3 (20 μg/well), somatic antigen (10 
μg/well) or media (controls) in total volume of 200 μl in each well and incubated for 
48 hours at 37ºC and 5% CO2.  
 
2.5.2. Flow cytometry analysis on lung cell populations 
For analysis of the cellular compositions of lung inflammatory infiltrates, aliquots of 
1x106 single-cell lung suspensions from individual mouse lungs were transferred into 
FACS tubes and stained with a cocktail of antibodies (refer to Appendix B and C for 
antibody details and gating strategies, respectively). To identify the different cell 
types we used the following antibody panels: anti-CD3, anti-CD4 and anti-CD8 for T 
cell staining, anti-CD11c and anti-MHCII for alveolar macrophages, anti-GR-1 and 
anti-CCR3 for eosinophils and neutrophils and anti-B220 for B-cells. All cell staining 
was performed in FACS buffer (PBS supplemented with 0.1% BSA and 0.05% NaN3) 
containing 1% heat-inactivated rat serum and 1% anti-FcγRII/III. Total viable cell 
counts (determined by trypan blue exclusion) and flow-cytometric data was used to 
determine absolute numbers of cell populations. A total of 50 000 cells were acquired 
per sample on a FACS Calibur (BD Biosciences, San Jose, CA, USA) and the 
acquisition data analysed using CellQuest Pro (BD Biosciences, San Jose, CA, USA) 
and FlowJo v7.2 (Tree Star, Inc., Ashland, Oregon, USA).  
 
2.6. Alveolar Macrophage cell sorting by FACS 
Alveolar macrophages were defined according to Kirby et al. (2009) 196, as 
autofluorescent CD11cHi MHC-IIInt/Lo. Single-cell suspensions of pooled lungs (as 
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described above) were stained with CD11c-PE and MHC-II-Biotinylated/APC, 
isolated using a magnet cell sorting (MACS) bead system (Miltenyi Biotec, Germany) 
and sorted above 98% purity on a FACSVantage (Becton-Dickinson, South Africa) 
for subsequent RNA extraction and analysis under sterile conditions. (Refer to 
Appendix B for FACS antibody details and to Figure 14, Chapter 3.3 for the gating 
strategy.) Essentially, lung digest cells were stained with anti-CD11c-PE (1:160 
dilution in FACS buffer containing 1% heat-inactivated rat serum and 1% FCyR 
blocker (anti-FcyRII/III)) and were enriched by positive selection for CD11c+ cells on 
MACS columns (Miltenyi Biotec, Auburn CA, USA), as per manufacturer’s 
instructions. Enriched CD11c+ cells were stained with biotinylated anti-MHC-II 
antibody (with 1% anti-FcyRII/III), followed by Allophycocyanin (APC) conjugated 
to streptavidin (SpA-APC; 1:400 dilution) in MACS Buffer (0.5% BSA, 2mM EDTA 
in 1X PBS at pH 7.2). Sterile FACS buffer (PBS supplemented with 0.1% BSA and 
0.05% NaN3) was used for the final wash and cells were re-suspended to a 
concentration of 5x106 cells/ml. Cells were sorted, for CD11c-PEHi MHC-II-Biot-
APCLo/int using a FACSVantage cell sorter and a 100μm nozzle. Dead cells were 
excluded by 7-AAD staining (Sigma).  
 
2.6.1. RNA extraction 
Purified alveolar macrophages (CD11cHi, MHC-IILo) 196 of >98% purity, were lysed in 
RLT Buffer (Qiagen, Valencia, CA, USA) and stored at -80ºC until ready for use. 
RNA was extracted using the RNeasy Plus Micro Kit (Qiagen, Valencia, CA, USA), 
as per manufacturer’s instructions. Deviations from the manual included: β-
mercaptoethanol was added to RLT Buffer before use and cells were lysed in 350-700 
μl RLT buffer by repetitive pipetting; and the elution step was repeated and both 14μl 
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RNA elutes pooled. The RNA was stored at -80oC until used. The quality, integrity 
and quantity of the RNA (2 μl aliquots) were assessed on a BioAnalyzer 2100 
(Agilent, Santa Clara, California, USA) at the Centre for Proteomics and Genomics 
Research (University of Cape Town).  
 
2.6.2. Microarray Design and Analysis 
To examine gene expression profiles of murine CD11cHi, MHCIILo alveolar 
macrophages196 (AlvM) during N. brasiliensis infection, microarrays were run in 
collaboration with Dr. Alun Kirby (University of York), according to a two-colour 
experimental reference design. An outline of the design is shown in Figure 7. The 
author isolated the AlvMs and extracted the RNA from naïve and infected mice lungs 
and performed the final data analysis and statistical tests, while microarrays were 
custom-designed, printed, assayed and the raw data processed by the laboratory of Dr 
Kirby. Each microarray contained cDNA probes for 460 gene targets that were 
annotated by Dr. Kirby with Gene Ontology (GO) terms including: apoptosis, 
cytokines, chemokines, surface receptors, signalling, pathogen recognition and 
immunoregulation (gene symbols, full names and aliases, functional clustering and 
accession numbers are listed in Appendix E). Targets were selected based on 
preliminary whole-genome analysis of murine alveolar macrophages (AlvM) (A. 
Kirby; unpublished data), and on published reports of molecules potentially involved 
in AlvM (and dentritic cell) function, to facilitate the definition of macrophage-
specific gene expression profiles (researched by A. Kirby). 
 
Comparison of each test sample to an identical, pooled reference RNA in this 
experimental design permits both intra- and inter-group comparisons to be made. The 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
46 
reference (“Ref.”) RNA samples were extracted by Dr. Kirby from unelicited 
peritoneal macrophages which were isolated from naïve mice. “Naïve” and “infected” 
refer to RNA samples extracted by the author, using the RNeasy Plus Micro Kit 
(Qiagen), from AlvMs of naïve mice or mice that were infected with N. brasiliensis, 
respectively as described above (Sections 2.6.1 and 2.6.2). Each biological infection 
experiment was performed independently of each other by the author and none of the 
RNA samples from the biological repeat experiments were pooled.  
 
The genomic DNA-free total RNA was then sent to the laboratory of Dr Kirby, where 
the RNA samples were processed for microarray analysis using their standardized 
protocols. These custom “macrophage microarray” slides were manufactured in-house 
at the Genomics Division of the Technology Facility (University of York, UK) where 
a Genetix QArrayMini compact arrayer was used to print 70-mer oligonucleotides 
from Operon (Eurofins MWG Operon, Ebersberg, Germany) onto Nexterion slide E 
glass slides (Schott North America, Inc., Elmsford, NY, USA).  
 
Briefly, RNA from test samples or reference RNA were linearly amplified (single 
round) using the Amino Allyl (aa) MessageAmp™ II CyDye aRNA Amplification Kit 
(Applied Biosystems Inc., Foster City, CA, USA) as per the manufacturer’s 
instructions. Amplified aaRNA was then labeled with either Cy3 (for reference RNA) 
or Cy5 dye (for test sample RNA) using the same kit, and equal amounts of labeled 
reference and test RNA (min 500ng, max 5000ng) were combined and hybridized 
overnight in a humidified chamber to custom macrophage microarray slides at 42oC 
according to the Nexterion Slide E protocol 197. After hybridization, the microarray 
slides were washed and dried using Nexterion protocols. The microarray slides were 
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scanned immediately using an Axon GenePix 4000A (Axon Instruments/Molecular 
Devices Corporation, Sunnyvale, CA, U.S.A) scanner and GenePix Pro 5.1 software 
running on a Windows XP operating system using standardized parameters of the 
Technology Facility (University of York, UK). All RNA amplification, hybridization 
and subsequent image analysis, data normalization and background correction was 
done by Dr Kirby. Image data was normalized using GenePix Pro 5.1 software so that 
arithmetic mean of the expression ratios of the housekeeping genes was equal to 1. 
The background fluorescence was calculated by applying the internal background 
algorithm of GenePix Pro 5.1. Median backgrounds were subtracted from mean 
fluorescence values to obtain specific fluorescence levels for each spot on the chip. Dr 
Kirby provided normalized, background-corrected data to the author for in-depth 
analysis and biological interpretation.  
 
2.6.2.1. Microarray Data Analysis 
The normalized, background-corrected microarray data was analysed in Microsoft 
Excel 2003 and TM4 Multi-experiment Viewer (MeV) Software Package 198. Due to 
artifacts of the hybridization process, some negative Cy5/Cy3 expression ratios 
(Naive vs. Reference; or Infected vs. Reference) were obtained after background 
subtraction, and were subsequently discarded. Gene expression values that were >10 
were considered “saturated” and given a maximum default value of 10. The gene 
expression ratios were then log2 transformed (now called M-values) to optimally 
measure and visualize the degree to which different genes alter their transcription 
levels.  
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Significantly differentially expressed genes were identified by a two-tailed, paired T-
test comparing the M-values of both experimental repeats of one mouse group with 
the another mouse group. Genes were considered to be significantly differentially 
expressed only if p < 0.05. The fold change (FC) in gene expression between IL-4Rα-
/lox
(Naïve), IL-4Rα-/lox (infected), LysMCreIL-4Rα-/lox (infected) and IL-4Rα-/-(infected) groups at 
different times post-infection, was calculated by subtracting the M-values of one 
group from another using the equation below: 
FC(Group1 vs. Group2) = M-value(Group1) - M-value(Group2) 
The FC-values were exported into the TM4 Multi-experiment Viewer (MeV) 
Software Package 198 and heat-maps generated to visualize global and significant 
changes in gene expression between experimental groups. In accordance with 
Minimum Information about Microarray Experiments (MIAME) compliance 199, the 
microarray design, methodology and data will be deposited in a MIAME compliant 
public database (by Dr Kirby) at a later date. Preliminary literature database mining 
was carried out using MILANO, created by Rubinstein et al (2005)200. The Milano 
Literature mining tool 200 (http://milano.md.huji.ac.il) was used to search the PubMed 
201 database to see if any of the differentially expressed genes has been shown to play 
a role in N. brasiliensis infection, inflammation, lung remodelling, and/or macrophage 
activation (MILANO search keywords: “macrophage activation”, “alternatively 
activated macrophage”, “activation”, “lung remodelling”, “lung”, “inflammation”, 
“emphysema”, “alternative activation”, “M2”). Manual literature searches were done 
for a smaller set of candidate genes using PubMed 201, AceView 202, OMIM 203 and 
Entrez Gene 204 databases.  
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Figure 7: Experimental design for the microarray analysis of AlvM genes. The 
gene expression patterns of Naive vs. Reference or Infected vs. Reference within each 
experimental mouse group were compared. Each white rectangle represents a two 
channel microarray interrogating 460 genes known to be expressed in macrophages. 
The Reference sample (naive unelicited peritoneal macrophages) was labelled with 
Cy3 dye (labelled “Ref” in red text) and the experimental samples (from naïve IL-
4Rα-/lox (WT) mice, or N. brasiliensis infected WT, IL-4Rα-/- (KO) and LysMCreIL-
4Rα-/lox (LysM) mice at 5, 42 or 180 days p.i.) were labelled with Cy5 (green text). 
Comparison of the M-values (Log2-transformed Cy5/Cy3 expression ratios) between 
each mouse group generated fold change (FC) values (depicted by yellow arrows). 
Significance (p < 0.05) of differentially expressed genes were identified by a two-
tailed, paired T-test, which compared M-values of duplicate experiments between 
mouse groups . Two independent biological repeat experiments were analysed over 23 
individual arrays (there was only one naïve IL-4Rα-/lox (WT) sample for day180). 
Key: WT: IL-4Rα-/lox, KO: IL-4Rα-/-, LysM: LysMCreIL-4Rα-/lox . 
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2.7. Ex vivo T-cell re-stimulation 
CD4+ T-cells were enriched (> 80% purity) from pooled mediastinal lymph nodes 
(MST LN) at 5 days p.i. using the BioMag bead system (Qiagen). Briefly, MST LN 
were removed aseptically and kept in DMEM on ice. Single-cell suspensions were 
prepared by forcing the tissue through 70 μm nylon cell strainers (BD Biosciences), 
and subjected to red cell lysis. Remaining cells were collected by centrifugation 
(1200rpm, 4ºC, 5 minutes) and stained with anti-CD8 (53.6.72), CD11b (M1/70), GR-
1 (RB68C5), B220 (RA36B2) and the FcγII and III receptors were blocked with anti-
FcγRII/III (2.4G2) antibody (antibody dilutions and details in Appendix B). Stained 
cells were depleted using goat anti-rat-IgG coated BioMag beads (Qiagen). The 
remaining CD4+ T-cells in the supernatant were collected and counted on a Neubauer 
haemocytometer. Sorted CD4+ T-cells were plated at 2x105 cells/well in a 96-well 
plate (Nunc Maxisorb) and re-stimulated with anti-CD3 (20 μg/well) in IMDM 
(containing 10% FCS, 100 U/ml penicillin G, 100 μg/ml streptomycin) and cultured 
for 48 hours at 37ºC in a humidified 5% CO2 incubator. To determine the purity of 
CD4+ cell populations, remaining cells were stained with anti-CD4 Phycoerythrin 
(PE)-conjugated antibodies (Appendix B; procedure similar to above) and analysed on 
a FACS Calibur using CellQuest Pro software. 
 
2.8. Cytokine ELISAs 
Sandwich ELISAs were performed on cell culture supernatants from ex-vivo T-cell 
and lung digest re-stimulations to measure IL-4, IL-13, IFN-γ and IL-10 levels in the 
mediastinal lymph nodes (MST LN) and lungs, respectively. For all solutions and 
ELISA antibody details, refer to Appendix A and D. Briefly, 96-well plates (Nunc 
Maxisorb) were coated with 50 μl capturing antibody (diluted in 1X PBS) and 
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incubated overnight at 4oC. The coated plates were washed four times (between each 
step) in Wash Buffer and subsequently blocked with 200 μl Blocking Buffer 
overnight at 4ºC. Three-fold dilutions of the samples were prepared in Dilution Buffer 
ranging from a 1/3 dilution to a 1/27 dilution, while recombinant standards were 
diluted two-fold from either 100ng/ml or 250ng/ml. After blocking, 50 μl of the 
diluted standards, samples and blanks were added and incubated overnight at 4ºC. For 
each cytokine, 50μl of the corresponding biotinylated anti-mouse detection antibody 
was added and the plates incubated at 37 ºC for 3 hours. 50 μl of streptavidin 
conjugated to horse radish peroxidise (HRP) (1/5000 dilution) was added to the wells 
and incubated at 37 ºC for 1 hour. 50μl of ELISA Substrate Buffer was added and the 
developing reaction was stopped by adding 25μl of 1M H3PO4. The absorbance of the 
samples were measured at 450nm (against its reference measurement at 540nm) on a 
VersaMax microplate reader (Molecular Devices Corporation, Sunnyvale, CA, 
U.S.A).  
 
2.9. Myeloperoxidase (MPO) Assay 
The MPO activity assay, adapted from Remaux et al. (2003) 205 was used as a 
measure of activated neutrophil infiltration within tissues. MPO activity was 
quantified, by measuring its hydrogen peroxide (H2O2) hydrolysis in a colorimetric 
reaction, on individual N. brasiliensis-infected and naïve lung tissue. Perfused (1X 
PBS, 1mM EDTA) individual lungs (upper left lobes) were weighed and placed in 
300 μl MPO Buffer (0.5% hexadecyl trimethyl ammonium bromide (HTAB); 1mM 
EDTA in 1X PBS). The lung tissue was homogenized for 30 seconds, sonicated (20 
pulses, 9 watts, 900 Hz) for 40 seconds using a Sonicator3000 (Misonix Inc., 
Farmingdale, NY, USA) and the resulting homogenate was centrifuged for 10 minutes 
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at 10 000 rpm. The supernatants were collected and stored at -80ºC until analysis. 
Frozen samples in MPO Buffer were thawed to release MPO stored in the azurophilic 
granules of neutrophils, and diluted in MPO Buffer in four three-fold dilutions 
(starting from undiluted sample to 1/27 dilutions). Twelve two-fold serial dilutions of 
horseradish peroxidise (HRP) standards (Sigma-Aldrich, Munich, Germany) in MPO 
Buffer, starting at 0.25 U/ml, were prepared. Sample dilutions and standards were 
added at 50 μl per well in a 96-well plate (Nunc Maxisorb). 50 μl per well of O-
dianisidine (1.25 mg/ml) was added to all wells and the plate was incubated at 35ºC 
for 10 minutes. Immediately thereafter the plate was read at 460 nm to obtain a 
background reading, using a VersaMax microplate reader. 50 μl of freshly made 
0.005% H2O2 was then added to all wells. The plate was monitored for a colorimetric 
reaction (5 minutes), and the reaction was stopped by adding 1% NaN3 at 50 μl/well. 
The final plate reading was then read at 460 nm and subtracted from the background 
OD values. Final MPO activity was calculated from the standard curve (U/ml) and 
divided by the mass of lung tissue in 50 μl to give a final MPO activity expressed as 
units of activity per gram tissue (U/g).  
 
2.10. Eosinophil peroxidase (EPO) Assay 
EPO is an effector molecule secreted by mature eosinophils 14. The colorimetric EPO 
Assay was used to assess activated eosinophil recruitment 206 within the lungs of N. 
brasiliensis-infected mice. Individual lungs (lower left lobes) were perfused (1X PBS, 
1mM EDTA), excised, weighed and placed in 300 μl EPO Buffer (Tris 100mM, 0.1% 
Triton-X100 in 1x PBS). As described in the MPO Assay, the individual lungs were 
homogenized, sonicated, centrifuged (10 minutes at 10 000 rpm) and the supernatants 
collected and stored at -80ºC. The thawed samples were diluted, three-fold, in EPO 
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Buffer and 50 μl added per well to a 96-well plate (Nunc Maxisorb). Similarly, 12 
HRP standards (Sigma-Aldrich, Munich, Germany) were diluted, starting at 0.5 U/ml 
in two-fold serial dilutions, and added 50 μl/well. The plate was incubated at 37ºC and 
a background reading was measured at 490 nm. 50 μl of the substrate solution 
consisting of 16 mM o-phenylenediamine (OPD) (Sigma-Aldrich, Munich, Germany) 
in EPO Buffer containing fresh 0.01 % HRP was added per well to samples and 
standards. The reaction was stopped after 1 minute with the addition of 50 μl 2M 
H2SO4 and absorption was measured at 490nm using a VersaMax microplate reader. 
Final EPO activity readings were calculated, as described in the MPO assay, to give 
Units/gram (U/g) EPO activity. 
 
2.11. Arginase Assay 
Lung cell digests were prepared as stated above (Section 2.5.). Cells were plated out 
at 4x105 cells per well in IMDM (containing 10% FCS, 100 U/ml penicillin G, 100 
μg/ml streptomycin). Culture plates were then incubated at 37 ºC for 72 hours. Using 
a protocol adapted from Pesce et al. (2006) 207 and Corraliza et al. (1994) 208 and 
following stimulation, cells were washed repeatedly with 1X PBS and lysed with 
0.1% TritonX-100. Lysates were incubated with 50 μl of 10 mM MnCl2 and 50 mM 
Tris HCl (pH 7.5) to activate the enzyme for 10 minutes at 55°C. 25 μl of the lysate 
solution was then transferred to 1.5 ml eppendorf tubes with 25 μl 500mM L-Arginine 
(pH 9.7) and incubated for 1 hour at 37ºC. The reaction was then stopped using 400 μl 
of acid mixture (H2SO4:H3PO4:H2O at a ratio of 1:3:7). Thereafter, the colorimetric 
reaction was initialised by adding 25ul of 9% α-Isonitrosopropiophenone (ISPF) and 
incubated at 100ºC for 45 minutes, followed by 10 minutes in the dark (at room 
temperature). 200 μl aliquots were added and serially diluted, three-fold, in ddH2O on 
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a 96-well plate (Nunc Maxisorb) and read at 540 nm on a VersaMax microplate 
reader. Controls had ddH2O instead of L-Arginine and blanks had ddH2O added 
instead of cell lysates. Standards consisting of doubling dilutions of 1000 μg/ml urea 
were treated under identical assay conditions. Arginase activity was calculated from 
the standard curve using urea concentrations (μg/ml). 
 
2.12. Nitric oxide (NO) measurements 
Cell culture supernatants from re-stimulated lungs were analysed for the production of 
gaseous NO using the Griess reaction assay, which measures the concentration of 
nitrite, a stable liquid product from the reaction of NO with O2 209. Supernatant 
samples of re-stimulated lung cells were collected after 72 hours of incubation at 37ºC 
and stored at –20ºC until analysis. Supernatant sam les were serially diluted three-
fold and standards (1mM NaNO2 solution) were serially diluted two-fold in IMDM 
(supplemented with 10% FCS, 100 U/ml penicillin G, 100 μg/ml streptomycin) in a 
total volume of 50 μl per well in a flat bottomed 96-well plate (Nunc Maxisorb). 25 μl 
of Griess Reagent 1 (1% sulfanilamide in 2.5% phosphoric acid) and then 25 μl of 
Griess Reagent 2 (0.1% napthyl-ethylene-diamine in 2.5 % phosphoric acid) were 
sequentially added to each well. The plate was incubated at room temperature for 5 
minutes to allow the reaction to develop. The colorimetric reactions were read at 540 
nm and the reference wavelength at 690 nm using a VersaMax microplate reader. The 
absorbance reading of the samples (in OD units) was correlated to the nitrite 
concentration (in mM) as calculated by the standard curve.  
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2.13. Statistical analysis 
For each experiment, statistical analysis of the mouse groups were compared to WT 
controls (IL-4Rα-/lox), using either the Student’s t-test or One-way ANOVA followed 
by the Bonferroni post-test. All graphical representations showed means with error 
bars representing the standard error of the mean (SEM). A p < 0.05 was considered 
significant ( * ), and values of p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****) were 
used to emphasise increasing values of significance. Numbers of experiments are 
indicated in the figure legends.  
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3. RESULTS – Chapter 3.1: Lung Pathology 
 
 
IL-4Rα−responsive macrophages/neutrophils provide protection against the 
onset of N. brasiliensis-induced chronic lung pathology 
 
3.1.1 Introduction 
 
Previous studies have clearly demonstrated that N. brasiliensis infection causes acute 
lung pathology 1, 2, 4, 109, which then develops into a chronic inflammatory and 
emphysemic-like disease 1, 2. IL-4Rα signalling plays a key role in the resolution of N. 
brasiliensis infections 4, 60, 61 and development of host pathology associated with 
infection4, 5. In this chapter, we focused on how N. brasiliensis infection impacts on 
the associated lung pathology during acute (day 5 p.i.) and chronic (day 42 and 180 
p.i.) pulmonary pathology.  
 
During acute lung pathology associated with N. brasiliensis infection, animals 
develop an allergy-like pathology due to the excretory and secretory products (NES) 
of the parasite which alone can cause asthmatic pathology 2, 3, 109. This is characterised 
by increased airway hyperresponsiveness (AHR) and infiltration of predominantly 
mononuclear inflammatory cells to the peribronchial region of the lung 1, 109. 
Additionally, the infected animal develops considerable airway goblet cell hyperplasia 
and mucus production 4, 116, similar to those seen in experimental murine models of 
allergy such as the ovalbumin-induced allergic airway inflammation model 3, 210, 211. In 
both N. brasiliensis-induced acute lung pathology and ovalbumin-induced asthmatic 
disease, the pathology is reduced in mice deficient in IL-4Rα responsiveness 4, 151. 
Furthermore, this pathology is typically related to signalling of IL-13, and to a lesser 
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extent IL-4, which signal via their respective heterodimeric receptors containing IL-
4Rα 6, 16, 212, 213.  
 
In the case of N. brasiliensis-induced chronic lung pathology far less is understood of 
how it is induced and whether IL-4Rα plays a direct role. Indeed, a recent study 
indicated that IL-4Rα does not influence the development of emphysema in mice 1. In 
general, few studies of chronic lung pathology have addressed the influence of TH2-
driven immunity in inducing chronic lung pathology. In models of chronic lung 
inflammation, such as Sendai Virus (SeV) infection which is an influenza model 145 
and murine models of spontaneous emphysema 18, Type 2 responses have been 
associated with driving chronic pulmonary diseases. In SeV it has been demonstrated 
that chronic IL-13 signalling and the induction of alternatively activated macrophage 
(AAM) populations in the lung play an important role in driving the onset of COPD 
145. Furthermore, it has been reported that increases in either IL-13 121 or IFN-γ 143 
levels in the lung can induce metalloproteinase-dependent emphysema 119. These 
studies indicate that the onset of chronic lung pathology can be either Type 1- or Type 
2-driven host responses. The specific mechanisms underlying these two potential 
immunological factors of pulmonary inflammatory diseases have yet to be explained.  
 
From these previous studies it is apparent that the understanding of how chronic lung 
pathology develops in an infection model is fragmented 119. Previous studies have 
indicated that alternatively activated macrophages (AAM), or M2 monocytes, appear 
to influence the onset of a range of chronic lung pathology 1, 7, 59, 166, 167, 214. In the data 
presented here, we determined whether IL-4Rα responsiveness by macrophages plays 
a role in the onset of N. brasiliensis-induced chronic lung disease.  
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In order to investigate this question, infectious studies were conducted on IL-4Rα-/lox, 
IL-4Rα-/- and LysMCreIL-4Rα-/lox mice at days 5, 42 and 180 p.i. and compared to 
naïve IL-4Rα-/lox control mice. At the defined time points we carried out detailed 
pathological studies on the lungs of these mice.  
Specifically, lung pathology was addressed by assessing the following: 
• Inflammation: Classification of lymphocytic inflammation is subdivided into 
severity (quantitative), location (perivascular or peribronchial), early (polar) or 
late (concentric) and acute or chronic (defined by the predominance of 
neutrophilic or plasma cell infiltrates, respectively). For example, “early 
moderate perivascular chronic pulmonary inflammation” describes moderate 
levels of inflammation associated with blood vessels i.e. small numbers of 
immune cells, which are predominantly plasma cells, and surrounding blood 
vessels.  
 
• Alveolar dilatation (or distended alveoli, alveolar septa loss, septal disruption 
or dilatation of distal airspaces): This describes the destruction of alveolar air 
sacs, due to mechanical damage, resulting in enlarged “spaces” in the lung. 
This is the classical histological marker of emphysema morphology.  
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3.1.2 Results: 
3.1.2.1 N. brasiliensis infection induces airway hyperresponsiveness (AHR) 
independently of IL-4Rα-responsiveness. 
 
In order to confirm the development of chronic lung pathology following N. 
brasiliensis infection, AHR was assessed in infected mice at defined points following 
infection. AHR is associated with asthma 210, 215, COPD 130 and emphysema 1, 130. 
Therefore, should AHR increase over time in previously infected animals (irrespective 
of exposure to a contractile stimulant), it is indicative of the development of a chronic 
and irreversible lung pathology 1. AHR was determined as PenH values by whole 
body plethysmography and was measured in IL-4Rα-/lox, IL-4Rα-/- and LysMCreIL-
4Rα-/lox N. brasiliensis-infected mice and also uninfected control IL-4Rα-/lox mice. At 
days 5, 42 and 180 p.i., mice were exposed to the aerosolised airway stimulant β-
metacholine (MCh) (10 mg/ml) or PBS (stimulant control).  
 
As expected, naïve IL-4Rα-/lox mice (“Day 0”) showed no increase (p > 0.05) in 
airway hyperresponsiveness (PenH values) when challenged with β-metacholine 
(“+MCh”), compared to unstimulated lungs (“- MCh”; PBS controls). Similarly, there 
was no change (p > 0.05) in PenH values between MCh-challenged mouse groups 
when compared to PBS-challenged groups at all time points post infection (Figure 8). 
Additionally, no difference in PenH values was observed between mouse groups at 
any time point. However, importantly, a positive correlation in increased PenH values 
compared to time post infection was found in all mouse groups irrespective of MCh 
challenge. Together, these results showed that N. brasiliensis infection induces AHR 
in an IL-4Rα independent manner.  
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Figure 8: Increase in AHR baseline levels indicate chronic and irreversible lung 
pathology in N. brasiliensis-infected mice. AHR measurements of naïve (“Day 0”), 
and infected mice with N. brasiliensis at 5, 42 and 180 days p.i. AHR was measured 
using Metacholine (MCh) (10 mg/ml) and a whole body, unrestrained chambered 
plethysmograph. Enhanced pause (PenH) were averages of the first 5 minutes 
(normalised against individual baseline readings) after aerosol MCh challenge; n = 5 
mice per group (and the same mice were used for each time point); Data is 
representative of 4 experiments.  
 
 
3.1.2.2 N. brasiliensis-induced acute and chronic pulmonary pathology is increased 
in mice deficient for IL-4Rα-responsive macrophages and neutrophils 
 
In order to define the nature of N. brasiliensis-induced lung pathology indicated by 
the increase in AHR, detailed pathological analyses were carried out. Lungs from 
infected IL-4Rα-/lox and IL-4Rα-/- mice showed similar or equivalent levels both in 
alveolar dilatation and inflammation at all time points analysed (Figure 9A, 10 & 
Table 3). Emphysemic-associated alveolar dilatation in lungs from IL-4Rα-/lox and IL-
4Rα-/- mice increased from mild (day 5) to moderate by day 42 p.i. and remained 
chronically moderate throughout the study (Figure 10A). In contrast, in infected 
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LysMCreIL-4Rα-/lox mice, alveolar dilatation in lungs was significantly increased (p < 
0.05) compared to IL-4Rα-/lox (and IL-4Rα-/-) mice by day 5 p.i. before it developed to 
a similar and persistent alveolar dilatation (or emphysemic-like pathology) compared 
to the other mouse strains (Figure 10A & Table 3).  
 
Inflammation severity was similar between lungs from IL-4Rα-/lox and IL-4Rα-/- mice 
at all time points analysed (Figure 9A, 10B & Table 3). At 5 days p.i., littermate 
controls (IL-4Rα-/lox) and IL-4Rα-/- mice displayed an obvious mild pulmonary 
inflammatory response, which decreased during the course of the study, with minimal 
and diminished pulmonary inflammation evident at 180 days p.i. In contrast, the 
inflammation scores were consistently and significantly increased (p < 0.05 and p < 
0.0001) in LysMCreIL-4Rα-/lox mice, compared to both IL-4Rα-/lox and IL-4Rα-/- mice 
at all time points analysed (3). At day 42p.i., a strong and severe inflammatory disease 
phenotype was evident in LysMCreIL-4Rα-/lox lungs, which reduced significantly at 
180 days p.i., but was still increased when compared to IL-4Rα-/lox and IL-4Rα-/- 
lungs at day 180p.i. (Figure 9A, 10B & Table 3).  
 
Microscopic analysis of the lung infiltrating cell populations showed additional 
differences between the infected mouse groups. In IL-4Rα-/lox mice the infiltrate was 
granulocytic while in IL-4Rα-/- mice this granulocyte population was absent (Figure 
9A, yellow arrows; Table 3). In LysMCreIL-4Rα-/lox mice the sites of inflammation in 
the lungs showed an increased granulocytic infiltration at day 5 p.i. when compared to 
IL-4Rα-/lox mice. By day 42 p.i., IL-4Rα-/lox and LysMCreIL-4Rα-/lox mouse groups 
showed equivalent levels of granulocytes. It should be noted that in all mouse groups, 
a reduction in granulocytes was apparent over time at the sites of inflammation, 
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concomitant with an increase in lymphocytes. The inflammation observed at days 5 
and 42 in IL-4Rα-/lox and LysMCreIL-4Rα-/lox lungs were therefore classified as “acute 
inflammation” due to a predominantly neutrophilic infiltrate. By 180 days p.i., lung 
inflammation in both IL-4Rα-/lox and LysMCreIL-4Rα-/lox mice was classified as 
“chronic inflammation” due to the predominance of lymphocytes and plasma cells 
present. Interestingly, in IL-4Rα-/- mice, the observed cellular composition of the lung 
inflammation at day 5 p.i. was similar to day 42 and 180 days p.i. The inflammation 
was therefore classified as “chronic inflammation” due to the predominant 
lymphocytic and plasma cell infiltrate in IL-4Rα-/- mice at all time points in the study.  
 
In agreement with previous studies 1, signs of haemorrhaging, characteristic of 
hemosiderin-laden macrophages (brown in appearance as a result of hemosiderin 
deposition from the phagocytosis of erythrocytes and digestion of haemoglobin), were 
prominent throughout the study. Furthermore, there seemed to be no spatial or 
quantity differences between the mouse groups studied (data not shown). Signs of 
pulmonary pathology such as alveolar dilatation, peribronchial and perivascular 
inflammation, haemorrhaging and AHR, persisted in the chronic stages (day 180 p.i.) 
in all three mouse groups, even after the parasite had been expelled. This is indicative 
that N. brasiliensis infection could initiate chronic damage to the lung and this is in 
agreement with previous reports 1, 2. The pathological evidence of perivascular and 
peribronchial inflammation, alveolar dilatation and the presence of hemosiderin-laden 
macrophages, could be explained by worm migration during its life cycle.  
 
In summary, all three mouse groups showed perivascular and peribronchial 
inflammation, which was composed primarily of lymphocytes. While pulmonary 
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inflammation was diminished in all three groups at 180 days p.i., the emphysemic-like 
pathology (alveolar dilatation) and hemosiderin-laden macrophages evidence of 
haemorrhaging persisted. However, infected LysMCreIL-4Rα-/lox mice developed 
increased early (day 5 p.i.) alveolar dilatation and increased pulmonary inflammation 
at all time points analysed, when compared to IL-4Rα-/lox and IL-4Rα-/- infected mice.  
 
 
 
Figure 9: N. brasiliensis-infected LysMCreIL-4Rα-/lox mice demonstrate increased 
pulmonary inflammation. H&E sections of (A) N. brasiliensis–infected lungs of IL-
4Rα-/-, LysMCreIL-4Rα-/lox and littermate controls (IL-4Rα-/lox) at 5, 42 and 180 days 
p.i. and (B) naïve littermate control histological sections. First panels: 40x 
Magnification; second panels 400x magnification. n = 8-20 mice per group, from 2 to 
5 experiments per time point.  
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Table 3: Summary and scores of pulmonary histopathology induced by N. 
brasiliensis. 
 
 
 
 
 
 
 
 
 
Figure 10: N. brasiliensis-infected LysMCreIL-4Rα-/lox mice demonstrate earlier 
and increased pulmonary pathology. Relative histological evaluation scores of (A) 
alveolar dilatation and (B) inflammation lung pathology on individual N. brasiliensis–
infected lungs of IL-4Rα-/-, LysMCreIL-4Rα-/lox and littermate controls (IL-4Rα-/lox) at 
5, 42 and 180 days p.i. Histological sections (H&E) from all lobes of individual 
mouse lungs were evaluated and graded (0 to 3) with a registered Pathologist (Prof. 
Govender) using a relative histopathological score as defined in Materials and 
Methods (modified from Radosevic et al. 2007) 195. n = 8-20 mice per group from 2 to 
5 experiments per time point. * p < 0.05 ; **** p < 0.0001.  
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3.1.3 Discussion  
 
In this study we showed that macrophage/neutrophil-specific IL-4Rα deficient mice 
develop consistently increased pulmonary cellular inflammation following N. 
brasiliensis infection when compared to control mice. We further confirmed previous 
results that N. brasiliensis infection leads to the development of emphysema, which is 
independent of IL-4Rα-responsiveness 1. 
 
The recent findings by Marsland and colleagues (2008)1 were the first to show that N. 
brasiliensis-infected mice develop lung emphysema. They also demonstrated that IL-
4Rα does not play a role in N. brasiliensis-induced emphysema, which was also 
confirmed in our study since we found no differences between all three groups in 
AHR and in alveolar dilatation manifestation during the chronic stages (day 42 and 
180 p.i.) following N. brasiliensis infection.  
 
Although not apparent in the AHR, the increased alveolar dilatation in LysMCreIL-
4Rα-/lox mice at day 5 p.i. may represent an earlier commitment to the manifestation 
of emphysema, which may indicate that IL-4Rα-responsive macrophages and/or 
neutrophils may contribute to prevent destruction of alveolar septa in the early stages 
of disease manifestation. Our observation of the rapid induction (day 5 p.i.) of 
alveolar dilatation in the lungs of LysMCreIL-4Rα-/lox mice may be explained by: (i) a 
reduced ability in a population of cells (i.e. AAM) capable of repairing N. 
brasiliensis–induced mechanical damage to the lung 1; or (ii) increased levels of IL-13 
which is associated with metalloproteinase-dependent emphysema121 and COPD 
induced by SeV infections 145; and/or (iii) the increased phagocytosis of denatured 
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collagen by alveolar macrophages, which further disrupts alveolar wall integrity, 
resulting in alveolar dilatation 216. Indeed, increased IL-13 (and IL-4) production 105, 
following N. brasiliensis infection has been shown to be induced by innate NK T-cells 
145, which activate macrophages in the lung to become AAMs 165. These AAMs are 
able to secrete metalloproteinases 1, 2, and are responsible for collagen and 
extracellular matrix degradation in the lung 144. Secretion of metalloproteinases and 
simultaneous phagocytosis of degraded collagen potentially causes disruption of 
alveolar septa (or alveolar dilatation), a sign of emphysema 216. To better define a 
possible involvement of AAM in the onset of emphysema, further studies are needed 
to investigate protease and protease inhibitors and other factors involved in 
emphysema development 119, 140 in relation to IL-4Rα-responsive macrophages. 
Additional future work could include that the lungs across all mice groups be fixed 
with formalin at a constant pressure to achieve maximum accuracy in alveolar 
dilatation analysis.  
 
Pathological analysis indicated that IL-4Rα-responsive macrophages and/or 
neutrophils are able to down-regulate N. brasiliensis-induced lung inflammation. The 
involvement of IL-4Rα-responsive AAMs in the down-regulation of inflammation 
has been previously demonstrated in S. mansoni–induced pathology, while neutrophils 
did not play a role in reducing this pathology 59, 72. However, a contribution by IL-
4Rα-responsive neutrophils cannot be excluded, as it is not yet distinguishable 
whether IL-4Rα-responsive macrophages or neutrophils are involved in the pathology 
demonstrated here. The underlying cellular interactions that define this regulation of 
inflammation and subsequent protection are only now starting to be unravelled. 
Importantly, AAMs are strongly associated with controlling pathological levels of 
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inflammation by modulating T-cell behaviour 7, 178. Possibly the most similar 
demonstration of this to date is the widely reported suppression of T-cell proliferation 
by AAM populations 7, 72, 170, 178, 217. From our histological data it could be suggested 
that such an interaction also occurred in this study. We suggest that the reduced 
inflammation in IL-4Rα-/lox mice when compared to LysMCreIL-4Rα-/lox mice is due to 
the generation of AAM populations controlling the proliferation of pathogenic 
lymphocytic infiltrates. IL-4Rα-/- mice do not produce AAMs either 163, yet have 
similar levels of inflammation compared to IL-4Rα-/lox mice. These equivalent levels 
of inflammation seen between IL-4Rα-/- and IL-4Rα-/lox mice could be as a result of 
the previously reported disrupted recruitment of lymphocytes t  the lung in IL-4Rα-/- 
mice 4. However, in LysMCreIL-4Rα-/lox mice this potentially pathological increase in 
lymphocyte populations in the lung is unable to be controlled by AAM. To ensure that 
the there are no differences in the number of N. brasiliensis worms migrating through 
the lung and therefore potentially affecting lung damage and subsequent differences in 
inflammation, future studies could include assessing the worm burden in the lung at 0, 
12, 24 and 48 hours p.i. 
 
To further investigate the role of immunological relevant cells in the onset of early 
pulmonary inflammation, which could be a potential cause for the development of 
increased and chronic inflammation in LysMCreIL-4Rα-/lox mice, a detailed analysis of 
the lung was performed at day 5 p.i., presented in the following chapter.  
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3. RESULTS – Chapter 3.2: Immunology 
 
Analysis of acute immune responses in N. brasiliensis-infected LysMCreIL-4Rα-/lox 
lungs that underlie the rapid onset of chronic lung inflammation 
 
3.2.1 Introduction 
 
In the previous chapter (3.1), we established that mice impaired for IL-4Rα-
responsiveness by macrophages and neutrophils (LysMCreIL-4Rα-/lox) rapidly 
developed enhanced lung inflammation when compared to controls. In this chapter we 
investigated the potential underlying immune mechanisms that may cause this rapid 
onset of inflammation. This aspect of the current study will focus on the development 
of the immune response at day 5 p.i., where the earlier onset in pathology was 
apparent in N. brasiliensis-infected LysMCreIL-4Rα-/lox mice. 
 
It is known that N. brasiliensis induces immunological changes in the lung upon 
infection. These changes are associated with high levels of TH2 cytokines and Type 2 
antibody production 97, as well as recruitment to the lung of T-cells 4, eosinophils 218 
and basophils 92. Macrophage populations are also greatly increased and typically of 
the alternatively activated phenotype 97, 105. The TH2 cytokine response is 
characterised primarily by the production of IL-4 and IL-13, in addition to other 
cytokines such as IL-5, IL-9 and IL-10 219. In chronic pulmonary pathology, IL-13 is 
the TH2 cytokine most commonly associated with the onset of pulmonary diseases 
such as asthma 212, fibrosis 50 and COPD 145, including emphysema 121. Important 
cellular sources of IL-13 include T-cells, eosinophils, basophils and macrophages, all 
of which are recognised as playing important roles in chronic lung pathology 14, 97, 137, 
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145, 153, 212, 220. These early IL-13 responses, along with T-cell-antigen presenting cell 
(APC) interactions, can drive T-cell associated chronic lung inflammation. 221.   
 
In our study, microscopic analysis revealed lymphocytic, granulocytic and 
macrophage infiltrates in the lungs of N. brasiliensis-infected mice (Chapter 3.1). In 
this chapter we examined these immune cell populations and markers of their activity 
in the lungs of mice at day 5 p.i. to determine why LysMCreIL-4Rα-/lox mice exhibit 
such a rapid and early onset of chronic lung inflammation when compared to 
littermate controls during N. brasiliensis infection. 
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3.2.2 Results: 
 
3.2.2.1 Acute pulmonary inflammation in infected LysMCreIL-4Rα-/lox mice is 
associated with increased T-cell numbers and TH2 cytokine responses. 
 
To examine whether the increased inflammatory phenotype in LysMCreIL-4Rα-/lox 
mice at day 5 p.i. could be explained by increased numbers of lymphocytes in the 
lung, the cellular composition of the lungs were analysed by flow cytometry from 
single-cell suspensions of lung digests in both infected and naïve mice at day 5 p.i.  
 
Quantification by flow cytometry of T-cell populations in the lung, including CD3+, 
CD3+CD4+ and CD3+CD8+ cells, showed that infected IL-4Rα-/lox and IL-4Rα-/- mice, 
cell numbers at 5 days p.i. remained similar to those found in naïve mice (Figure 
11A, B & C). Interestingly, LysMCreIL-4Rα-/lox mice showed significant increases in 
the absolute and relative numbers of CD3+ T-cell populations when compared to the 
other mouse strains (Figure 11A). This was predominantly due to CD4+ T-cells, as 
they exceeded approximately twice the number of CD8+ T-cells (Figure 11B & C).  
 
To ascertain whether cytokines were playing a role in the initiation and progression of 
inflammation, the TH2 cytokines, IL-4 and IL-13, the Th1 cytokine, IFN-γ, and the 
immunoregulatory cytokine IL-10, were measured in vitro after anti-CD3 re-
stimulation of collagenase-treated cells from lungs isolated from mice at day 5 p.i. Re-
stimulated collagenase-treated cells from infected lungs of IL-4Rα-/lox mice showed 
increased IL-10, IL-4 and IL-13 secretion, when compared to naïve lung cell 
preparations (Figure 11D). As expected, IL-4Rα-/- lung cell suspensions had reduced 
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IL-4 production, but increased IFN-γ production when compared to re-stimulated IL-
4Rα-/lox lung cell suspensions. However, lung cell suspensions from LysMCreIL-4Rα-
/lox and IL-4Rα-/lox mice produced similar levels of IFN-γ compared to cells from naïve 
mice. Interestingly, LysMCreIL-4Rα-/lox lung cell suspensions produced higher levels 
of IL-4, IL-13 and IL-10 compared to IL-4Rα-/lox and IL-4Rα-/- re-stimulated lung cell 
suspensions (Figure 11D).  
 
Indeed, IL-4 and IL-13 measurements after anti-CD3 re-stimulation from isolated 
CD4+ T-cells of the draining mediastinal (MST) lymph nodes (LN), showed that a 
TH2 response evident in control mice was increased in LysMCreIL-4Rα-/lox mice, but 
abrogated in IL-4Rα-/- mice (Figure 11E).  
 
Quantification of B220+ B lymphocytes showed that there were no significant 
differences between B-cell numbers in naïve and infected mice at 5 days p.i. (Figure 
11F).  
 
Together, these results show increased pulmonary TH2 cell and cytokine responses in 
N. brasiliensis-infected LysMCreIL-4Rα-/lox mice at 5 days p.i. 
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Figure 11: T and B lymphocyte populations and cytokine production in lungs of 
IL-4Rα-/lox, IL-4Rα-/- and LysMCreIL-4Rα-/lox N. brasiliensis-infected mice. (A) 
CD3+, (B) CD3+CD4+ and (C) CD3+CD8+ T-cell numbers and percentages, analysed 
by flow cytometry; and anti-CD3 re-stimulated (D) IL-4, IL-13, IFN-y and IL-10 
levels in collagenase-treated lung cell suspensions from individual naïve and infected 
mice. (E) Anti-CD3 re-stimulated cytokine production of CD4+ cells (> 80% purity) 
from pooled mediastinal (MST) lymph nodes. (F) B220+ B cell numbers and 
percentages from naïve and N. brasiliensis-infected lungs. All data is at 5 days p.i. (n 
= 5 mice per group). Data represents individual mice from one experiment, except 
data for MST cytokines (E) which were from pooled lymph nodes and representative 
of 3 experiments. Det. Lim.: Detection limit of assay. NS: not significant. * p < 0.05, 
** p < 0.01, *** p < 0.001 (compared to IL-4Rα-/lox █ ). 
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3.2.2.2 Normal granulocyte infiltration and activation in LysMCreIL-4Rα-/lox mice  
 
The granulocyte populations during N. brasiliensis infections consist predominantly 
of neutrophils and eosinophils, both of which can release strong cytotoxic proteins 
such as myeloperoxidase (MPO) 222 and eosinophil peroxidise (EPO) 14, respectively. 
Neutrophils, which were defined in previous studies as GR-1+CCR3- and eosinophils 
(GR-1intCCR3+) 223, were analysed by flow cytometry and by the MPO and EPO 
assays respectively, to ascertain whether the phenotypic pulmonary inflammation seen 
in LysMCreIL-4Rα-/lox mice was associated with changes in granulocyte infiltration 
and function.  
 
Granulocyte numbers were increased in the lung at day 5 p.i. in all mouse groups 
(Figure 12 A). This granulocyte population consisted predominantly of GR-1+CCR3- 
neutrophils with no significant differences in numbers between experimental groups 
(Figure 12 B(i)). However analysis of the neutrophil activation and maturation status 
by MPO assay showed significantly increased MPO levels from IL-4Rα-/lox and 
LysMCreIL-4Rα-/lox lungs, but not from IL-4Rα-/- lungs when compared to naïve 
controls (Figure 12 B(ii)).  
 
The number of eosinophils was low in lungs at 5 days p.i. (Figure 12 C(i)). 
Eosinophil infiltration (Figure 12 C(i)) and activity, measured by EPO levels (Figure 
12 C(ii)), was not seen at day 5 p.i in any mouse groups.  
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Figure 12: The effects of IL4Rα signalling on granulocyte infiltration and 
activity in N. brasiliensis-infected lungs. Flow cytometry was analysed on whole 
lung single-cell digests and calculated against total cell counts to give percentages and 
cell numbers of (A) granulocytes (B) neutrophils (GR-1+,CCR3-) and (C) Eosinophils 
(GR-1int,CCR3+) in the lung. MPO (B (ii)) and EPO (C (ii)) were measured as 
markers of activated neutrophils and eosinophils, respectively, in naïve and N. 
brasiliensis-infected lungs at 5 days p.i. (n = 4-5 mice per group). Data represents 
individual mice from one experiment. Det. Lim.: Detection limit of assay. * p < 0.05; 
** p < 0.01; *** p < 0.001 (compared with IL-4Rα-/lox █ ).  
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3.2.2.3 IL-4Rα-responsiveness affects alveolar macrophage activation 
 
Resident macrophage populations, or alveolar macrophages, are constitutively found 
in the lung and are the first cells to encounter inhaled pathogens and particles 
involved in lung diseases 196, 224. Alveolar macrophages are increased in acute stages 
of N. brasiliensis infections 87 and are chronically present in COPD 123.  
 
In order to identify any changes in alveolar macrophage populations following N. 
brasiliensis infection, these populations were defined as autofluorescent 
CD11c+MHCIILo SSCHI cells 196 and quantified from single-cell suspensions of lung 
digests by flow cytometry. These alveolar macrophages were significantly increased 
in number in all mouse groups at 5 days p.i. when compared to naïve controls (Figure 
13A), and the cell number percentages from IL-4Rα-/lox and LysMCreIL-4Rα-/lox mice 
were significantly elevated compared to IL-4Rα-/- mice (Figure 13A).  
 
Nitric oxide synthase-2 (NOS2) and arginase activity in single-cell suspensions of 
lung digests were assessed as biomarkers for classical or alternatively activated 
macrophages, respectively. Nitric oxide (NO) or NOS2 activity, measured as nitrite 
levels, was below detection limit levels in all mouse groups (Figure 13B). In contrast, 
arginase activity, measured as urea production, was significantly increased in infected 
IL-4Rα-/lox lung cells compared to naïve and the infected mouse groups (Figure 13C). 
However IL-4Rα-/- and LysMCreIL-4Rα-/lox arginase activity was significantly 
decreased compared to IL-4Rα-/lox levels.  
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
76 
Together, these data show normal pulmonary granulocyte infiltration and activation in 
LysMCreIL-4Rα-/lox mice, while IL-4Rα-/lox control mice may have a predominant 
alternative activation of alveolar macrophages, following in N. brasiliensis infection.  
 
 
 
 
Figure 13: IL-4Rα effects on alveolar macrophage recruitment and function. (A) 
Numbers and percentages of alveolar macrophages (autofluorescent SSCHI CD11c+) 
in the lung. (B) Nitric oxide (NO) levels and (C) Arginase activity measurements in 
naïve and N. brasiliensis-infected lungs at 5 days p.i. (n = 4-5 mice per group). Data 
represents individual mice from one experiment. Det. Lim.: Detection limit of assay.  
* p < 0.05, ** p < 0.01, *** p < 0.001 (compared with IL-4Rα-/lox  █ ).  
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3.2.3 Discussion:  
 
In this chapter, we further investigated the underlying causes of the increased 
inflammation observed in N. brasiliensis-infected lungs of LysMCreIL-4Rα-/lox mice at 
5 days p.i. (Chapter 3.1). At this early time point, we observed increased pulmonary 
T-cell numbers in LysMCreIL-4Rα-/lox mice, with an associated heightened response in 
TH2 cytokine production of IL-4 and IL-13 and elevated levels of IL-10. The cellular 
composition of the increased inflammation seen previously in LysMCreIL-4Rα-/lox 
mice (Chapter 3.1) was not associated with B-cell, neutrophil, eosinophil and 
macrophage cell numbers, since these cell populations were unaltered in the lungs of 
infected mice. Neutrophil and eosinophil activation was also unaffected in LysMCreIL-
4Rα-/lox lungs, as determined by MPO and EPO assays respectively. Additionally, 
although there were no overall differences in macrophage cell numbers between 
infected groups, IL-4Rα-/- and LysMCreIL-4Rα-/lox mice showed reduced arginase 
activity compared to IL-4Rα-/lox collagenase-treated lung cell suspensions.  
 
Flow cytometry was used to quantify the cellular compositions of lung inflammation. 
Although analysis of bronchoalveolar lavage (BAL) fluid is an alternative method, the 
evaluation of cell numbers in the inflamed lung by flow cytometry is a more accurate 
method, as concluded by previous reports 7, 223. Additionally, the BAL method 
excludes inflammatory cells associated with peri-vascular inflammation, while flow 
cytometry quantifies cells in both peribronchial and peri-vascular inflammation, 
which were both present in N. brasiliensis-induced pulmonary immuno-pathology as 
observed by our histological examinations (Chapter 3.1).  
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A previous study by Mearns and colleagues (2008) 4, showed increased numbers of 
CD4+ T-cells in the lungs of IL-4Rα-/lox and IL-4Rα-/- N. brasiliensis-infected mice at 
7 days p.i.. We found at 5 days p.i. significantly increased numbers of CD4+ and 
CD8+ T-cells, only in the lungs of LysMCreIL-4Rα-/lox mice. Since IL-4 can induce 
CD8+ T-cell proliferation 225, it is not clear at this stage whether the increase in CD8+ 
T-cells is a pathological response or whether it is merely a consequence of 
exaggerated levels of IL-4 in infected LysMCreIL-4Rα-/lox lungs. Previous studies have 
shown, particularly in asthma (CD4+) 150 and COPD (CD8+) 152, that increases in the 
populations of pulmonary T-cell populations correlate strongly with the onset of 
inflammation. Our data indicates this may also be the case in the N. brasiliensis-
infected lung and that this significant increase in CD4+ T-cell numbers may underlie 
the early onset of TH2-driven pulmonary inflammation in LysMCreIL-4Rα-/lox mice. 
 
It has been previously shown that CD4+ T-cells in the lung are responsible for the 
induction of TH2 cytokines, particularly IL-4 and IL-13, during N. brasiliensis 
infection4. Analysis of cytokine responses in re-stimulated lung cells in our study, 
showed that the early onset of chronic inflammatory pathology at day 5 p.i. was 
associated with increased IL-4, IL-13 and IL-10 production by anti-CD3 stimulated 
LysMCreIL-4Rα-/lox cells when compared to infected mouse groups. IL-13 is a 
cytokine involved in allergic pulmonary inflammation and several other pathological 
outcomes 16, 212, 226, 227. In contrast, IL-10 is commonly referred to as an anti-
inflammatory cytokine and is produced by T-cell and non-T-cell populations 228-230. 
However, under long-term exposure, IL-10 can induce T and B lymphocyte 
inflammation in the lung 231. Therefore, both IL-13 and IL-10 could play a potentially 
vital role in N. brasiliensis-induced chronic lung pathology. For example, the 
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observed increased IL-4 and IL-13 production from MST CD4+ T-cells may play a 
role in the induction of TH2 inflammation in the lungs of infected LysMCreIL-4Rα-/lox 
mice 4. In contrast, the increased IL-10 production could be induced in the infected 
lung in an attempt to counteract and down-modulate the accelerated and increased 
inflammatory responses present in infected LysMCreIL-4Rα-/lox lungs at 5 days p.i. 229, 
231. In support of this, it has been reported that elevated IL-10 levels were associated 
with increased inflammation in LysMCreIL-4Rα-/lox mice during S. mansoni infection, 
and that increased IL-10 levels could not substitute for IL-4Rα-responsive 
macrophages in the role of down-modulating inflammation, as seen in our study 59. 
Although the histological studies show that the pulmonary inflammation in 
LysMCreIL-4Rα-/lox mice does eventually decrease at 180 days p.i. to a mild 
inflammation level similar to the other infected grou s, it is not clear how or if IL-10 
is playing a direct role. Hence, further in vivo studies by IL-10 
neutralisation/supplementation or studies with IL-10 transgenic mice might help to 
uncover the role of IL-10 following N. brasiliensis infections.  
 
Eosinophil cell number and activation by EPO was unaltered compared to naïve mice 
in all infected mouse groups. While MPO quantifications confirmed histological 
evaluations (Chapter 3.1) that shared low granulocyte numbers at the sites of 
inflammation in the lungs of IL-4Rα-/- mice, the neutrophil quantification by flow 
cytometry did not agree with this data. A possible explanation for this may be that 
microscopic evaluations are based on an activated neutrophilic criteria, while the flow 
cytometry data presented here encompasses not only activated, but also non-activated 
progenitor cells (GR-1+CCR3-) 223, as there were no significant differences in the 
amounts of inflammation between IL-4Rα-/- mice and IL-4Rα-/lox control mice. 
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Additionally, while EPO activity is specific to eosinophils, sources other than 
neutrophils have been described for MPO, including monocytes 222, 232 and vascular 
non-haematopoietic cells 233.  
 
Importantly, neutrophil activation and recruitment in LysMCreIL-4Rα-/lox lungs was 
not affected, despite disrupted neutrophil (and macrophage) IL-4Rα expression. This 
may suggest that neutrophil recruitment is dependent on IL-4Rα signalling by cells 
other than neutrophils and macrophages. Furthermore, this study suggests that it is 
unlikely that IL-4Rα-responsive neutrophils play a role in controlling N. brasiliensis-
induced pulmonary immuno-pathology. Instead, IL-4Rα-responsive macrophages 
seem to play a central role in controlling the increased pulmonary pathology in 
LysMCreIL-4Rα-/lox mice (Chapter 3.1), as demonstrated in other helminth studies 59.  
 
AAMs are impaired in LysMCreIL-4Rα-/lox mice, since they lack IL-4Rα-responsive 
macrophages 59. In support of this, we found decreased arginase levels in lung cells at 
5 days p.i., indicative of impaired development of AAMs 72, 166, 170. This, however, 
needs to be further confirmed by arginase assays and quantitative real-time PCR 
(qRT-PCR) for Arg-1 mRNA on isolated alveolar macrophages. It is likely that the 
absence of IL-4Rα-responsive alternatively activated macrophages are responsible for 
the observed increased inflammation (Chapter 3.1) and increased CD3+ T-cell 
numbers in the LysMCreIL-4Rα-/lox lung, since these AAMs are known to down-
modulate inflammation and proliferation of CD4+ T-cells 72, 178, 188, 214. Additionally, it 
has been shown that helminth-induced AAMs show anti-proliferative activity of T 
lymphocytes, through the suppression of the cell cycle (G1 and G2/M phases) in 
CD4+ T-cells through direct macrophage-T-cell contact 178. Other possible 
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mechanisms by which AAMS inhibit T-cell proliferation include factors such as 2/15-
lipoxygenase 188, Fizz1 214 or apoptosis by an arginase-induced mechanism 72, 234. 
Therefore, these data together may demonstrate an impaired ability of LysMCreIL-
4Rα-/lox pulmonary macrophages to control exacerbated T-cell proliferation, as a 
result of these pulmonary macrophages not being able to become alternatively 
activated. Although these data may support our hypothesis, it should be further tested 
by performing infected macrophage-T-cell co-culture proliferation studies and 
macrophage characterization of isolated alveolar macrophages in N. brasiliensis-
infected lungs. 
 
It is unclear why neither of the IL-4Rα-deficient mouse groups do not have increased 
NO production in the supernatants of whole lung cell suspensions, since peritoneal 
macrophages from IL-4Rα-/- and LysMCreIL-4Rα-/lox mice was found to have increased 
NO production in a previous study 59. However, collagenase-treated cell suspensions 
from infected lungs were used in this study at 5 days p.i. and the low cell number 
could have an effect on NO production after 5 days. In order to identify if these 
macrophages were classically activated, future work would include assessing NO 
production, qRT-PCR on NOS RNA and protein levels of IL-12 on isolated 
macrophages from the infected lungs of naïve and infected mice. 
 
The question arises why global IL-4Rα-/- mice do not have as exacerbated 
inflammation and increased pulmonary T-cell numbers compared to LysMCreIL-4Rα-
/lox mice in our study, even though both do not produce IL-4Rα-responsive 
alternatively activated macrophages 59, 163. Importantly, IL-4Rα-/- mice lack IL-4Rα 
on all cells 62, 235 and thus lack IL-4Rα-responsive T-cells as well 4. As a consequence, 
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IL-4Rα-/- mice have an impaired TH2 response 4, 60, 235, also confirmed in our study by 
decreased IL-4 and IL-13 production in MST CD4+ T-cells. Additionally, IL-4Rα-/- 
mice have disrupted recruitment of CD4+ T-cells to the lung during N. brasiliensis 
infection 4. Therefore, in the complete absence of IL-4Rα expression, T-cell 
recruitment to the lung is severely reduced 57, resulting in the lack of T-cell mediated 
inflammation in IL-4Rα-/- mice as shown in our study. 
 
Together, these data support previous findings and suggests that AAM are involved in 
controlling the onset of chronic lung inflammation following N. brasiliensis infection 
as early as day 5 p.i., by suppressing either or both recruitment and proliferation of T- 
cells 72, 178, 188, 214. The data further suggests that IL-4Rα-responsive macrophages 
down-modulate IL-4 and IL-13 cytokine production in the lung and CD4+ T-cell IL-4 
and IL-13 production in draining lymph nodes following N. brasiliensis infection, in 
agreement with previous studies 2, 105. In order to further investigate the phenotype of 
these macrophages and their role in the lung during infection, we carried out a 
detailed molecular analysis of their gene expression profile in the following Chapter.  
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3. RESULTS – Chapter 3.3: Microarray 
 
Analysis of differential gene expression of alveolar macrophages from naïve and 
N. brasiliensis-infected lungs 
 
3.3.1 Introduction 
 
We established in the previous chapters that mice with disrupted IL-4Rα expression 
on macrophages and neutrophils (LysMCreIL-4Rα-/lox) rapidly developed enhanced 
acute and chronic lung inflammation following infection with N. brasiliensis as 
demonstrated by histopathological studies (Chapter 3.1). This increased inflammation 
was associated with increased numbers of CD4+ and CD8+ T-cells in the lung and 
increased secretion of TH2 cytokines in LysMCreIL-4Rα-/lox mice (Chapter 3.2). 
Though similar numbers of alveolar macrophages (AlvM) were present in the lung, 
LysMCreIL-4Rα-/lox lung cell suspensions showed impaired alternative macrophage 
activation. Together these data suggest that AAMs down-regulate lung inflammation 
by influencing T-cell responses following N. brasiliensis infection. This chapter 
investigates the differential gene expression patterns of AlvMs in N. brasiliensis-
infected IL-4Rα-/lox, IL-4Rα-/- and LysMCreIL-4Rα-/lox mice and discusses how 
variations in gene expression may influence N. brasiliensis-induced lung pathology.  
 
Murine AAM activity is typically characterised as IL-4Rα-driven increase in 
arginase-1 expression 72, 166-170. Arginase-1 activity, in AAMs, is associated with 
repression of NO production, control of TH2 cytokine activity 72 and production of 
proline 169, 174. This response is generally associated with anti-inflammatory and tissue 
repair responses. Other markers of AAMs include increased expression of mannose 
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receptor (MMR) 165 and chitinase and FIZZ family members (ChaFFs) 171. ChaFFs 
include resistin-like molecules such as found in inflammatory zone 1 (FIZZ1; or 
resistin-like alpha or relmα) 172, chitinase-like molecules such as acidic mammalian 
chitinase (AMCase) 171 and Ym1 (or chitinase 3-like 3) 172, 173. These AAMs 
biomarkers have been associated with the control of helminth-induced inflammation 
72, 214. In particular, AAMs are associated with the inhibition of potentially 
exacerbated T-cell responses in other helminth studies 72, 178.  
 
Along with these markers are a range of other molecules including chemokines and 
cytokines that are also associated with AAM function 169, 192, 193. Secretion of 
chemokines and cytokines by macrophages is particularly associated with recruitment 
of cells such as leukocytes and granulocytes by chemotaxis. Of potential relevance in 
the current study may be the chemokines CXCL9, CXCL10 and CXCL11 which are 
secreted by AlvMs and are associated with the onset of COPD 139. Furthermore, 
CXCL11 (or ITAC) has a dual role as a caM associated chemokine 1, 169, 192, 236, 237. 
 
In the following chapter, preliminary analysis was presented from a macrophage-
targeted microarray that could enable further understanding of AAM phenotype and 
function in the N. brasiliensis-infected lung. The expression of 460 target genes were 
examined possibly associated with alveolar macrophage (AlvM) function (A. Kirby; 
unpublished data ; Appendix E). From these results data was generated that could help 
to define how the biology of IL-4Rα-responsive AlvMs in N. brasiliensis infections 
may control the onset of chronic lung inflammation. Importantly, this work may 
identify potential molecular markers that may underlie the rapid onset of the chronic 
lung pathology observed in LysMCreIL-4Rα-/lox mice.  
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3.3.2 Results: 
 
3.3.2.1 Isolation of Alveolar Macrophages (AlvMs) 
 
In order to analyse gene expression patterns of AlvMs following N. brasiliensis 
infection, a homogenous macrophage population, defined as autofluorescent 
CD11c+MHCIILo SSCHI cells 196, were isolated by FACS at days 5, 42 and 180 p.i. 
(Figure 14A). Cytospins of the isolated AlvM samples revealed a homogenous 
population of macrophages with no discernable differences between the mouse groups 
or between the time points analysed (Figure 14B). An average yield of 80,000 AlvMs 
were obtained per lung with more than 98% purity (Table 4).  
 
 
3.3.2.2 Preparation of isolated AlvM RNA for chip analysis 
 
Total RNA was extracted from the isolated AlvMs and quantity, quality and integrity 
of the RNA was assessed using a BioAnalyzer 2100. The yield of extracted RNA 
ranged between 9 ng and 461 ng per experimental group (Table 4). The quality of the 
isolated RNA was assessed using the 28S:18S rRNA ratio which ranged from 0.3-1.0, 
while RNA integrity number (RIN) ranged between 4.7 and 7.6 (Table 4). Though 
these numbers were relatively low compared to an optimal rRNA ratio of 2.0 and RIN 
values above 7, clear 28S and 18S peaks were observed on the chromatograms (data 
not shown). The low integrity of the RNA may be partly attributed to accidental 
introduction of RNases during the purification or extraction processes. The RNA was 
then sent to the laboratory of Dr Alun Kirby (University of York, UK) for RNA 
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amplification, processing and hybridization to microarrays. All RNA samples were 
successfully linearly amplified to more than 20-fold amplification prior to 
hybridization to the microarrays (Table 4). 
 
 
 
 
Figure 14: Alveolar macrophage sorting and morphology. (A) Sorting strategy for 
viable alveolar macrophages (autofluorescent SSCHi CD11cHi MHCIILo) 196. (B) 
Cytospins of sorted (99% purity) alveolar macrophages from gate R4 were stained 
(Rapiddif Quick) and viewed under a microscope (40x). Pooled lungs (n = 4 -5 mice 
per group). Representatives of duplicate experiments from all time points analysed.  
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Table 4: Summary of results of alveolar macrophage (SSCHi,CD11cHi,MHCIILo) 
isolation, RNA extraction and amplification. 
 
 
 
3.3.2.3 Microarray of alveolar macrophage RNA  
 
Following amplification, RNA was labelled and the reference RNA (Cy3), extracted 
from naïve unelicited peritoneal macrophages (or NUPM), and test RNA (Cy5) were 
hybridised onto a targeted microarray chip. All test RNA gene expression values were 
compared against NUPM reference RNA, log2 transformed, and expressed as M-
values (i.e. log2 transformed Cy5/Cy3 ratios). Since the M-values of each test sample 
were compared to an identical, pooled reference RNA from NUPMs, inter- and intra- 
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group analyses could be carried out by comparing M-values from one group (e.g. 
infected IL-4Rα-/lox) against M-values of another group (e.g. IL-4Rα-/lox naïve), to give 
the fold change (FC) expression values of the 460 genes analysed (Appendix E). 
Significantly differentially expressed genes (p < 0.05) were identified by a two-tailed, 
paired T-test that compared mouse groups in both experiments for each gene (as 
described in Methods and Figure 7). Thus a stringent analysis was reached since 
statistical tests identified only those genes which had similar regulation, but a large 
enough difference between M-values from both experimental repeats. The microarray 
analysis of AlvMs, presented below, were analysed for comparisons between: (1.) 
infected IL-4Rα-/lox vs. naïve IL-4Rα-/lox mice, (2.) IL-4Rα-/- vs. IL-4Rα-/lox mice and 
(3.) LysMCreIL-4Rα-/lox vs. IL-4Rα-/lox mice, following N. brasiliensis infection for all 
three time points.  
 
 
3.3.2.3.1 Effect of N. brasiliensis infection on gene expression in alveolar 
macrophages (infected IL-4Rα-/lox vs. naïve IL-4Rα-/lox) 
 
Preliminary data analysis identified 36 genes that were significantly (p < 0.05) 
differentially expressed (14 at day 5 p.i. and 22 at day 42 p.i.) in AlvMs of infected 
IL-4Rα-/lox (WT) mice when compared to naïve IL-4Rα-/lox mice (Figure 15A). 
Functional clustering (Appendix E) of these significantly differentially expressed 
genes revealed the following:  
• 5.6% encoded chemokines and their receptors (i.e. BCA1, CCR5)  
• 5.6% were cytokines and their receptors (IRF7, TNFR2p75)  
• 11.1% were TLR-related (TIRAP, RIG-1, TLR7, TLR5) 
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• 5.6% were involved in tissue/lung remodelling (cathepsinS, cathepsinH) 
•  16.7% were involved in signalling (SMAD4, SOCS2, SOCS3, Wnt7b, Lyn, 
SMAD6) 
• 27.8% were APC surface receptors or macrophage-related genes (CIITA, 
CD1d2, Mr1, DCAR, PIR-A2, FFAR2 (day 5 and 42 p.i.), CD40L, IgSR, Ym1).  
 
Of particular interest were genes associated with alternative activation of 
macrophages and regulation of pulmonary inflammation. Of the analysed genes 
associated with AAM, significant differences in expression were only found for Ym1, 
7, 105 172 which was down-regulated at day 42 p.i. in AlvMs of IL-4Rα-/lox mice when 
compared to naïve IL-4Rα-/lox controls (Figure 15A).  
 
Analysis of those genes that were significantly differentially expressed showed 36% 
of these genes to be associated with inflammation. Of the inflammatory genes, the 
following genes showed a significant down-regulation in expression in infected IL-
4Rα-/lox mice when compared to naïve control mice: TNFR2p75 238, 239, SOCS3 240, 
TIRAP 241, FFAR2 242, 243, HDAC5 244, IRF7 245, and cathepsinH 120. The following 
inflammatory genes showed significantly increased expression in IL-4Rα-/lox mice 
when compared to naïve control mice: BCA1 246, 247, CathepsinS 120, BMPR1B 248, 
CCR5 249, SOCS2 240 and the Toll-like receptor (TLR)-related genes TLR5 250, TLR7 
251 and RIG-I 252, 253 (Figure 15A).  
 
Together, this preliminary analysis may indicate that some of these AlvM genes were 
involved in host protective functions against pathogens and inflammation control.  
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3.3.2.3.2 Comparison of the gene expression profiles of IL-4Rα-/- AlvMs vs. IL-
4Rα-/lox AlvMs following N. brasiliensis infection  
 
Gene expression profiling between IL-4Rα-/- and IL-4Rα-/lox AlvMs revealed 28 
genes out of 460 to be significantly (p < 0.05) differentially expressed (8 at day 5p.i., 
6 at day 42 p.i. and 14 at 180 days p.i.) (Figure 15B). Functional clustering of these 
significantly differentially expressed genes showed the following:  
• 21.4% of the genes encoded chemokines and their receptors (CXCL16, BRAK, 
PF4, ITAC, CCR1, IL-8Ra);  
• 3.6% were cytokines (IL-17B)  
• None were TLR-related 
• 7.1% were involved in tissue/lung remodelling (MMP13, cathepsinF) 
• 10.7% were involved in signalling (RXRg, Dkk-2, Syk)  
• 21.4% were APC surface receptors or macrophage-related genes (CLIP, PIR-
B, PIR-A1, NFAM-1, PILR-a, CD200R1) 
• 10.7% were integrins (ItgB6, CD51 (days 42 and 180 p.i.))  
• 3.6% were associated with apoptosis (BCL2).  
 
None of the typical AAM marker genes analysed (Arg1 72, 166, MR 165, FIZZ1 172, 173, 
214, Ym17, 105 172, MGL1 189, PPARγ 176, nor caM marker gene Nos2 166) showed 
significant differential expression in AlvMs from infected IL-4Rα-/- mice when 
compared to AlvMs from infected IL-4Rα-/lox mice at all three time points analysed.  
 
Similar to our previous analysis, significant differential gene expression was found to 
be strongly associated with genes involved in modulating inflammation. We found 
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33% of such genes to be associated with inflammation. Of these the following were 
up-regulated in IL-4Rα-/- AlvMs: CCR1 254, CXCL16 255, IL-17B 256, CLIP 257, BRAK 
258 and ItgB6 259. Down-regulated inflammatory genes in IL-4Rα-/- AlvMs comprised 
of the following: IL-8Ra 260, 261, ITAC 139, CathepsinF 120 (Figure 15B).  
 
Differential expression profiles of isolated AlvMs from infected IL-4Rα-/- mice 
(compared against infected IL-4Rα-/lox AlvMs) uncovered candidate genes potentially 
involved in controlling inflammation. Interestingly, none of the genes on the chip 
which represented known macrophage activation markers were significantly 
differentially expressed. 
 
 
3.3.2.3.3 Comparison of the gene expression profiles of LysMCreIL-4Rα-/lox AlvMs 
vs. IL-4Rα-/lox AlvMs following N. brasiliensis infection  
 
Comparison of AlvM gene expression profiles between LysMCreIL-4Rα-/lox and IL-
4Rα-/lox mice revealed 33 genes that were significantly (p < 0.05) differentially 
expressed following N. brasiliensis infection (6 at day 5p.i., 20 at day 42 p.i. and 7 at 
180 days p.i.). The majority (81.8%) of these significant genes were up-regulated in 
LysMCreIL-4Rα-/lox AlvMs when compared to IL-4Rα-/lox AlvMs (Figure 15C). 
Functional clustering of these significantly differentially expressed genes revealed the 
following:  
• 6.1% encoded chemokine receptors (CCR5, IL-8Rb)  
• 6.1% were cytokines (TNF, IL-1b) 
• 12.1% were TLR-related (card9 (days 5 and 42 p.i.), TLR2, NOD2) 
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• None were involved in tissue/lung remodelling  
• 15.2% were involved in signalling (RelB (days 5 and 42 p.i.), SOCS3, SOCS1, 
Dkk-4) 
• 21.2% encoded APC surface receptors or macrophage-related genes (FFAR2, 
LAIR1, ICAM-1, Lamp1 (days 5 and 42 p.i.), Ym1, SOD2)  
• 9.1% were integrins and lectins (integrinB7, CD11b, DCIR).  
 
Of the AAM marker genes analysed, only Ym1 was up-regulated in infected 
LysMCreIL-4Rα-/lox AlvMs when compared to infected IL-4Rα-/lox AlvMs (Figure 
15C).  
 
Similar to the other two mouse groups, of the 33 significantly differentially expressed 
genes in LysMCreIL-4Rα-/lox AlvMs, 48% were involved in regulating inflammation. 
The gene transcripts for card9 262 (at days 5 and 42 p.i.), CCR5 249, SOD2 263, TLR2 
264, TNF 265, FFAR2 242, 243, DCIR 266, IL-1β 267, RelB 268 (at days 5 and 42 p.i.), 
SOCS1 240, 269, SOCS3 240 and TRIM30 270 were up-regulated; while ACVR1 248, IL8Rb 
271, 272, Nod2 273 and CD11b 274 were down-regulated in the LysMCreIL-4Rα-/lox AlvMs 
when compared to IL-4Rα-/lox AlvMs following infection (Figure 15C). Interestingly, 
RelB 268 and card9 262, known to promote inflammation, were up-regulated at day 5 
p.i. and sustained at day 42 p.i. in LysMCreIL-4Rα-/lox AlvMs. At this time point (day 
42 p.i.), SOCS1 and SOCS3, known to suppress pro-inflammatory cytokine responses 
240, 269, were up-regulated. Importantly, strong pro-inflammatory genes, including TNF 
265, IL-1β 267 and TLR2 264, were amongst the significantly up-regulated genes in 
LysMCreIL-4Rα-/lox AlvMs. (Figure 15C).  
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Together, these preliminary microarray analyses indicated that AlvMs from infected 
LysMCreIL-4Rα-/lox mice portray gene expression profiles associated with control of 
inflammation as opposed to induction of known AAM-associated genes, similar to the 
other mouse groups. Furthermore, LysMCreIL-4Rα-/lox AlvMs showed up-regulation of 
TNF 265 and IL-1β 267 cytokine transcripts, indicating a more pronounced pro-
inflammatory response compared to control IL-4Rα-/lox AlvMs.  
 
 
 
 
Figure 15: Significant differential expression of Alveolar Macrophage genes 
following N. brasiliensis infection. (A-C) Gene expression heatmaps of significantly 
(p < 0.05) differentially expressed genes in AlvM from infected: (A) IL-4Rα-/lox (WT) 
vs. naïve WT, (B) IL-4Rα-/- (KO) vs. WT, (C) LysMCreIL-4Rα-/lox (LysM) vs. WT 
mice. FC values (log2 scale), ranked in descending order, were used to generate 
heatmaps of significantly up-regulated (yellow) and down-regulated (blue) genes of 
duplicate biological experiments. The gene symbols used are fully annotated in 
Appendix E. Exp1, Exp2: biological experiment 1 and biological (repeated) 
experiment 2. FC: Fold change. Significance could not be determined for WT genes at 
day 180 p.i., since there was only one naïve (WT) sample. 
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3.3.3 Discussion: 
 
Based on our findings in the previous chapters, we hypothesized that IL-4Rα-
responsive macrophages control N. brasiliensis-associated lung inflammation. In a 
transcriptomics approach, we analysed and compared the expression patterns of 
AlvMs from N. brasiliensis–infected LysMCreIL-4Rα-/lox, IL-4Rα-/- and IL-4Rα-/lox 
control mice. Data from these preliminary microarray analyses suggests the following:  
• A trend for down-regulation of anti-inflammatory-associated genes (i.e. 
TNFR2p75, SOCS3) and an up-regulation of genes associated with 
TLR/MyD88/NF-κB (innate) signalling pathways (TLR5, TLR7, RIG-I) and 
IL-13- and IL-4-induced genes (CCR5, CD1d; and SOCS2) in IL-4Rα-/lox 
AlvMs isolated from N. brasiliensis-infected lungs when compared with naïve 
IL-4Rα-/lox AlvMs.  
• Following N. brasiliensis infecti n, LysMCreIL-4Rα-/lox AlvMs demonstrated 
up-regulated pro-inflammatory cytokine gene expression (TNF and IL-1B) 
when compared to infected IL-4Rα-/lox AlvMs. Additionally, the IL-13 induced 
gene, CCR5, and genes associated with innate responses, such as the TLR 
family genes (card9, RelB, TLR2) were also up-regulated in LysMCreIL-4Rα-
/lox AlvMs.  
• The gene expression profile of IL-4Rα-/- AlvMs differed substantially from the 
expression profiles of both IL-4Rα-/lox and LysMCreIL-4Rα-/lox AlvMs.  
 
Taken together, these results indicate that specific disruption of IL-4Rα expression on 
macrophages (LysMCreIL-4Rα-/lox AlvMs) results in a heightened expression of genes 
associated with pro-inflammatory responses. 
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Interestingly, our analysis did not show the previously reported up-regulation of known 
AAM-associated markers in IL-4Rα-/lox AlvMs compared to naïve mice. No significant 
changes in expression of the following AAM associated genes were found: Arg1 72, 166, 
MR 165, FIZZ1 172, 173, 214, MGL1 189 or PPARγ 176. However Ym1 expression was reduced 
in AlvMs from infected IL-4Rα-/lox mice, but increased in infected LysMCreIL-4Rα-/lox 
AlvMs compared to infected IL-4Rα-/lox AlvMs. Increased Ym1 expression is generally 
considered to be associated with induction of AAM 166, 169, 237 and has also been shown to 
be up-regulated in CD11c+ AlvMs during N. brasiliensis infection 7. However, our data 
indicates that Ym1 expression could be reduced following N. brasiliensis infection and 
also can be expressed independent of IL-4Rα-responsiveness. In support of this 
observation, it has recently been demonstrated that Ym1 (as well as MR) expression can 
be independent of IL-4Rα-responsive macrophages during S. mansoni-induced 
inflammation 275.  
 
Along with the above AAM biomarkers, it has been hypothesized that AAMs have a 
signature chemokine profile 169, 192, 193. For example, from this chemokine spectrum, 
AAMs should have an up-regulation of IL-8Ra (CXCR1) and IL-8Rb (CXCR2), while 
ITAC (CXCL11) and CXCL16 should be down-regulated 192, 193. Again, the proposed 
AAM biomarker signatures were not evident in our study in AlvMs from IL-4Rα-/lox 
mice. However, AlvMs from LysMCreIL-4Rα-/lox mice showed a down-regulation of IL-
8Rb (at 42 days p.i.), indicating that they could have a caM phenotype. Transcriptome 
analysis of AlvMs from IL-4Rα-/- mice gave a conflicting result, as the up- and down-
regulation of CXCL16 and IL-8Ra, respectively, at day 5 p.i. indicated a caM phenotype, 
while the down-regulation of ITAC at day 180 p.i. indicated an AAM phenotype. These 
conflicting results may suggest that macrophage activation is not a fixed phenotype, but 
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are dynamic and could be re-programmed, as shown in previous reports 276. However, 
these are only a few genes from a proposed spectrum of numerous chemokines and their 
corresponding receptors and therefore no conclusions can yet be made. 
 
Of particular importance in this study was our finding that macrophages isolated from 
N. brasiliensis–infected lungs show an IL-4Rα−dependent expression pattern for a 
range of genes associated with inflammation (Table 5), which may explain the rapid 
onset of inflammation observed in the lungs of LysMCreIL-4Rα-/lox mice compared to 
IL-4Rα-/lox mice (Chapter 3.1). These genes included the suppressor of cytokine 
signalling (SOCS) family and TLR family genes, since their significance were 
common to both IL-4Rα-/lox and LysMCreIL-4Rα-/lox AlvMs and have previously been 
shown to act as regulators of inflammation 240, 268, 277. The most striking difference we 
found between LysMCreIL-4Rα-/lox and IL-4Rα-/lox AlvM gene expression profiles in 
this study was the significantly up-regulated expression of pro-inflammatory cytokine 
genes TNF 265 and IL-1β 267 in LysMCreIL-4Rα-/lox mice. If confirmed by qRT-PRC 
and protein analysis, these pro-inflammatory cytokines could play a role in the 
observed increased pulmonary inflammation in infected LysMCreIL-4Rα-/lox mice.  
 
The exacerbated TH2 responses in the lungs of infected LysMCreIL-4Rα-/lox mice 
(Chapter 3.2) may be explained, in part, by the observed (two-fold) up-regulated 
expression of CCR5, since this chemokine receptor induces IL-13-mediated 
inflammation 190, 249. CCR5 is also induced by IL-13 249, therefore able to induce a 
positive feedback loop. However, protein quantification and further intracellular 
signalling analysis needs to be carried out to confirm if this is the case.  
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Table 5: Significantly differentially expressed genes associated with 
inflammatory responses from AlvMs following N. brasiliensis infection.  
 
Gene Expression Patterns associated with Promoting Inflammation 
Day 
p.i. 
IL-4Rα-/lox 
(vs. naïve) 
IL-4Rα-/- 
(vs. WT) 
LysMCreIL-4Rα-/lox 
(vs. WT) 
5 
TNFR2p75 238, 239 È 
cathepsinS 120, 140 Ç 
BCA1 246, 247 Ç 
CCR1 254 Ç 
CXCL16 255 Ç 
card9 262 Ç 
CCR5 249 Ç 
42 
SOCS3 240 È 
CCR5 249 Ç 
TLR5 250 Ç 
BMPR1B 248 Ç 
TLR7 251 Ç 
RIG-I 252, 253 Ç 
IL17B 256 Ç 
CD11b 274 È 
SOD2 263 Ç 
TLR2 264 Ç 
TNF 265 Ç 
FFAR2 242, 243 Ç 
DCIR 266 Ç 
card9 262 Ç 
180 C.N.D. CLIP 
257Ç 
BRAK 258 Ç IL1b 
267 Ç 
Gene Expression Patterns associated with Suppressing Inflammation 
Day 
p.i. 
IL-4Rα-/lox 
(vs. naïve) 
IL-4Rα-/- 
(vs. WT) 
LysMCreIL-4Rα-/lox 
(vs. WT) 
5 
TIRAP 241È 
FFAR2 242, 243È 
HDAC5 244È 
IL8Ra 260, 261 È 
ItgB6 259 Ç 
ACVR1 248 È 
RelB 268 Ç 
42 
IRF7 245 È 
FFAR2 242, 243È 
cathepsinH 120È 
SOCS2 240Ç 
no genes 
IL8Rb 271, 272 È 
SOCS1 240 Ç 
TRIM30 270 Ç 
SOCS3 240 È 
RelB 268 Ç 
180 C.N.D. ITAC 
139 È 
cathepsinF 120 È Nod2 
273 È 
Ç Up-regulated or È down-regulated genes known to Promote (red) or Suppress 
(blue) inflammation. C.N.D. = could not determine; WT: (infected) IL-4Rα-/lox. 
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Genes of the SOCS family that showed macrophage IL-4Rα−dependent differential 
expression in this study included SOCS1, SOCS2 and SOCS3. In macrophages and T-
cells, SOCS function by suppressing cytokine signalling through the blocking of 
cytokine receptor interactions or through degradation of JAK family proteins, which 
are key cytokine signalling proteins 278. SOCS1 is induced by both IFN-γ and IL-4 and 
can suppress IL-4 signalling via STAT-1 and STAT-6 respectively 269. Induction of 
SOCS3 is IFN-γ- or IL-10-dependent but independent of STAT-1 regulation and also 
suppresses IL-4 signalling 240, 269. In contrast, SOCS2 is induced by IL-4 and exerts its 
effects in a STAT-6 dependent manner, however it is unclear which cytokine 
signalling pathways SOCS2 suppresses. Interestingly, macrophages from day 42 p.i. 
N. brasiliensis–infected IL-4Rα-/lox mice showed up-regulation of SOCS2 in 
agreement with an IL-4 (and IL-13) dominated immune response (Chapter 3.2). 
Macrophages from infected LysMCreIL-4Rα-/lox mice showed up-regulation of SOCS1 
and SOCS3 at day 42 p.i., which could be a consequence of the absence of IL-4-
responsiveness and subsequent induction of the IFN-γ-induced genes, SOCS1 and 
SOCS3 240. However, any suppressive activities driven by SOCS1 and SOCS3 may be 
insufficient in down-modulating inflammation in the lungs of N. brasiliensis-infected 
LysMCreIL-4Rα-/lox mice, since these mice still displayed significantly higher 
pathology scores at day 5 and 42 p.i. when compared to IL-4Rα-/lox and IL-4Rα-/- mice 
(Chapter 3.1).  
 
In addition to SOCS genes, a number of significantly differentially expressed genes 
were observed which belong to the TLR family. AlvMs from infected IL-4Rα-/lox mice 
showed up-regulation of TLR5 250, TLR7 251 and RIG-I 252, 253 at day 42 p.i., while 
TIRAP 241 was down-regulated at day 5 p.i. AlvMs from LysMCreIL-4Rα-/lox mice 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
99 
showed up-regulation of card9 262 and TLR2 264 at day 42 p.i., while Nod2 273 was 
down-regulated at day 180 p.i. In contrast, AlvMs from infected IL-4Rα-/- mice did 
not show significant differential expression of TLR-related genes. Although TLR 
genes are usually associated with innate immunity and the induction of inflammatory 
responses 9, they have recently been associated with chronic inflammation 277, 279. 
Since necrotic cell death has also been associated with inflammation 279, 280, it has 
recently been suggested that TLRs could recognise these endogenous ligands from 
necrotic cells and thus further induce inflammatory responses via TLR signalling 279 . 
This could be a potential reason for the significant up-regulation of TLR genes at day 
42 p.i. However, it does not explain why IL-4Rα-/- AlvMs did not show this similar 
up-regulation of TLR genes at day 42 p.i., nor does it explain the down-regulation of 
the other TLR-related genes (TIRAP and Nod2). Currently, it is not known whether N. 
brasiliensis infections induce TLR expression or signalling. Apart from an asthmatic 
study which showed that the suppressive effects of NES on OVA-induced asthma was 
TLR2- and TLR4-independent 281 and a TLR4-responsiveness study to LPS in N. 
brasiliensis-infected mice 282, only a few studies have shown a relationship between 
pulmonary inflammation and TLR signalling in a TH2 environment (such as asthma 
283 and pulmonary virions inducing TH1 and TH2 cytokines 164, 284). Since TLRs have 
been associated with inflammation and innate responses, it would be interesting to 
study this further, if confirmed by qRT-PCR.  
 
Interestingly, significantly differentially expressed genes from IL-4Rα-/- AlvMs were 
not present in the profile of LysMCreIL-4Rα-/lox AlvMs, even though both macrophage 
populations lack IL-4Rα. Besides establishing a unique gene expression profile 
compared to the other mouse groups analysed, IL-4Rα-/- AlvMs did not show 
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significant expression of TLR-related genes and SOCS genes. Furthermore, IL-4Rα-/-  
AlvMs showed significant down-regulation of the caM biomarker ITAC (CXCL11), 
while ITAC was not significantly differentially expressed in the other mouse groups. 
These results reflect that the global IL-4Rα deficiency in IL-4Rα-/- mice is affected by 
the many immunological reactions during infection, and emphasizes the importance of 
studying gene expression using cell specific models. For example, IL-4Rα-/- mice 
showed a predominantly TH1 cytokine response in the lung while LysMCreIL-4Rα-/lox 
mice showed an increased TH2 response in the lung (Chapter 3.2). Furthermore, 
pulmonary inflammation in IL-4Rα-/- mice was significantly less severe than in 
LysMCreIL-4Rα-/lox mice (Chapter 3.1). Therefore, the drastic differences in the gene 
expression profiles between the IL-4Rα deficient macrophage populations could 
explain the drastic phenotypic differences in cytokine, physiological and 
inflammatory responses between IL-4Rα-/- and LysMCreIL-4Rα-/lox mice.  
 
In summary, gene expression profiling of AlvMs showed significant differentially 
expressed genes in the infected strains with possible candidate genes involved in the 
increased inflammation in the lungs of LysMCreIL-4Rα-/lox mice.  
 
Since a full analysis is beyond the scope of this thesis, future work would include 
further bioinformatic analysis, experimental repeats, quantification of selected genes 
by quantitative real-time PCR (qRT-PCR) and functional analysis including in vitro 
siRNA experiments in macrophages. Furthermore, since genes expression levels do 
not necessarily correlate with protein translation, the protein products of candidate 
genes will be quantified to establish possible relationships between gene expression 
and protein translation. Moreover, further experimental repeats are needed to reliably 
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detect significance and reduce variability (see Appendix E) between biological 
experiments. Variability can be minimized with more robust quality control 
procedures to control for biological and technical biases. For example intra- and inter-
group fluorescent testing and quality assessment using Expression ConsoleTM 
Software to test for unusually bright or dim chips, high sensitivity and specificity, 
correction of fluorescence intensities and assessment of RNA hybridization. Further 
rigorous bioinformatical analysis could be done to investigate each gene in more 
detail. This would entail compiling in-depth information for each gene by (i) 
extensive literature mining - either manually or using software such as MILANO 200, 
(ii) determining enrichment scores for over- and under-represented gene functions and 
Gene Ontology annotations using DAVID (Database for Annotation Visualization and 
Integrated Discovery)285, (iii) mapping the differentially expressed genes to signalling 
pathways and constructing protein-protein interaction networks using Ingenuity 
Pathway Analysis (Ingenuity Systems, www.ingenuity.com).  
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
102 
4. CONCLUSION 
 
 
In this study we explored the role of IL-4Rα-responsive macrophages in lung 
pathology resulting from N. brasiliensis infection. Our data demonstrated that 
macrophage-specific IL-4Rα-signalling is important in controlling chronic N. 
brasiliensis-driven lung pathology. The data confirmed previous reports of N. 
brasiliensis infection driving a largely IL-4Rα-independent development of chronic 
emphysemic-like pathology. Associated with this rapid development of a chronic lung 
inflammation at 5 days p.i. in LysMCreIL-4Rα-/lox mice, increased CD4+ and CD8+ T-
cell numbers and increased TH2 cytokine responses were apparent in the lungs of 
infected LysMCreIL-4Rα-/lox mice when compared to IL-4Rα-/lox controls and IL-4Rα-/- 
mice. While macrophage cell numbers and morphology remained unaltered, arginase 
activity, indicative of alternative activation, was impaired in macrophages from 
infected LysMCreIL-4Rα-/lox mice. RNA transcriptomic studies of isolated alveolar 
macrophages showed a strong up-regulation of IL-13-associated inflammatory 
chemokine receptor, CCR5, and the pro-inflammatory cytokine genes IL-1B and TNF 
from LysMCreIL-4Rα-/lox mice.  
 
Taken together, these data suggest that IL-4Rα-responsive macrophages are important 
for the down-modulation of pulmonary inflammation and TH2 cytokine responses 
during N. brasiliensis infection. These responses are characteristic of AAM-associated 
control of inflammation previously described in a range of helminth infection models 
where transgenic mouse models lacking AAMs demonstrated increased inflammation 
59, 72, 214 and increased TH2 cytokine production 72, 214. For example, S. mansoni 
infection studies in transgenic mice lacking either Relmα/Fizz1 (Retnla-/-) 214 or 
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macrophage-specific Arginase1 (LysMCreArg1-/flox) 72, which were therefore unable to 
generate AAM, demonstrated increased inflammation and TH2 cytokine production.  
 
Our microarray analysis of macrophages isolated from lungs of N. brasiliensis mice 
also agrees with our and other’s previous findings that N. brasiliensis infection leads 
to the development of macrophage populations with anti-inflammatory properties 7. 
Three important findings in our microarray study were of special interest as they 
suggested a different AAM phenotype to the M2 macrophage: 
(i) A large percentage ( > 32%) of significantly differentially expressed genes 
were associated with controlling inflammation.  
(ii) A lack of robust AAM biomarkers in IL-4Rα-/lox mice AlvMs and a lack of 
either AAM or caM biomarkers in LysMCreIL-4Rα-/lox mice.  
(iii) Up-regulation of TNF and IL-1B in LysMCreIL-4Rα-/lox mice 
 
Cytokines and chemokines are associated with both macrophage differentiation 192, 193, 
236, 286 and chronic inflammatory diseases 287. Furthermore, TLRs induce chemokine 
production 287 and are associated with chronic inflammation 279, 287. Therefore, the 
observed up-regulation of TLRs, cytokines and chemokines in LysMCreIL-4Rα-/lox 
mice, could be potential candidate genes involved in the early onset of inflammation 
in LysMCreIL-4Rα-/lox mice.  
 
AAM-associated biomarkers, such as Arg1 72, 166, MR 165, FIZZ1 172, 173, 214, MGL1 189, 
PPARγ 176, have been shown to be up-regulated in lungs or macrophages from N. 
brasiliensis-infected mice. However, in our study, we did not find this up-regulation 
to be statistically significant in IL-4Rα-/lox mice. We also did not find an up-regulation 
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of iNOS, IL-12 or any other biomarker of classically activated macrophages in 
LysMCreIL-4Rα-/lox (or IL-4Rα-/lox) mice. Therefore, it may be possible that the AlvMs 
in N. brasiliensis-infected mice have different characteristics of activation. It has been 
proposed that there are other sub-types of AAMs, based on biomarkers and 
functionality from other helminth studies that sub-divides the AAM classification 
into: M2a, M2b and M2c (outlined in Introduction) 167, 193.  
 
Since we did not find clear differences in Arginase1 regulation or AAM biomarkers in 
IL-4Rα-/lox AlvMs, but did observe significant increases in TLR and matrix or tissue 
remodelling genes, this could be indicate that these macrophages may have 
characteristics that fall under the M2b or M2c classification, rather than the M2a 
classification (Figure 16). The AAM sub-classification M2b refers to macrophages 
that are involved in TH2 activation and immunoregulation, while M2c AAMs are 
referred to as “deactivated” macrophages and are involved in tissue remodelling and 
immunoregulation. These properties of both AAM subtypes were evident in our 
studies. The activation of macrophages in N. brasiliensis-infected LysMCreIL-4Rα-/lox 
mice suggest that they could be M2b AAMs as shown by their significant increases in 
TNF and IL-1β and TLR-related genes and a lack of up-regulation of caM biomarker 
genes, such as NOS2. However, further experimentation and functional studies are 
needed to further elucidate the exact properties of LysMCreIL-4Rα-/lox and IL-4Rα-/lox 
AlvMs. Since macrophages have such diverse and varied roles in infection and other 
general functions, it has been suggested that macrophage activation is not a fixed 7 or 
linear process 167, 193, but rather a dynamic one which could have overlapping 
properties 237. This study may indicate that this is the case in N. brasiliensis-induced 
chronic pulmonary pathology.  
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From the work presented here we have demonstrated a clear requirement for the 
development of an anti-inflammatory, IL-4Rα-responsive pulmonary macrophage 
population as playing a key role in the inhibition of the development of N. 
brasiliensis-induced chronic lung inflammation. Moreover, our findings provide an 
excellent model for future studies on the identification of molecular targets that may 
control the onset of chronic lung disease. Together, these studies may provide 
therapeutic targets for treatment and reversal of chronic lung diseases.  
 
 
Figure 16: Properties of classically activated macrophages and M2a, M2b and 
M2c AAM sub-types. Taken from Mantovani et al. (2004) 193. 
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5. FUTURE WORK 
 
 
The following future work is suggested: 
 
To address the question whether IL-4Rα-responsive AAMs directly control the 
increase in CD4+ T-cell numbers in the lungs of LysMCreIL-4Rα-/lox mice, 
proliferation studies should be carried out 178. Here pulmonary macrophages and T-
cells would be isolated from the lungs of infected mice and naïve control mice and co-
cultured. Assessment of T-cell proliferation by CFSE staining (or similar) would 
establish whether IL-4Rα signalling on macrophages is required to control potentially 
pathogenic T-cell proliferation. 
 
Other mechanisms suppressing proliferation could be explored including induction of 
T-cell apoptosis 178, 234 or T-cell responsiveness to arginase 72, which could affect T-
cell proliferation. Depletion or the addition of arginine to macrophage/T-cell co-
cultures and/or T-cell-only cultures would demonstrate whether macrophage arginase 
plays a direct role in controlling T-cell proliferation. To determine whether T-cell 
apoptosis can be induced by macrophages following N. brasiliensis infection, TUNEL 
and AnnexinV staining of CD4+ T-cell populations isolated from lungs of infected 
mice could be carried out.  
 
IL-10 is known to play a role in controlling inflammation 231 and regulating AAM 
biomarkers such as Ym1 and Mannose receptor 275. Therefore, it would be interesting 
to determine whether IL-10 over-expression can counteract the heightened 
inflammation seen in LysMCreIL-4Rα-/lox mice. Interbreeding inducible lung-specific 
IL-10 transgenic mice that over-express IL-10 in the lung, using the Clara cell 
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promoter 231, with LysMCreIL-4Rα-/lox mice may allow to study the effects of IL-10 in 
the N. brasiliensis–induced pulmonary inflammation model.  
 
Of particular interest would be to investigate the roles of the potential candidate genes 
associated with promoting inflammation, such as Card9, or suppressing inflammation 
such as SOCS3 and RelB. The genes Card9 and RelB were chosen as they were both 
up-regulated at two time points (5 and 42 days p.i.) in AlvMs from infected 
LysMCreIL-4Rα-/lox mice when compared to IL-4Rα-/lox AlvMs, and they were 
associated with TLR-dependent inflammation. It would be interesting to further 
investigate the role of SOCS3 in IL-4Rα−responsive macrophages as it was up-
regulated in LysMCreIL-4Rα-/lox AlvMs and down-regulated in IL-4Rα-/lox AlvMs. 
Furthermore, it would be interesting to include a naïve LysMCreIL-4Rα-/lox mouse 
control group to investigate which genes are pathogen-specific or specific to IL-
4Rα signalling in our AlvM expression profile from LysMCreIL-4Rα-/lox mice. 
Subsequently, the RNA and protein expression of the candidate genes would first be 
confirmed by qRT-PCR and western blots respectively, in isolated AlvMs. Studies of 
these genes using transgenic mice (except for SOCS3 which is lethal when abrogated 
240), or antibodies which bind and inactivate the proteins, or siRNA studies which 
inhibit mRNA gene expression, are feasible approaches to determine how these genes 
influence N. brasiliensis-induced chronic lung pathology.  
 
It is envisaged that these investigations will gain further insight into anti-
inflammatory mechanisms of AAMs in chronic lung pathology. Such findings are 
likely to be important in the future development of therapies against chronic lung 
inflammation.  
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7. APPENDIX 
 
APPENDIX A: General Media Recipes and Equipment used 
This Appendix contains recipes for media and buffers used in the project which were 
obtained from shared laboratory protocols and documentation. 
 
 
Digestion Buffer.  
0.002g DNase I (Roche Germany) 
0.0200g g Collagenase Type IV (Gibco-Invitrogen)  
Dissolve reagents in 150 ml DMEM (containing 100U/ml penicillin G, 100μg/ml 
streptomycin). Filter sterilize with a 0.22μM filter and store at 4oC for up to 7 days. 
 
ELISA Blocking Buffer 
20g Powder Milk 
0.2g NaN3 
Dissolve reagents in a final volume of 1000ml 1X PBS and store at 4ºC.  
 
ELISA Dilution Buffer 
10g BSA  
0.2g NaN3  
Dissolve the above reagents in a final volume of 1000ml of 1xPBS and store at 4ºC.  
 
ELISA Washing Buffer (20 X)  
20g KCL 
20g KH2HPO4.2H2O 
800g NaCl 
50ml Tween-20 
100ml 10% NaN3 
Make up to 5L with ddH2O and store at room temperature. Dilute in 1:20 in ddH2O. 
 
ELISA Substrate Buffer (for horseradish peroxidase conjugates) 
Peroxidase Substrate Solution B (Roche Diagnostics GmbH, Mannheim, Germany) 
TMB Peroxidase Substrate Solution A (Roche Diagnostics GmbH) 
Just before use, mix equal volumes of TMB Peroxidase Substrate (Solution A) with 
Peroxidase Substrate Solution B.  
 
Griess Reagent 1  
1g sulfanilamide 
100ml 2.5% phosphoric acid 
Dissolve 1g sulfanilamide in 100ml 2.5% phosphoric acid. Cover bottle in foil to 
protect from light and store at 4oC. 
 
Griess Reagent 2  
0.1g napthyl-ethylene-diamine 
100ml 2.5 %phosphoric acid 
Dissolve 0.1g napthyl-ethylene-diamine in 100ml 2.5% phosphoric acid. Cover bottle 
in foil to protect from light and store at 4oC. 
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1 X Phosphate Buffered Saline (PBS) 
8g NaCl 
0.2g KCl 
1.44g Na2HPO4 
0.24g KH2PO4 
Weigh out reagents and dissolve in 900ml of ddH2O and adjust pH to 7.4. Bring final 
volume to 1000ml and filter sterilize with a 0.22μM filter. 
 
Red Cell Lysis Buffer 
8.34g NH4Cl  
0.037g EDTA  
1.0g NaHCO3 
Dissolve reagents in 1000ml ddH2O. Filter sterilize (0.22μM) and store at 4 or 25oC.  
 
Equipment, Reagents and suppliers 
 
Equipment Supplier 
Maxisorb 96 well ELISA plates  Nalge Nunc International, Naperville, IKL,USA 
VersaMax microplate reader Molecular Devices Corporation, Sunnyvale, CA, U.S.A
0.22μM filter  Millipore Corporation, Bedford, USA 
 
Reagent or Kit Supplier 
3,3’,5,5’-tetramethylbenzidine (TMB) Roche Diagnostics GmbH, Mannheim, Germany 
Bovine Serum Albumin (fraction V) Roche Diagnostics GmbH, Mannheim, Germany 
Dulbecco's Modified Eagle's Medium 
(DMEM) for Cell Culture 
Gibco, Invitrogen Corporation, Carlsbad, CA, USA 
Foetal Calf Serum (FCS) Delta Bioproducts, Johannesburg, Gauteng Province, 
South Africa 
Penicillin G and Streptomycin Solution 
(100X)  
Gibco, Invitrogen Corporation, Carlsbad, CA, USA 
Peroxidase Substrate (Solution B) Roche Diagnostics GmbH, Mannheim, Germany 
TMB Peroxidase Substrate (Solution A) Roche Diagnostics GmbH, Mannheim, Germany 
Triton-X100 BDH Chemicals Ltd., Poole, England 
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APPENDIX B: FACS Antibodies 
 
 
Antibody Conjugation Dilution Factor Type Company 
Catalogue 
No. 
CD4 Biotin 1:160 Rat IgG2b Home-grown  
CD3e FITC 1:640 Hamster IgG1 Home-grown  
CD8a PE 1:160 Rat IgG2a BD-pharmingen 553033 
B220 FITC 1:160 Rat IgG2b Home-grown  
GR-1 FITC 1:80 Rat IgG2b BD-pharmingen 553125 
CCR3 PE 1:80 Rat IgG2a R&D system FAB729P 
CD11c PE 1:160 Hamster IgG1 BD-pharmingen 553802 
MHC II Biotin 1: 200 Rat IgG2a Home-grown  
FcγRII/III purified 1% Rat IgG2b BD-pharmingen 553141 
SpA-PerCP PerCP 1:600 N/A BD-pharmingen 554067 
SpA-APC APC 1:400 N/A BD-pharmingen 340130 
Isotype PE 1:200 Hamster IgG1 BD-pharmingen 554711 
Isotype PE 1:80 Rat IgG2b BD-pharmingen 556925 
Isotype FITC 1:80 Rat IgG2b BD-pharmingen 553988 
CD8 (Ly2) purified 1:200 Rat IgG2a Home-grown  
CD11b 
(MAC1) purified 1:800 Rat IgG2b Home-grown  
GR-1 Purified 1:100 Rat IgG2b Home-grown  
FcγRII/III purified 1:400 Rat IgG2bκ Home-grown  
B220 purified 1:200 Rat IgG2b Home-grown  
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APPENDIX C: Flow Cytometry Gating Strategies 
 
The gating strategies of cellular quantifications in the lung in Chapter 3.2 are given 
below, showing positive controls. Refer to Methods (Section 2.5.2) and Appendix B 
for methodology and antibody details.  
 
1.) T-cells  
Cells were labelled with anti-CD3-FITC, anti-CD4-Biotin (with streptavidin (SpA)-
PerCP) and anti-CD8-PE antibodies, and gated as follows:  
 
 
2.) B-cells  
Cells were labelled with anti-B220-FITC antibodies and gated as follows:  
 
 
3.) Neutrophils and Eosinophils 
Cells were labelled with anti-GR-1-FITC and anti-CCR3-PE antibodies. The 
following gating strategies were used to differentiate between neutrophils (GR-
1+CCR3-) and eosinophils (CCR3+GR-1int).  
 
 
4.) Alveolar Macrophages   
Cells were labelled with anti-CD11c-PE and anti-MHCII-Biotin (and SpA-PerCP) 
antibodies and defined as autofluorescent (AF+) SSChi CD11c+ MHCIILo/+. 
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APPENDIX D: Cytokine ELISA Antibodies  
 
 
 Capture Detection Standard Sensitivity 
IL-4 1:500 1:1000 250ng/ml 10 pg/ml 
Type Rat anti-mouse Biotinylated Rat anti-mouse Recombinant  
Company 
& Clone 
BD-pharmingen 
BVD4-1D11 
BD-pharmingen 
BVD6-24G2 
Pepro Tech EC 
LTD London 
 
 
 
IL-13 1:500 1:500 100ng/ml 46 pg/ml 
Type  Rat anti-mouse Biotinylated Rat anti-mouse Recombinant  
Company 
& Clone 
R&D Systems, 
Germany 
38213.11 
R&D Systems, 
Germany 
BD 
Biosciences  
INF-γ 1:500 1:1000 100ng/ml 46 pg/ml 
Type  Rat anti-mouse Biotinylated Rat anti-mouse Recombinant  
Company 
& Clone 
BD-pharmingen 
R4-6A2 
BD Biosciences 
XMG1.2 
BD 
Biosciences  
IL-10 1:500 1:1000 100ng/ml 120 pg/ml 
Type  Rat anti-mouse Biotinylated Rat anti-mouse Recombinant  
Company 
& Clone 
BD-pharmingen 
JES5-2A5 
BD Biosciences 
SXC-1 
BD 
Biosciences  
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APPENDIX  E: Gene details and Microarray analysis 
 
The gene symbols (in alphabetical order), their full names and aliases, functional clustering and accession numbers (all provided by Alun Kirby) 
which were used in microarray analysis of 460 genes, and their associated Fold Change (FC) values (Log2 scale). Columns represent FC values 
from individual experiments, with one biological repeat. WT: infected vs naïve IL-4Rα-/lox; KO: infected IL-4Rα-/- vs infected IL-4Rα-/lox;  
LysM: infected LysMCreIL-4Rα-/lox vs infected IL-4Rα-/lox. Raw values which were below detection limit were omitted (empty FC squares).  
 
Gene 
Symbol Full name(s) and Aliases 
Functional 
Clustering 
Accession 
No. (major)
WT  
Day5 
WT 
Day42 
WT 
Day180
KO  
Day5 
KO 
Day42 
KO 
Day180
LysM 
Day5 
LysM 
Day42 
LysM 
Day180 
28SRNA ribosomal protein S28 (Rps28) House 
keeping 
NM_016844 0.6 -0.6 0.5 1.0 -0.2 0.1 -0.6 -0.3 0.0 -1.1 1.6 0.5 -0.5 0.4 -0.2 -0.5 -0.3 0.9 
ABCB2 transporter 1, ATP-binding cassette B, TAP1 APC NM_013683 -2.5  3.6 0.2 2.2 -0.5 -2.8 -0.1 0.6  0.5 
ABCB3 transporter 2, ATP-binding cassette B, TAP2 APC NM_011530 -1.3 -0.8  -2.3 -1.6 1.1 -1.3 1.5 -0.1 0.1 -0.6 0.8 0.4 
ACVR1 
(ALK2) 
activin A receptor, type I  BMPs NM_0011102
04 
-0.5 -0.7 0.2 0.8 -0.9 0.0 -0.7 0.1 0.0 -0.6 1.1 0.6 -0.3 -0.3 0.5 -0.5 1.3 0.2 
ACVR2A activin A receptor, type IIA BMPs NM_007396 -0.1 -0.1 0.1 -0.4 1.1 0.2 0.9 -0.1 0.6 0.2 -0.3 1.8 0.6  0.2 
ACVR2B activin A receptor, type IIB BMPs NM_007397 -1.0  -3.8 0.8 4.3 3.5 -2.0 -0.7   
ACVRL1  activin A receptor type II-like 1 (ALK1) BMPs NM_009612 -2.0 -0.7 -0.2 2.4 -1.1 4.8 0.6 -2.6 -1.2 -3.0 1.9 -2.7 0.6 
AhR aryl-hydrocarbon receptor (Ahr) Signalling NM_013464 0.3  3.8 -0.7 0.8 -0.4 -0.7 -0.4 -1.9 0.1 2.4 -2.9 -0.2 -0.2 
ALDOA aldolase A, fructose-bisphosphate (ALDOA) House 
keeping 
NM_007438 0.5 0.5 0.2 0.8 0.0 -1.4 -0.5 -1.0 -0.3 -0.8 -0.6 1.3 -1.0 -0.3 -0.2 -0.3 0.6 0.9 
ALOX12 arachidonate 12-lipoxygenase (Alox12) Other 
(enzyme) 
NM_007440 -1.1 3.6 -3.0 -0.3 -2.8 2.2 -2.5 1.1 -1.0 2.3 -3.2 -3.0 1.8 -0.6 1.6 
ALOX15 arachidonate 15-lipoxygenase (Alox15), 12-LO, L-12LO, 
Alox12l 
Other 
(enzyme) 
NM_009660 0.4 -0.7 0.3 -1.2 0.0 0.4 -0.6 1.2 0.2 1.9 2.2 0.9 -0.1 0.5 -0.1 1.8 0.3 0.9 
ANAC019 Arabidopsis NAC domain containing protein 19 Negative NM_104167 -4.0  3.9 1.4 4.2 -1.0 -0.5 1.7  -1.4 
Arg1 arginase, liver (Arg1) Macrophage 
related 
NM_007482 0.1 -1.2 -0.2 -0.2 -0.1 0.4 0.3 -0.3 -0.4 -0.3 -0.2 -1.4 -0.9 1.8 -0.4 0.1 
ARGHDIA Rho GDP dissociation inhibitor (GDI) alpha 
(ARHGDIA) 
House 
keeping 
NM_133796 -4.5 1.4 -3.3 -0.4 -1.3 -1.2 0.5 1.3 0.5 0.9 -0.4 2.1 -1.6 1.1 0.5 
AT1G62250 Arabidopsis thaliana unknown protein (AT1G62250) Negative NM_104905 -2.2  2.5 -5.4 -1.4 3.3 -3.1 3.9 4.2 4.1 -0.6  0.9 
AT1G75170 Arabidopsis thaliana transporter (AT1G75170) Negative NM_0010362
07 
-0.7 2.7 0.2 1.1 0.7 3.8 -1.9 2.2 0.9 -2.5  -1.1 
AT1G76370 Arabidopsis thaliana protein kinase, putative  Negative NM_106286 -1.4  -1.5 0.8 2.7 -0.8 1.1 -0.4 3.0  0.6 
AT2G43280 Arabidopsis thalianaFAR1 family protein  Negative NM_129890 -2.3 -1.6 6.0 -2.7 5.1 2.4 0.2 -0.1 -0.8 4.7 -1.3 -0.3 -1.3 -0.6  
B2M beta-2-microglobulin (B2M) House 
keeping 
NM_009735 -0.7 -0.4 0.3 -3.0 1.0 0.0 0.7 0.0 -0.3 3.3 -0.6 0.6 0.7 0.2 0.5 3.0 -0.4 0.5 
b-actin actin, beta House 
keeping 
NM_007393 0.9 -0.1 0.7 0.3 0.4 -0.8 -0.1 -0.5 -0.5 0.3 -0.7 1.0 -0.6 -0.1 -0.3 0.0 -0.1 0.6 
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BAMBI BMP and activin membrane-bound inhibitor (Bambi) BMPs NM_026505 0.6 -0.4  -3.5 1.2 0.8 -0.8 -1.9 0.3  
BAX BCL2-associated X protein (Bax) Apoptosis NM_007527 -0.7 0.3 0.7 0.6 0.7 0.0 -0.5 -0.2 -0.3 -0.1 -0.1 0.6 1.2 -1.2 -0.5 0.0 0.1 0.2 
BCA1 CXCL13 Chemokine NM_018866 0.5 0.8 -0.6 -3.0 0.7 -0.5 0.4 1.1 0.3 2.8 -1.3 0.7 0.4 1.1 0.6 2.7 -1.6 0.4 
BCL10 B-cell leukemia/lymphoma 10 (Bcl10) Apoptosis NM_009740 -0.9 1.5 -1.4 -0.9 1.9 0.2 -0.8 1.1 0.2 -3.9 -1.2 0.9 0.6 
BCL2 B-cell leukemia/lymphoma 2 (Bcl2) Apoptosis NM_009741 -1.1  0.6 0.9 2.6 -1.7 1.4 1.4 0.5 -0.9 0.5  
BIK BCL2-interacting killer (Bik) Apoptosis NM_007546 -0.8  -2.6 1.7 6.7 -1.9 -3.3  3.8 
BMP1 bone morphogenetic protein 1 (Bmp1), Tolloid BMPs NM_009755 -0.2 -0.8 0.4 -0.2 -0.1 -0.6 0.7 1.0 -0.2 0.1 -0.8 1.3 -0.5 0.1 -0.5 0.4 -0.8 1.0 
BMP2 bone morphogenetic protein 2 (Bmp2) BMPs NM_007553 -1.6 -0.3  1.5 -0.7 -2.9 0.6 0.4 -3.7 0.6 6.4 0.8 -0.8 1.1 -0.8 -0.1 -1.3 
BMP4 bone morphogenetic protein 4 (Bmp4) BMPs NM_007554 -0.2 -0.1 -0.4 -1.1 -1.8 -0.1 -0.1 0.8 0.4 0.7 1.0  0.9 
BMP5 bone morphogenetic protein 5 (Bmp5) BMPs NM_007555 -0.2 -0.4 0.7 3.4 1.4 3.2 1.2 -1.2 -1.6 2.4 0.7 1.1 -3.2 2.2 0.4 
BMP6 bone morphogenetic protein 6 (Bmp6) BMPs NM_007556   -1.4 -3.2 1.5 3.7 2.5  2.7 
BMP7 bone morphogenetic protein 7 (Bmp7) BMPs NM_007557 -0.6 -0.3  -2.5 1.5 -0.5 0.9 -0.1 -1.3   
BMPR1A  bone morphogenetic protein receptor, type 1A, ALK3 BMPs NM_009758 -0.9 0.3 0.6 -1.5 -1.5 -2.3 0.2 -0.3 -0.2 1.3 -0.6 1.6 -0.3 0.1 -0.3 1.4 0.9 2.2 
BMPR1B  bone morphogenetic protein receptor, type 1B, ALK6  BMPs NM_007560 -0.5 -1.0 1.9 0.9 -2.7 0.9 0.2 -0.2 -0.6 3.6 -0.4 -1.3 -0.6 0.4 -0.1 3.3 -0.2 
BMPR2 bone morphogenic protein receptor, type II  BMPs NM_007561 -1.7  2.7 2.2 -0.5 1.2 2.3  -0.1 
BRAK CXCL14 Chemokine NM_019568 0.3  0.3 -6.3 -2.6 -1.4 0.7 3.4 0.8 -3.2 0.8 -1.7 -0.6 
BTLA B and T lymphocyte associated, BTLA1, CD272 Cytokine 
receptor 
NM_0010377
19 
0.6 2.4 1.8 2.6 1.0 3.4 -0.1 -0.1   
C5aR complement component 5a receptor 1 (C5AR1) Surface 
receptor 
NM_007577 -3.3 1.5 -5.0 2.8 1.2 -0.7 3.6 1.1 0.3 -0.2 2.3  
CAC2 acetyl co-enzyme A carboxylase biotin carboxylase Negative NM_122927 -0.2 -0.3 0.3 1.4 -0.7 -0.6 0.5 0.6 -0.6 0.4 0.4 -2.3 -0.8 -0.2 -0.9 0.7 0.5 
card9 caspase recruitment domain family, member 9 
(Card9) 
TLR related NM_0010377
47 
-0.3 -0.2 -1.1 -2.0 -1.0 -0.1 0.1 -0.1 1.5 -0.4 0.6 0.6 0.5 1.0 1.5 -0.3 0.3 
Caspase1 caspase 1 (Casp1) IL-1B converting enzyme Apoptosis NM_009807 -0.3 -0.3 0.1 -1.8 -0.8 -0.3 0.2 0.1 0.2 2.0 1.0 0.4 -0.9 0.2 0.0 2.0 0.4 0.3 
Caspase2 apoptosis-related cysteine peptidase (CASP2) Apoptosis NM_007610 0.4 -0.5 0.3 -0.1 0.1 -1.0 -2.2 0.2 0.0 -0.2 0.1 0.6 -0.7 -0.1 0.3 -0.2 0.5 
Caspase3 caspase 3, apoptosis-related cysteine peptidase  Apoptosis NM_009810 -1.7  1.1 2.6 1.1   
Caspase7 caspase 7, apoptosis-related cysteine peptidase Apoptosis NM_007611 -1.6 1.8 -5.3 2.1 2.5 -1.1 1.1 -2.5  
Caspase8 apoptosis-related cysteine peptidase,  MCH5, FLICE Apoptosis NM_009812 -0.9  -2.4 -1.5 1.6 -1.0 2.0 0.5 -0.5 0.7 2.0 -0.2 
Caspase9 apoptosis-related cysteine peptidase (CASP9) Apoptosis NM_015733 -1.1  1.5 -1.3 1.6 -1.0 -1.2 -0.2 1.7   
cathepsinB cathepsin B Cathepsin NM_007798 0.9 0.1 0.8 -0.9 -0.6 -1.5 -0.8 -0.3 0.0 0.7 0.1 0.6 -0.5 0.1 -0.4 0.9 0.2 0.9 
cathepsinD cathepsin D Cathepsin NM_009983 0.6 0.7 -0.4 0.5 0.1 -1.0 0.5 -0.8 -0.3 0.0 -1.3 0.6 0.1 0.2 -0.4 0.0 0.5 0.1 
cathepsinF cathepsin F Cathepsin NM_019861 0.3 0.9 -0.9 -0.7 -0.3 -0.5 0.5 -2.1 -1.2 -0.5 -0.5 -0.4 -0.4 -6.5 0.4 0.2 
cathepsinH cathepsinH Cathepsin NM_007801 -0.4 0.4 -0.5 -0.9 0.1 -0.5 0.4 -0.1 -0.4 1.2 -0.5 0.1 -0.4 -0.1 0.5 1.0 0.1 0.4 
cathepsinK cathepsin K (CTSK) Cathepsin NM_007802 0.2 0.0 -1.1 0.4 -0.6 -0.6 0.0 -0.5 0.0 0.1 0.8 0.7 0.0 0.9 0.0 0.9 0.2 
cathepsinL cathepsin L Cathepsin NM_009984 0.5 0.6 0.5 -0.4 0.0 -0.6 -0.5 -0.2 0.7 -0.5 0.1 -0.8 0.1 0.0 0.4 0.4 0.2 
cathepsinS cathepsin S Cathepsin NM_021281 0.4 0.4 0.7 -1.1 0.4 -0.4 -0.3 -1.0 -0.5 1.4 -0.7 0.6 -0.1 -0.1 -0.2 1.2 -0.1 0.5 
cathepsinZ cathepsin Z Cathepsin NM_022325 0.1 1.4 -0.5 -1.1 -0.1 -0.5 -0.3 -0.8 -0.3 1.1 -0.7 0.6 -0.6 -0.3 0.7 1.7 -0.2 0.1 
CCL1 CCL1 Chemokine NM_011329 2.0 0.0 1.6 -0.4 1.5 -0.9 1.5 1.9 0.7 -4.0 -2.4 1.3  1.0 
CCR1 CCR1 Chemokine 
receptor 
NM_009912 0.4 -0.5 0.4 1.3 -0.4 -1.0 0.3 0.4 0.3 -0.5 0.6 1.0 -0.6 -0.4 0.0 -1.0 0.8 0.6 
CCR2 CCR2 Chemokine 
receptor 
NM_009915 -0.2 -0.6 3.0 1.6 -0.5 1.3 -2.1 -0.3 0.2 1.0 1.2 -1.7 -0.3  -0.6 
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CCR3 CCR3 Chemokine 
receptor 
NM_009914 -0.8  0.0 -1.0 2.1 0.1 0.7 -0.4 -1.3 0.8  1.4 
CCR4 CCR4 Chemokine 
receptor 
NM_009916 -2.9 -1.3 1.2 -0.9 0.1 1.9 -0.2 0.8 0.1 0.0 3.4 -1.7 -0.3 -1.0 0.1 -0.6 
CCR5 CCR5 Chemokine 
receptor 
NM_009917 -0.7 -0.6 0.2 0.3 0.0 -0.2 0.7 0.0 -0.4 0.2 -0.3 1.0 1.1 0.7 0.0 0.3 -0.4 0.4 
CCR6 CCR6 Chemokine 
receptor 
NM_009835 0.5 -0.2 0.2 1.5 -0.3 0.0 -1.4 0.4 -0.1 -0.6 0.0 -0.3 -0.1 -0.2 -0.4 -0.4 -0.3 -0.5 
CCR7 CCR7 Chemokine 
receptor 
NM_007719 1.1 -0.5 0.1 2.6 -0.9 -1.7 1.2 0.3 -1.5 0.3 0.9 -2.8 -0.4 0.3 -1.0 0.3 0.8 
CCR8 CCR8 Chemokine 
receptor 
NM_007720 -0.4 -0.9  1.9 0.0 -2.2 0.3 2.0 -1.5 0.0 1.9 -1.3 0.2 3.1 -0.5 -0.5 1.4 
CD115 colony stimulating factor 1 receptor (Csf1r), Fms, CD115 Surface 
receptor 
NM_0010378
59 
-0.7  -1.8 1.8 -6.9 0.9 -5.3  -0.7 
CD11b CR3, CR3A, MAC1, Cd11b, integrin alpha M (Itgam) Integrin NM_0010829
60 
0.6 0.3 2.2 -0.8 -1.2 -0.8 -1.0  -0.7 
CD11c Integrin alpha x, CD11c Integrin NM_021334 -2.0  -0.8 1.0 2.2 -0.2 0.6 -0.2 -0.3 0.2 0.8  
CD123 interleukin 3 receptor, alpha (low affinity) (IL3RA), 
CD123 
Cytokine 
receptor 
NM_008369 -0.1 0.3 -1.0 -0.9 -0.8 -0.6 0.3 -0.3 0.0 1.1 -0.2 0.8 0.5 0.6 0.1 1.2 -0.1 0.1 
CD14 CD14 molecule (CD14) Macrophage 
related 
NM_009841 -0.7 1.0 -0.3 -2.5 -1.0 -1.0 0.8 0.1 -0.4 2.0 -0.4 1.0 0.8 0.1 0.4 2.7 0.2 0.9 
CD18 Cd18, Lfa1, integrin beta 2 (Itgb2) Integrin NM_008404 0.4 -0.2 -0.4 -1.8 -0.4 -0.9 -1.7 -0.2 -0.4 1.5 -0.2 0.5 -0.5 0.1 0.6 1.7 0.1 0.4 
CD1d1 CD1d1 antigen (Cd1d1) APC NM_007639 -1.4 -0.1 1.3 0.9 0.1 -0.3 1.0 -0.2 0.0 0.0 -0.1 1.3 0.2 0.3 0.0 0.7 -0.2 
CD1d2 CD1d2 antigen (Cd1d2) APC NM_007640 0.6 1.5 1.7 -1.7 -1.0 0.7 0.6 -0.6 0.7 0.3 -1.6 -0.1 -0.1 1.8 0.2 
CD200 CD200 antigen (Cd200) Surface 
receptor 
NM_010818 -0.1 -0.8 1.0 -1.4 -0.6 -0.7 -3.4 -0.7 -0.9 0.9 0.5 0.9 0.5 -0.9 -0.1 1.0 -0.5 0.7 
CD200R1 CD200 receptor 1 (Cd200r1) Surface 
receptor 
NM_021325 -0.8 0.2 0.4 0.6 0.3 0.0 -0.4 -0.2 0.0 -0.4 0.2 0.3 0.9 -0.1 -0.2 -0.3 0.3 0.0 
CD200R2 Cd200 receptor 2 (Cd200r2) Surface 
receptor 
NM_206535 0.9 -1.3  -2.3 1.8 -0.9 1.7  4.0 
CD200R3 Cd200 receptor 3 (Cd200r3) Surface 
receptor 
NM_0011281
32 
0.1 -0.3 0.2 -2.0 -0.3 -0.2 -0.4 0.0 0.0 2.1 0.6 0.3 -1.1 0.2 -0.2 2.2 -0.1 0.3 
CD200R4 Cd200 receptor 4 (Cd200r4) Surface 
receptor 
NM_207244 -1.4 1.5 1.4 -0.4 -3.5 2.0 -0.6 -1.0 0.0 2.0 -0.1 -2.0 2.7 
CD205 lymphocyte antigen 75, CD205, CLEC13B, DEC-205 Surface 
receptor 
NM_013825 -2.7 -0.8  -2.7 -1.6 2.3 -0.5 1.7 -0.5 -2.2 -0.5 1.7 -0.3 
CD32 Fc fragment of IgG, low affinity IIb, receptor (CD32) Surface 
receptor 
NM_0010771
89 
0.5 -0.3 0.5 -1.8 0.3 -0.6 0.1 -0.1 0.1 1.9 -0.2 0.5 0.1 0.0 -0.7 1.9 0.0 0.2 
CD33 CD33, p67, SIGLEC3, SIGLEC-3 Lectin NM_0011110
58 
-1.4 -0.9  5.5 0.2 -1.8 1.4 -1.8 -2.1 3.8 1.9  1.4 
CD36 CD36 molecule (thrombospondin receptor) Surface 
receptor 
NM_007643 -2.9 -1.2 -1.5 -0.1 0.2 5.0 2.2 3.4 -1.5 2.2 0.6 3.2 0.8 2.1 -0.9 2.4  
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CD4 CD4 molecule (CD4) Surface 
receptor 
NM_013488 0.0 0.3 3.6 -1.8 -0.6 1.4 -1.9 -0.8 -0.1 0.4 -0.5 0.1 0.8 0.2 
CD40 CD40, TNF receptor superfamily member 5 APC NM_011611 -1.4 -1.2 -0.8 3.0 3.0 -1.1 0.0 -0.5 1.7 -2.9 -0.7  
CD40L IGM, IMD3, Ly62, TRAP, gp39, CD154, Cd40l,HIGM1, 
Ly-62, T-BAM, Tnfsf5 
Surface 
receptor 
NM_011616 -2.8 0.7 0.6 0.7 -1.7 -1.8 -0.1 -1.1 0.6 3.7 -0.8 0.3 -0.1 0.7 0.1 
CD44 CD44 molecule (Indian blood group) Surface 
receptor 
NM_009851 2.2  0.0 0.5 -0.6 0.6 1.5 1.1 -0.5 -2.4 -4.4 1.1 -1.2  -1.3 
CD47 CD47 antigen (Rh-related antigen, integrin-
associated signal transducer) (Cd47) 
Apoptosis NM_010581 0.1 -0.3 0.3 -1.6 0.3 -0.6 0.6 0.2 -0.2 1.6 -0.2 0.6 0.6 0.2 -0.4 1.7 0.2 0.2 
CD48 CD48, BCM1, BLAST, Bcm-1, BLAST1, SLAMF2 Surface 
receptor 
NM_007649 -0.7 -0.5 1.8 -4.2 -0.3 0.0 0.9 -0.9 2.7 1.3 0.7 0.4  -1.3 
CD51 integrin, alpha V (vitronectin receptor alpha, CD51) Integrin NM_008402 0.1 0.1 0.9 0.9 1.0 1.4 4.4 1.4 0.7 1.7 -2.1 -1.3 2.3 -0.7 -1.9 
CD61 integrin, beta 3 (platelet glycoprotein IIIa, CD61) Integrin NM_016780 -0.1 0.6 -0.5 0.3 -3.2 -3.3 -0.6 -0.6 0.8 -0.7 0.2 1.1 -0.1 -0.3 0.4 -0.6 0.4 -2.0 
CD68 CD68, GP110, SCARD1, macrosialin Macrophage 
related 
NM_009853 -0.6 1.2 -0.8 -2.5 -0.1 -0.7 0.6 0.0 0.4 2.0 -0.6 0.3 0.5 0.0 0.8 2.2 0.0 0.5 
CD8 CD8alpha  (CD8a) Surface 
receptor 
NM_0010811
10 
1.3 -0.4 -3.1 0.2 0.2 -0.4 -0.6 0.3 -1.5 0.0  
CD80 CD80 molecule (CD80) APC NM_009855 0.4 -0.7 -0.3 2.3 -1.9 -0.1 1.2 1.3 -0.8 1.5 -0.2 -1.5 0.0 0.4 -0.3 0.4 -0.3 
CD84 CD84, LY9B Surface 
receptor 
NM_013489 0.7 -0.4 0.3 0.1 -1.2 -1.5 -0.8 -0.2 0.4 0.1 -0.2 0.9 -0.8 0.2 0.1 0.2 -0.1 0.7 
CD86 CD86 molecule, B70, B7-2 APC NM_019388 -0.9  -3.2 -2.2 2.2 -0.2 2.3 0.8 0.0 -5.6 -0.8 0.9 -1.1 
CHORDIN chordin (Chrd) BMPs NM_009893 -0.1 -0.8 1.1 -1.4 0.5 -0.6 -1.0 1.8 -1.5 1.9 -0.8 0.7 -0.5 1.2 -0.7 1.8 -1.2 0.4 
CIITA MHC classII  transactivator APC NM_007575 -0.6 -0.5 -0.5 -0.6 -0.1 0.0 0.5 0.8 0.0 1.3 0.8 1.2 0.1 0.6 0.3 1.7 0.3 0.9 
CLEC1b C-type lectin domain family 1, member B, CLEC2 Lectin NM_019985 6.5 -0.1  1.1 0.6 0.4 -0.5 3.5 2.3 0.2 2.5 -1.8 0.0 1.9 -0.1 -1.2 -0.7 
CLIP CD74, major histocompatibility complex, class II invariant 
chain 
APC NM_0010426
05 
-0.4 -0.2 0.4 -1.1 -1.1 -0.7 -2.1 -0.4 -0.5 0.7 0.9 0.8 0.8 -1.1 0.7 0.5 -0.2 0.6 
cYc interleukin 2 receptor, gamma,CD132, 
commongammachain 
Cytokine 
receptor 
NM_013563 -0.2 0.4 -0.5 -0.7 -0.8 -0.5 -1.3 -0.2 -0.5 0.4 0.3 -0.2 -0.1 0.1 0.6 0.7 0.3 0.2 
CV2 BMPER, Cv2, CRIM3, CROSSVEINLESS BMPs NM_028472   -1.4 2.3 0.3 1.7 -3.5 0.3 2.7  -0.9 
CRP C-reactive protein, pentraxin-related (Crp) Other (acute 
phase) 
NM_007768 -0.8 3.3 1.7 0.9 -2.3 0.1 -0.6 -0.3 -0.8 -4.8 
CTACK CCL27 Chemokine NM_0010481
79 
-1.0 0.2  -1.0 1.5 6.0 -1.9 3.6   
CX3CR1 CX3CR1 Chemokine 
receptor 
NM_009987 -1.5  2.6 1.6 1.0 3.1 1.0 3.3 2.7  -2.0 
CXCL16 CXCL16 Chemokine NM_023158 0.1 -2.6 1.9 1.4 1.7 2.1 0.9 0.2 -1.3 1.8 -1.2 -1.7   
DAP12 TYRO protein tyrosine kinase binding protein (Tyrobp) 
Ly83 DAP12 KARAP 
TLR related NM_011662 1.7 2.1 -1.0 -0.1 -0.6 -2.4 0.7 -1.2 -0.2 0.0 0.7 -9.0 -0.4 -0.4 2.5 0.6 
DCAR DCAR, Aplra2, Clec4b, mDcar2, DCARbeta Surface 
receptor 
NM_027218 4.6 0.8 0.0 -0.2 0.5 0.1 -0.7 -0.4 -0.4 4.0 -0.4 -0.2 0.3 -0.2 -0.9 
DCAR1 C-type lectin domain family 4, member b2 (Clec4b2) 
Aplra1, mDCAR1 APC lectin-like receptor A1 
Lectin NM_0010041
59 
-0.4 0.6 -0.8 -0.5 -0.8 -0.5 -0.2 -0.4 -0.3 0.2 0.3 0.6 -0.1 0.1 0.6 0.6 0.6 -0.6 
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DCIR C-type lectin domain family 4, member a, DCIR, LLIR, 
DDB27, CLECSF6 
Lectin NM_011999 -0.6 0.4 -0.7 -1.6 0.0 -0.4 1.2 -0.8 -0.5 1.4 -0.7 0.1 0.5 -0.3 0.8 1.3 -0.1 0.1 
DC-SIGN CD209, CLEC4L, DC-SIGN, DC-SIGN1, Lectin NM_133238 -3.2  2.4 5.2 1.8   
Dectin-1 C-type lectin domain family 7, member A Lectin NM_020008 0.2 -0.3 -0.2 1.4 0.4 -0.5 0.5 -0.4 0.7 -1.5 -0.8 0.5 -0.3 0.4 0.3 -1.5 0.1 0.0 
Dectin2 C-type lectin domain family 4, member n, CLECSF10 Lectin NM_020001 -0.3 0.4 -0.3 0.4 0.7 -0.4 0.3 0.0 -0.1 0.0 -1.7 0.9 0.1 0.0 0.2 0.0 0.1 -0.1 
Dkk-1 dickkopf homolog 1 (Xenopus laevis) (Dkk1) Signalling NM_010051 0.4 -0.6 -0.3 1.1 -0.7 -1.1 -5.4 0.5 1.3 0.0 -0.4 0.6 0.1 0.9 1.0 0.0 -0.7 0.6 
Dkk-2 dickkopf homolog 2 (Xenopus laevis) (Dkk2) Signalling NM_020265 1.6  1.8 -1.5 4.1 3.2 -2.2 2.1 -0.4 1.4 1.1 1.5 
Dkk-3 dickkopf-3 (dkk-3 gene) Signalling NM_015814 -3.6 -1.9 -2.5 3.0 1.9 5.6 0.5 -3.0 0.7 0.5 1.6  0.9 
Dkk-4 dickkopf homolog 4 (Xenopus laevis) (Dkk4) Signalling NM_145592 -0.1 0.4 -0.4 -0.4 -5.0 -5.5 -0.4 -0.2 2.6 7.0 0.0 1.6 0.3 2.5 2.8 
DR3 tumor necrosis factor receptor superfamily, member 25, 
TR3, Wsl, DDR3, LARD, APO-3, TRAMP, WSL-1, 
Apoptosis NM_033042 0.2 -0.7 0.4 -0.9 -0.2 -0.5 -0.8 -0.1 0.5 1.1 -0.2 1.3 -0.1 0.2 -0.3 1.3 -0.3 0.6 
DR5 tumor necrosis factor receptor superfamily, member 10b  
(Tnfrsf10b) Ly98  KILLER  TRICKB  TRAILR2 
Apoptosis NM_020275 -1.2 -1.1 0.8 1.0 0.3 2.0 0.6 -1.0 0.9 -0.5 1.7 0.2 -0.4 -3.2 0.7  
DR6 tumor necrosis factor receptor superfamily, member 21, 
DR6, death receptor 6 
Apoptosis NM_178589 0.0 -0.9 0.0 -0.3 -0.6 -0.3 -0.2 0.6 0.0 1.0 0.6 1.1 0.1 0.9 0.2 1.2 0.3 0.5 
EFNA1 ephrin A1 (Efna1) Ephrin NM_010107 -0.3  1.8 0.9 3.2 2.5 -0.9 -1.8 -2.0  -2.7 
EFNA1 ephrin A3 (Efna3) Ephrin NM_010108 -1.2 0.1  1.4 -1.3 1.7 -0.6 -0.9 -1.0 -0.1 -1.5   
EFNA2 ephrin A2 (Efna2) Ephrin NM_007909 0.4 -1.1  3.5 -1.5 -1.1 1.8 1.2 -0.6 1.2 0.4 -0.1 2.6 -1.8 0.7  
EFNA4 ephrin A4 (Efna4) Ephrin NM_007910 0.1 -0.7 -0.6 0.9 -1.7 -1.3 0.5 1.2 -0.8 0.9 0.5 0.0 -0.1 2.1 -0.6 0.4 -0.1 
EFNA5 ephrin A5 (Efna5) Ephrin NM_207654 -1.5 -0.3 0.5 -1.8 1.2 0.8 1.2 0.8 -0.5 2.4 -0.7 0.7 1.0 1.0 -1.1 2.2 -0.4 0.3 
EFNB1 ephrin B1 (Efnb1) Ephrin NM_010110 -1.7 -1.3 2.0 5.0 -1.7 0.4 2.0 0.4 -0.1 1.9 3.2 2.3 -0.3 -0.1 -0.5 1.4 -0.2 
EFNB2 ephrin B2 (Efnb2) Ephrin NM_010111 -0.3 1.1 -1.6 -0.8 2.6 2.0 -1.7 3.0 2.6 -1.6 0.7 2.3 0.1 1.5 
EFNB3 ephrin B3 (Efnb3) Ephrin NM_007911 -2.3 -0.7 0.4 -1.4 -1.6 -2.5 2.0 1.5 -0.6 2.1 3.6 0.8 -0.5 -0.1 -0.1 0.1  
ELC CCL19 Chemokine NM_011888 -1.1  0.2 1.8 -1.1 1.6 -2.4 2.4 -0.7 1.7 -6.2 -0.4 
ENA78 CXCL5, LIX, GCP-2, Scyb5, Scyb6, ENA-78, AMCF-II Chemokine NM_009141 1.4 -0.9 -4.2 -1.0 -2.3 -0.4 0.8 0.9 -0.3 1.2 -0.9 -0.1 4.2 0.3 -1.6 
Endoglin CD105, Endoglin BMPs NM_007932 1.4 0.4 0.2 0.2 -0.9 -1.5 -0.8 -0.5 -0.4 -1.0 0.1 1.3 -0.2 -0.3 0.4 -0.6 -0.4 1.0 
Eotaxin CCL11 Chemokine NM_011330 -1.5  1.0 0.0 -2.2 2.9 -9.5 0.2 -5.6 4.5  -0.7 
Eotaxin-2 CCL24 Chemokine NM_019577 -0.3 1.2 -0.1 -2.6 -0.5 -0.9 0.5 0.1 1.0 2.4 -0.1 0.6 0.5 0.1 0.7 2.4 -0.4 1.0 
Eotaxin-3 CCL26 Chemokine NM_0010134
12 
0.0 -3.7 2.4 2.0 2.2 5.4 2.5 -2.5 -0.3 0.0 1.5 1.7 -0.7 
EphA1 Eph receptor A1 (Epha1) Eph Family NM_023580 0.0  0.9 -1.8 2.1 -2.1 1.8 4.7 -2.6 0.5 
EphA2 Eph receptor A2 (Epha2) Eph Family NM_010139 0.0 0.3 1.0 0.6 -0.5 -0.6 0.1 0.4 0.3 -1.1 0.6 0.6 -1.2 0.1 0.1 -0.4 -0.3 0.3 
EphA3 Eph receptor A3 (Epha3) Eph Family NM_010140 4.2  -0.5 0.6 -0.8 -1.2 0.6 3.0 0.4 1.1 0.7 
EphA4 Eph receptor A4 (Epha4) Eph Family NM_007936 1.5 -0.2  1.5 -0.9 -2.1 1.7 3.7 2.0 -0.4 -0.7 -1.2  3.5 
EphB1 EPH receptor B1 (EPHB1) Eph Family NM_173447 -1.9  1.1 3.8 1.5 1.3 -3.8 -0.2  0.4 
EphB2 EPH receptor B2 (EPHB2) Eph Family NM_010142 -1.5  2.9 0.3 2.5 0.8 1.3 -0.5 0.9  -0.2 
EphB4 EPH receptor B4 (EPHB4) Eph Family NM_010144 0.0  1.2 2.4 1.9 -1.9 -4.0 6.0 1.4 -2.2  
F4/80 egf-like module containing, mucin-like, hormone 
receptor-like 1 (EMR1), Ly71, F4/80 
Macrophage 
related 
NM_010130 0.4 -0.3 0.2 -1.5 -1.0 -1.6 -0.6 0.4 1.2 1.1 -0.3 1.3 -0.1 0.5 0.5 1.5 -0.4 1.2 
FADD Fas (TNFRSF6)-associated via death domain (Fadd) Apoptosis NM_010175 -0.5  2.5 -6.5 1.9 -3.2 6.3 -0.9 -1.0 4.9  
Fas Fas (TNF receptor superfamily, member 6), APT1, 
CD95, FAS1, APO-1 
Apoptosis NM_007987 0.0  1.2 -1.8 -1.5 1.3 1.5 0.4 1.8 -0.1 1.1 0.6 
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Fas-L Fas ligand (TNF superfamily, member 6) (FASLG) 
CD178, CD95L 
Apoptosis NM_010177 -0.2 2.0 -2.8 -0.2 2.1 -2.5 -0.8 -1.1 -2.4   
FcgRIII Fc receptor, IgG, low affinity III (Fcgr3) Surface 
receptor 
NM_010188 -1.8 0.5 0.5 2.1 4.3 -0.2 1.7 -2.1 1.4 0.0   
FcGRIV Fc receptor, IgG, low affinity IV (Fcgr4) Surface 
receptor 
NM_144559 1.2 -0.2 0.6 -0.6 -0.1 -0.2 -0.7 -0.6 -0.3 0.4 -0.3 0.9 -1.0 0.1 -0.3 0.5 -0.5 0.6 
FcRe Fc receptor, IgE, high affinity I, alpha Surface 
receptor 
NM_010184 0.6 0.8 -0.5 -0.4 0.1 -1.1 0.4 -0.8 -0.2 0.9 -1.4 0.6 -0.1 0.1 -0.3 0.9 0.5 0.3 
FFAR2 free fatty acid receptor 2; FFA2R, GPR43 Surface 
receptor 
NM_146187 -0.9 -0.6 -0.7 -1.5 0.1 -0.7 0.5 -0.3 -0.3 1.5 -0.2 0.1 0.2 0.3 0.7 1.3 0.0 0.1 
FGF-1 fibroblast growth factor 1 (Fgf1) Cytokine NM_010197 0.8  2.1 2.3 1.1 -1.4 2.1 -1.2 0.6 2.0 -0.9 1.9 -0.5 0.3 
FGF-2 fibroblast growth factor 2 (Fgf2) Cytokine NM_008006 -0.4  3.3 1.9 1.6 1.2 -6.2 -3.5 
FGF-5 fibroblast growth factor 5 (Fgf5) Cytokine NM_010203 -0.6 -0.9 -0.1 2.1 -1.5 2.2 -4.5 1.5 1.1 -2.2  1.2 
FIZZ1 resistin like alpha (Retnla) Fizz1 RELMa RELMalpha Macrophage 
related 
NM_020509 0.5 2.1 1.0 -3.0 0.3 -0.9 -0.5 -1.0 -0.5 2.9 -0.7 0.9 0.0 -0.1 -0.5 2.8 -1.2 0.7 
Fractalkine CX3CL1 Chemokine NM_009142 0.2 1.7 -1.3 0.2 -0.3 -0.6 0.6 0.0 0.1 3.3 -0.2 -0.2 -1.5   
FURIN furin (paired basic amino acid cleaving enzyme), SPC1, 
PCSK3, FUR, PACE 
BMPs NM_011046 -1.1 0.2  0.6 -1.4 -0.2 1.3 -0.6 0.1 1.0 0.0 -0.6 0.6 -0.2 0.0 
FV1 Friend virus susceptibility 1 (Fv1)  TRIM Family NM_010244 0.1 -0.4 0.6 -7.4 -0.4 1.0 -0.5 -2.4 6.3 -1.2 -0.3 -0.4 5.4 0.0 
Fzd5 frizzled homolog 5 (Drosophila) (Fzd5) Signalling NM_022721 1.1 0.1 -0.7 0.0 -0.6 -0.7 -1.0 -0.3 1.0 0.0 0.0 0.9 -0.5 0.5 0.9 0.1 0.1 0.3 
GAIP regulator of G-protein signaling 19 (RGS19) GPR NM_026446 -1.3 -0.7 0.7 2.7 1.6 -2.7 1.2 1.7 -0.5 -2.8 1.2 1.6 1.9 -0.8 -2.9 -2.2 
Galphai1 guanine nucleotide binding protein (G protein), alpha 
inhibiting activity polypeptide 1 (GNAI1) 
GPR NM_010305 0.7 -0.7 -1.4 2.3 1.9 -0.1 0.9 0.5 -3.8 -0.6 0.1 -0.5 -0.5 -3.3 
Galphai2 guanine nucleotide binding protein (G protein), alpha 
inhibiting activity polypeptide 2 (GNAI2) 
GPR NM_008138 -0.6 -0.3 0.0 -0.7 0.8 0.1 0.3 -0.1 1.8 -0.1 0.2 -0.6 -1.1 -0.1 1.2 -0.2 -0.1 
Galphai3 guanine nucleotide binding protein (G protein), alpha 
inhibiting activity polypeptide 3 (GNAI3) 
GPR NM_010306 0.6 -1.9 1.2 0.0 -0.5 2.9 0.1 -0.6 0.1 0.0 1.8 -0.1 -1.2 -0.2 -0.1 4.1 
Galphaq/11 guanine nucleotide binding protein (G protein), alpha 
11 (Gq class) (GNA11) 
GPR NM_010301 0.3 0.7 0.5 -0.7 -0.9 1.3 0.2 -1.3 0.4 0.9 -0.7 -4.1 -1.6 -1.7 0.6 0.7 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) 
House 
keeping 
NM_008084 0.8 0.2 0.0 -0.6 -0.2 -1.1 -1.1 -0.3 0.8 0.6 0.6 0.8 -0.2 0.1 -0.3 1.0 -0.1 1.0 
GCP2 CXCL6 Chemokine NM_030712 -0.8 0.7 -0.2 1.0 1.2 2.3 1.1 0.4 -3.2 -2.3 -1.0 1.8 0.2 -3.5 -4.6 
G-CSF colony stimulating factor 3 (granulocyte) (CSF3) Cytokine NM_009971 -6.5 0.0  -0.9 0.9 1.5 7.6  -1.6 
GMCSF CSF2 (granulocyte-macrophage), GMCSF, CSF2 Cytokine NM_009969 -0.2  -1.1 0.3 1.2 -0.2 3.7 -0.3 -1.4 0.3 2.3 0.2 -0.6 0.5 0.0 
GMCSFR colony stimulating factor 2 receptor, alpha, low-
affinity, GMCSFR 
Cytokine 
receptor 
NM_009970 3.0 0.0 0.6 0.7 1.2 -2.8 3.7 5.1 -0.7 0.8 4.1 1.4 
GNB2L1 guanine nucleotide binding protein (G protein), beta 
polypeptide 2 like 1 (Gnb2l1) 
House 
keeping 
NM_008143 0.4 0.0 0.3 0.1 0.3 -1.1 -0.4 -0.7 -0.2 -0.5 -0.4 0.1 0.1 -0.1 -0.4 -0.1 -0.1 0.9 
GPCR160 G protein-coupled receptor 160, GPCR1, GPCR150 GPR NM_0011343
85 
0.5 -0.2 0.6 0.9 -1.1 -1.0 -0.6 -0.3 0.2 -0.7 0.3 1.1 0.0 0.0 0.0 -0.6 0.3 0.7 
GPR15 G protein-coupled receptor 15 (GPR15) GPR XM_916786 -0.2 -1.3 -0.7 1.3 -1.5 -2.4 -2.0 1.7 0.3 0.1 0.1 0.8 -1.4 -0.2 1.4 0.4 0.1 0.5 
GPR33 G protein-coupled receptor 33, pseudogene in human GPR NM_008159 0.1 -1.6 0.0 0.5 -1.0 1.0 0.7 -0.6 0.7 0.3 0.0 1.3 -0.5  -0.1 
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GPR34 G protein-coupled receptor 34, GPR34 GPR NM_011823 -0.9 -0.4 -2.7 2.3 0.9 -1.5 -3.2   
GPR85 G protein-coupled receptor 85 GPR NM_145066 -0.3 -1.1 1.4 1.9 0.6 -0.5 1.1 0.2 -1.5 -0.9 -1.1 -1.0 -1.1 -3.2  
GREMLIN gremlin 1 (Grem1) BMPs NM_011824 -1.6 -0.3 -0.6 0.8 0.5 -0.7 -0.1 1.0 -1.8  0.7 
GREMLIN2 Grem2, Prdc, FLJ21195, CKTSF1B2, DAND3  BMPs NM_011825 -0.1 -0.3 0.4 0.7 0.8 -1.0 1.2 0.0 0.1 -1.6 1.2 -1.7 
GROa CXCL1 Chemokine NM_008176 1.1 0.4 -0.4 -1.7 -0.8 -0.8 0.5 -0.3 -0.3 0.2 0.8 0.9 -0.1 0.3 2.2 -0.5 0.3 
GROb CXCL2 Chemokine NM_009140 -0.3 1.4 -0.9 -2.2 -0.9 -0.6 0.8 -0.8 -0.1 2.6 0.3 0.7 0.0 -0.1 0.8 3.1 -0.3 0.2 
GROg CXCL3 Chemokine NM_203320 0.0 0.7 -0.8 -2.4 -1.5 -0.7 0.7 -0.7 0.7 2.0 0.4 0.8 0.1 -0.3 0.8 2.1 0.2 0.5 
GUSB glucuronidase, beta (GUSB) House 
keeping 
NM_010368 -0.1 0.4 0.5 3.6 0.3 -1.4 0.3 1.7 1.0 -1.6 -0.8 1.6 0.9 -0.1 0.6 -3.0 0.3 1.1 
HDAC2 histone deacetylase 2 (Hdac2) Gene 
expression 
NM_008229 1.0 -0.9 1.9 1.6 -1.9 -1.4 1.2 0.6 0.3 1.3 0.7 -0.3 0.6 -0.8 1.2 0.3 
HDAC3 histone deacetylase 3 (Hdac3) Gene 
expression 
NM_010411 1.3 0.4  4.4 -2.9 -1.2 0.0 2.4 -0.1 1.5 -3.1 2.8 0.4 
HDAC5 histone deacetylase 5 (Hdac5) Gene 
expression 
NM_0010776
96 
-0.8 -0.5 0.3 0.5 -1.1 -0.9 1.0 0.4 -0.5 0.6 0.4 0.2 -0.5 0.2 -0.5 0.2 -0.7 
Helicard IFN induced helicaseC domain 1 (Ifih1),Hlcd, MDA5 TLR related NM_027835 -3.0 2.7 1.9 2.6 1.4 4.1 -1.6 3.6 -6.4 -1.0 -2.8  -1.9 
HIF1a hypoxia inducible factor 1, alpha subunit (Hif1a) Gene 
expression 
NM_010431 -1.1 4.0 -2.4 -1.5 3.5 -2.7 1.8 0.0 -0.4 -1.1 0.3 -0.5 
HIF1N hypoxia-inducible factor 1, alpha subunit inhibitor Hif1an Gene 
expression 
NM_176958 2.4 -1.4 -0.6 -1.4 -4.7 -9.3 0.5 2.7 -0.2 1.3 4.0 ### -1.4 -0.6 -0.1 2.3 0.3 7.9 
HMGB1 high mobility group box 1 (Hmgb1) Gene 
expression 
NM_010439 0.3 -0.1 0.5 -0.9 -0.5 -0.4 -1.2 0.3 -0.5 1.2 0.6 0.5 -0.1 0.4 -1.0 1.5 0.2 0.5 
HMOX1 heme oxygenase (decycling) 1 (Hmox1) Other 
(enzyme) 
NM_010442 -0.7 1.3 0.7 -1.8 0.5 0.1 -0.8 -0.8 -0.6 1.7 -0.1 0.1 -0.1 -0.6 -0.2 2.2 0.1 0.1 
HMOX2 heme oxygenase (decycling) 2 (Hmox2) Other 
(enzyme) 
NM_010443 0.3 -0.4 0.4 0.1 1.0 0.1 -3.9 0.2 -0.4 -0.3 -0.3 0.4 -4.0 0.3 -0.4 0.2 -0.4 0.3 
HPRT1 hypoxanthine phosphoribosyltransferase 1 (Lesch-
Nyhansyndrome) (HPRT1) 
House 
keeping 
NM_013556 -1.0 0.2 -0.2 -1.4 0.0 -0.2 1.0 -0.2 0.2 1.4 -0.4 0.5 0.1 0.4 0.0 1.3 0.6 0.2 
HRK harakiri, BCL2 interacting protein (only BH3 domain) Apoptosi  NM_007545 0.2 0.0 1.3 0.3 -0.8 -0.9 0.5 -0.8 0.0 0.6 1.4 -0.5 -1.0 0.3 0.4 0.1 1.0 
HSP90AB1 heat shock protein 90kDa alpha (cytosolic), class B 
member 1 (HSP90AB1) 
House 
keeping 
NM_008302 0.0 -0.2 -0.7 -2.3 -0.5 -0.7 -1.0 0.1 0.2 2.2 -0.1 0.5 -0.2 0.4 1.0 2.3 0.0 0.3 
ICAM-1 intercellular adhesion molecule 1 (CD54, ICAM1) Surface 
receptor 
NM_010493 0.4 0.4 0.1 -0.2 7.2 6.3 -4.1 -0.6 0.3 0.8 -0.4 0.2 -1.0 0.0 0.3 0.7 0.4 0.6 
IFNa interferon alpha 2, IFNA, INFA2 Cytokine NM_010503 0.4 -1.0  -1.8 0.3 -5.7 1.1 1.6 1.1 1.0 1.9  -0.6 
IFNa6 interferon, alpha 6 (IFNA6) Cytokine NM_206871 1.6 0.7 5.5 1.3 0.6 0.2 -0.1 2.7 -1.7 -0.1 -0.4  2.8 
IFNaR1 interferon (alpha and beta) receptor 1 (Ifnar1) Ifar, Ifrc, 
CD118 
Cytokine 
receptor 
NM_010508 -0.5 -0.1 1.0 -0.7 -1.8 5.2 1.3 0.0 1.1 0.6 2.6 -2.7  -0.4 
IFNb interferon, beta 1, fibroblast (IFNB1) Cytokine NM_010510 1.1 1.8  0.0 1.1 3.9 -0.5 -0.4 1.0 1.2 -3.2 2.1 -3.1 0.1 0.1 -0.2  
IFNg interferon, gamma (IFNG) Cytokine NM_008337 -8.2 -0.1  -0.4 -1.6 -0.2 ### 1.3 1.8 -3.6 2.5 ### -3.1 2.4 1.5 -1.1 
IFNgR1 interferon gamma receptor 1 (IFNGR1) Cytokine 
receptor 
NM_010511 0.8 -2.0 0.5 1.0 -1.1 -1.1 -2.3 0.4 0.1 -1.4 0.9 0.2 -0.3 0.3 -0.1 -0.9 0.4 0.9 
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IFNgR2 interferon gamma receptor 2 Cytokine 
receptor 
NM_008338 -1.8 -0.3 0.3 -1.2 0.6 -0.6 0.8 1.1 -0.4 1.9 -0.8 0.9 0.2 0.6 -0.5 1.4 -0.1 0.5 
IgSR Fc receptor-like S, scavenger receptor (Fcrls) IgSR  Msr2  
Fcrh2  FGP2  MMAN-g 
Macrophage 
related 
NM_030707 -1.1 0.4 -0.9 -1.7 -0.3 -0.2 0.8 -0.1 -0.6 1.7 -0.4 1.1 0.4 0.4 0.8 1.8 -0.5 0.4 
IKBb IKB-beta, nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, beta (Nfkbib) 
Signalling NM_010908 0.7 0.2 0.4 0.1 -0.3 -0.6 0.1 0.3 -0.4 0.6 1.1 -0.6 -0.1 0.3 -0.2 0.4 1.1 
IKK2b inhibitor of kappaB kinase beta (Ikbkb), IKK2, IKK-2, 
IKK[b], IKKbeta 
Signalling NM_010546   0.8 3.7 0.0 -2.7 -5.3 2.3 -3.2 
IL10 interleukin 10 (IL10) Cytokine NM_010548  0.8 1.1 -1.0 1.1 -0.3 0.8 -0.7 -0.6 -0.1 
IL10Ra interleukin 10 receptor, alpha, CD210A Cytokine 
receptor 
NM_008348 0.4 -0.1 0.5 1.8 2.5 1.0 -0.8 -1.4 -1.3 -0.6 2.6  -2.9 
IL10Rb interleukin 10 receptor, beta (IL10RB) Cytokine 
receptor 
NM_008349 0.9 -1.2 3.1 0.5 -4.2 1.1 -1.8 1.2 -1.9 0.2 2.6 -2.3 1.7  
IL12p35 interleukin 12A, p35,  Cytokine NM_008351 0.8 -2.0  1.5 3.0 2.9 1.6 -1.8   
IL12p40 interleukin 12B, p40) Cytokine NM_008352 -1.7  -4.3 -1.2 2.6 0.9 3.0 3.6 -0.1 
IL12Rb1 interleukin 12 receptor, beta 1 (IL12RB1) Cytokine 
receptor 
NM_008353  -1.6 1.0 -0.6 2.3 0.7 -0.7 0.6 2.8 0.1 0.3 -0.3 
IL12Rb2 interleukin 12 receptor, beta 2 (IL12RB2) Cytokine 
receptor 
NM_008354   -0.5 0.4 -0.2 0.4 -1.7 2.7 2.5 1.4 -0.3 -0.4 
IL13 interleukin 13 (IL13) Cytokine NM_008355 -0.6 -0.2 0.7 0.5 0.4 -1.2 0.7 -0.2 0.0 -0.5 -0.4 1.5 -0.4 0.0 0.2 -0.2 -0.7 1.2 
IL13Ra1 interleukin 13 receptor, alpha 1, CD213a1 Cytokine 
receptor 
NM_133990   -1.3 2.4 1.8 1.9  0.8 
IL13Ra2 interleukin 13 receptor, alpha 2 (IL13RA2), CD213a2 Cytokine 
receptor 
NM_008356 -0.9  -0.6 2.5 1.4 2.5 -1.1 0.1 6.0 -1.3 1.6 -1.1 
IL17A interleukin 17A (Il17a) Cytokine NM_010552 -0.8  1.4 -0.8 -3.5 -3.9  
IL17B interleukin 17B (Il17b) Cytokine NM_019508 0.3 -0.4 1.0 -1.0 3.4 2.4 2.9 2.7 1.2 1.0 -0.1 2.8 2.9 1.3 -1.9 -0.8 2.8 
IL17F interleukin 17F (Il17f) Cytokine NM_145856 -0.5 -2.1 0.7 2.7 0.0 1.7 -0.2 0.1 -0.2   
IL18 interleukin 18 (IL18) Cytokine NM_008360 0.1 0.7 -0.4 0.4 0.2 -1.2 0.7 0.0 0.3 -0.2 -1.3 0.9 0.7 0.3 0.8 0.0 -0.5 0.4 
IL18R1 interleukin 18 receptor 1 (Il18r1) Cytokine 
receptor 
NM_008365 -2.0 1.6 1.2 2.1 -0.9 -0.2 -3.6 1.2 -6.9  
IL1b interleukin 1, beta (IL1B) Cytokine NM_008361 0.5 2.6 -0.8 -2.6 -0.6 -1.5 0.1 -1.3 -0.8 2.6 -1.0 1.2 -0.6 -0.9 0.6 2.6 0.2 0.3 
IL1R interleukin 1 receptor, type I (IL1R1) Cytokine 
receptor 
NM_008362 0.1 0.2 -1.3 -1.3 -1.5 1.2 -0.3 0.7 -0.9 1.5 0.7  
IL1RA interleukin 1 receptor antagonist, IRAP, IL1F3, IL1RA Cytokine 
receptor 
NM_031167 0.0 0.5 -0.4 -1.9 -0.3 -0.8 1.5 0.4 0.3 1.4 0.0 0.3 -0.3 -0.3 1.0 1.6 -0.2 0.0 
IL21 interleukin 21 (IL21) Cytokine NM_021782 0.8 -1.5  -0.1 5.4 3.6 -1.4 0.6 -1.4 3.6 1.3 -2.1 -4.3   
IL23p19 interleukin 23, alpha subunit p19 (IL23A) Cytokine NM_031252 0.4  -3.3 0.5 -1.1 0.9 -1.5 -3.4 1.5 
IL23R interleukin 23 receptor (IL23R) Cytokine 
receptor 
NM_144548 -0.8  2.7 2.2 1.9 -0.2 1.8 0.6 1.8 0.1  
il27ra interleukin 27 receptor, alpha Cytokine 
receptor 
NM_016671 -2.2 -2.4 2.4 -4.1 -0.8   
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IL2Ra interleukin 2 receptor, alpha chain (Il2ra) Cytokine 
receptor 
NM_008367 -2.1 0.1 -0.2 -0.3 0.3 -0.5 1.2 1.1 0.4 1.1 -0.6 0.7 0.7 0.6 0.5 0.6 -0.1 0.4 
IL4 interleukin 4 (IL4) Cytokine NM_021283 0.4 -4.9 2.3 1.4 5.2 0.3 -3.5 1.9   
IL4Ra interleukin 4 receptor, CD124, IL4RA Cytokine 
receptor 
NM_0010087
00 
-1.3 1.5 1.9 2.3 -0.2 2.8 -2.0 2.6 -2.5 0.3 0.5 -2.0 0.3 -0.3 
IL6 interleukin 6 (interferon, beta 2) (IL6) Cytokine NM_031168 0.3  -1.4 2.8 0.2 -1.8 -2.5  -0.8 
IL8Ra CXCR1 Chemokine 
receptor 
NM_178241 0.3 0.1 0.0 -1.2 -0.2 -0.5 -0.6 -0.6 -0.9 1.2 -0.4 0.7 -1.2 0.4 0.3 1.6 -0.2 0.2 
IL8Rb CXCR2,CD128, CXCR2, IL8RA, CDw128, Cmkar2, 
Gpcr16, IL-8Rh, IL-8rb, mIL-8RH 
Chemokine 
receptor 
NM_009909 0.2 -0.6 0.8 1.3 -0.1 0.0 -2.3 0.1 -0.7 -1.6 0.6 0.4 -0.1 -2.1 -1.3 -1.4 0.4 0.0 
INHbA inhibin beta-A (Inhba) Signalling NM_008380 -0.2  0.7 -1.0 1.2 0.9 1.2 0.1 -0.7 -1.0 4.3 
integrinb7 integrin, beta 7 (ITGB7) Integrin NM_013566 1.0 -0.8 -0.4 -2.2 -1.4 0.7 0.0 -1.2 0.7 -0.2 0.6 0.6 -1.2 1.3 
intrgrinaE integrin, alpha E, CD103 Integrin NM_172944 -1.4 0.3 -1.0 -1.4 1.7 1.2 0.5 -1.0 0.6  -0.5 
IP10 CXCL10 Chemokine NM_021274 1.6 -1.8 -1.2 -1.7 0.1 0.7 0.6 1.9 0.4 0.1  1.2 
IRAK1 interleukin-1 receptor-associated kinase 1 (Irak1) Signalling NM_008363 -2.0  -3.2 4.9 1.8 1.3 -0.8 -3.3 -0.1   
IRAK4 interleukin-1 receptor-associated kinase 4 (Irak4) Signalling NM_029926 -2.3 -4.7 0.6 2.2 3.2 2.3 0.3 2.3 0.3  
IRAK-M interleukin-1 receptor-associated kinase 3 (Irak3) Signalling NM_028679 -0.4  1.4 0.1 4.0 0.5 -5.1 -0.1 1.0   
IRF3 interferon regulatory factor 3 (Irf3) Signalling NM_016849 0.5 -0.4 0.9 2.2 -2.2 -0.2 -2.0 0.8 2.2 -0.8 0.4 -2.1 0.7  
IRF7 interferon regulatory factor 7 (IRF7) Cytokine NM_016850  -4.4 -3.6 -4.4 4.5 5.3 2.5 1.3   
ITAC CXCL11 Chemokine NM_019494 -0.5 0.5 -1.8 0.4 0.4 0.4 1.0 -0.2 -0.4 -0.5 -0.6 0.9 0.5 3.1 -0.1  
Itchy itchy, E3 ubiquitin protein ligase (Itch) Signalling NM_008395 -1.5  1.8 2.4 1.4 -2.0 -1.8  -2.6 
ItgA5 integrin alpha 5 (fibronectin receptor alpha) (Itga5) Integrin NM_010577  -1.6 2.4 1.8 4.4 1.6 -1.8 -0.4 2.1 -0.9  -3.0 
ItgB5 integrin beta 5 (Itgb5) Integrin NM_010580 0.7 -3.7 0.0 3.1 4.8 3.1 0.2 2.2  0.1 
ItgB6 integrin beta 6 (Itgb6) Integrin NM_021359 -5.1 -1.2  -1.9 -0.7 4.7 4.3 1.0 0.8 2.8  -1.0 
JAK1 Janus kinase 1 (Jak1) Signalling NM_146145 1.7 0.0 1.5 -1.6 2.1 1.8 2.5 -1.0  0.2 
JAK2 Janus kinase 2 (Jak2) Signalling NM_008413 -0.8 -2.9 0.2 -0.1 4.1 1.6 -3.7 0.2 1.8 2.5 1.9 1.3 -4.7 
JAK3 Janus kinase 3 (Jak3) Signalling NM_010589 -1.1  1.7 0.2 0.0   
KCR Kupffer cell c-type lectin  receptor Lectin NM_016751 1.3  1.6 2.3 -1.0   
LAIR1 leukocyte-associated Ig-like receptor 1 (Lair1) Surface 
receptor 
NM_0011134
74 
0.7 0.1 -0.1 0.3 -0.5 -1.2 -0.9 -0.5 0.1 0.1 0.9 1.0 -1.1 -0.4 0.6 0.5 -0.1 0.8 
Lamp1 lysosomal-associated membrane protein 1 (Lamp1) Macrophage 
related 
NM_010684 -0.1 0.2 -0.7 -2.4 -0.1 -0.7 0.5 -0.4 -0.3 2.0 -0.8 0.8 0.4 0.3 0.8 2.1 -0.2 0.5 
LAMP-
2CD107b 
lysosomal-associated membrane protein 2, LAMP2, 
LAMPB, CD107b 
Macrophage 
related 
NM_0010179
59 
-1.0 0.3 -0.2 -2.3 -0.1 -0.8 0.6 0.5 -0.1 2.2 -0.9 0.6 0.4 0.7 0.2 1.9 -0.1 0.8 
Langerin CD207, Langerin Lectin NM_144943 0.0 -0.9 2.0 3.4 0.2 3.3 2.8 2.4 -3.2 0.8 -0.6 -1.6 0.0 -0.2 
LDHA lactate dehydrogenase A (LDHA) House 
keeping 
NM_010699 0.9 0.1 0.5 0.1 1.2 -0.9 -0.4 -0.6 -0.9 -0.1 -0.7 1.0 -0.3 0.1 -0.4 0.1 -0.1 1.1 
LeptinR leptin receptor (LEPR) Surface 
receptor 
NM_146146 -1.0 -0.2 -0.4 -3.2 -0.4 -0.5 1.1 -0.1 -0.4 3.0 -0.4 0.8 1.0 0.8 0.3 3.4 -0.6 0.5 
LIGHT TNF (ligand) superfamily, member 14, CD258, LIGHT Cytokine NM_019418 0.2 0.0 0.2 0.4 -1.7 -1.5 -0.2 0.3 0.5 -1.4 0.6 1.0 0.1 0.0 -0.2 -0.1 -0.6 0.5 
LTbR lymphotoxin beta receptor (TNFR superfamily, 
member 3) 
Cytokine 
receptor 
NM_010736 -0.6  1.8 2.4 0.2 2.5 0.4 -2.8 4.0 1.9   
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Ly49B killer cell lectin-like receptor subfamily A, member 2, 
KLRA2 
Surface 
receptor 
NM_008462 -0.3 -0.7 0.8 0.3 -0.7 -0.8 -0.4 0.3 -0.1 0.2 0.6 1.8 -0.3 0.4 -1.7 0.5 0.0 1.2 
Lymphotaxin CXCL1 Chemokine NM_008510 3.5 -1.2  0.8 0.7 3.3 3.0 -1.1 4.0 0.0  0.2 
LTA  lymphotoxin alpha (TNF superfamily, member 1) Cytokine NM_010735 -1.1 -0.4 -0.4 -0.1 -0.5 -0.5 0.9 -0.1 -0.1 1.1 -0.9 0.8 1.0 1.2 -0.4 1.5 -0.1 -0.2 
LTB lymphotoxin beta (TNF superfamily, member 3) Cytokine NM_008518 -1.4 -3.1 3.2 1.3 -0.3 2.0 0.4 2.2   
Lyn Yamaguchi sarcoma viral (v-yes-1) oncogene 
homolog  (Lyn) 
Signalling NM_0011110
96 
0.5 0.5 0.6 -2.2 -1.2 -6.3 1.5 -0.5 2.1 -0.3 0.6 -0.9 2.0 0.3 
M6P-R 
(CIMPR) 
mannose-6-phosphate receptor, cation dependent, 
insulin-like growth factor 2 receptor, MPRI, CD222,  
Macrophage 
related 
NM_010515 -1.0 -1.4 2.6 -0.4 0.3 0.6 1.7 -1.7 -0.3 0.6 1.1  0.0 
MARCO macrophage receptor with collagenous structure, MARCO, 
SCARA2 
Macrophage 
related 
NM_010766 0.4 1.3 0.7 0.1 -0.6 -0.9 -0.3 0.3 0.1 -0.4 0.0 0.2 -2.9 -0.1 -0.1 -0.3 0.0 0.4 
MCL C-type lectin domain family 4, member D Lectin NM_010819 0.0 -1.1 -0.5 -1.6 1.2 0.3 -1.1 0.4 -0.1 2.0 -0.3 0.2 -0.1 0.8 0.8 2.1 -0.1 0.0 
Mcl-1 myeloid cell leukemia sequence 1 (BCL2-related) Apoptosis NM_008562 0.1 0.2 -0.1 0.0 -0.4 -1.6 -0.4 -0.2 0.2 -0.3 -0.2 1.4 -0.2 0.2 0.0 -0.1 0.4 1.0 
MCP1 CCL2 Chemokine NM_011333 0.4 1.9 1.8 -3.1 -4.1 2.9 0.2 1.2 -2.9 0.3 -0.2  
MCP2 CCL8 Chemokine NM_021443 -0.4 0.4  -0.3 -0.7 0.2 -1.9 3.2   
MCP3 CCL7 Chemokine NM_013654 -0.9 0.8  0.8 0.0 0.7 2.8 -1.2 -3.2 4.7 -2.0 0.8 -0.2 -3.2 
MDC CCL22 Chemokine NM_009137 1.0 0.5 0.4 -0.2 -0.7 -1.6 -0.3 0.0 -0.2 -0.3 0.0 1.0 0.1 0.0 0.2 0.1 -1.8 
MEC CCL28 Chemokine NM_020279   0.6 0.1 -3.0 0.1 2.6  -0.6 
MerTK c-mer proto-oncogene tyrosine kinase (MERTK) Signalling NM_008587 -1.5   0.4 0.9 -1.2 4.5 -0.3 -1.7 1.5 4.5 -4.3 -0.5 1.3 
MGL1 macrophage galactose N-acetyl-galactosamine 
specific lectin 1 (Mgl1), Mgl, CD301a 
Lectin NM_010796 -0.2 0.1  5.0 1.5 -5.6 -1.2 0.6  -1.4 
MICL_CLL-1 C-type lectin domain family 12, member A Lectin NM_177686 0.2  2.2 -2.1 0.1 0.6 -1.5 3.0 2.0 2.2 0.5 2.2 3.0 2.4 
MIF macrophage migration inhibitory factor (Mif) Chemokine NM_010798 0.8 0.1 -0.1 0.7 0.2 -0.5 -0.8 -0.4 0.1 -0.4 0.9 0.9 -1.3 -0.5 0.4 -0.1 0.1 0.8 
MIG CXCL9 Chemokine NM_008599 -2.0 0.0  0.5 -1.6 -2.3 0.3 -2.3 0.7 0.5 -2.2 -0.5 1.4 
Mincle C-type lectin domain family 4, member E Lectin NM_019948 0.7 -0.8 0.6 0.1 -1.6 -3.2 1.5 0.1 -1.2 0.4 2.6 0.4 0.5 -0.9 0.2 2.4 
MIP1aS CCL3 Chemokine NM_011337 -1.0 -0.3 -0.9 -2.8 -0.6 -0.6 1.0 -0.2 -0.2 2.5 -0.2 0.6 1.0 0.8 0.7 3.0 -0.6 0.6 
MIP1b CCL4 Chemokine NM_013652 -2.0 -0.7 -0.3 -1.8 -1.3 -1.1 0.7 -0.6 1.8 -0.2 0.6 2.2 -0.3 0.8 1.8 -0.3 0.2 
MIP3a CCL20 Chemokine NM_016960 -0.1 -0.8 0.7 -0.1 -0.3 -0.7 -0.4 0.4 -0.4 0.7 0.2 1.9 -0.4 0.4 -1.7 1.0 -0.3 1.1 
MMP12 matrix metallopeptidase 12 , macrophage metalloelastase; 
macrophage elastase 
MMP/TIMP NM_008605 -0.2 -0.8  -0.5 0.4 -0.3 2.0 -1.4 0.0 1.0 -0.6 0.3 -0.3 0.1 
MMP13 matrix metallopeptidase 13 (Mmp-13), Clg, Mmp1 MMP/TIMP NM_008607 -0.2  1.9 -0.5 1.3 0.4 1.1 -0.3 0.7 0.7 0.5 
MMP14 matrix metallopeptidase 14 (Mmp14) MMP/TIMP NM_008608 -1.0  2.5 1.1 -1.8 0.4 0.2 -0.6 -1.8 
MMP9 matrix metallopeptidase 9 (gelatinase B, MMP9) MMP/TIMP NM_013599 -2.8  -3.7 2.7 -3.5 -0.9 -2.8  6.4 
MR1 MRC1 mannose receptor, C type 1, CD206, CLEC13D Lectin NM_008625 0.1 0.3 -1.2 -1.7 -0.9 -1.2 2.0 -0.9 0.2 -0.8 0.3 0.0 
Mr1 major histocompatibility complex classI-related (Mr1) APC NM_008209 -0.4 1.2 -3.1 -2.7 1.1 0.1 -0.4 1.8 -0.2 1.1 0.2 0.0 0.9 2.1 0.0 0.6 
MRC2 mannose receptor, C type 2 (Mrc2) Lectin NM_008626 0.7 0.1 -0.4 0.4 0.5 0.6 0.2 0.6 -0.6 -0.2 -2.8 -2.4 -0.3 0.8 1.0 0.3 -0.2 
MyD88 myeloid differentiation primary response gene (88) TLR related NM_010851 -0.1 0.1 0.0 -1.0 -1.0 -1.2 -0.2 -2.4 0.7 0.5 0.9 -1.0 0.0 0.5 0.9 0.2 0.1 
NAP2 CXCL7, LDGF, MDGF, TGB1, CTAP3, Scyb7, LA-PF4, Chemokine NM_023785 -0.9 -1.3 1.4 -0.6 -0.3 -0.3 0.1 1.2 -0.4 1.3 -0.1 0.5 0.6 1.5 -1.8 1.5 -0.3 -0.3 
NEU1 neuraminidase 1, sialidase 1; lysosomal sialidase Sialidase NM_010893 -2.2 0.9 0.0 -2.5 -4.3 2.3 0.9 -4.2 -2.7 -0.8 1.6 -3.4 0.4 -1.3 0.5 -0.5 
NEU2 neuraminidase 2, brain sialidase; cystolic sialidase Sialidase NM_015750 -0.3 -0.5 0.0 0.2 -1.0 -1.4 0.8 0.0 -0.5 -0.3 0.2 1.8 -0.5 0.6 -0.4 0.0 0.5 1.3 
NEU3 neuraminidase 3 (Neu3) membrane sialidase Sialidase NM_016720 -0.4 -2.4 3.3 0.5 0.0 2.4 0.9 -2.9 1.4 0.8   
NEU4 sialidase 4 (Neu4)  Sialidase NM_173772 -1.1 -1.8 -0.9 1.0 -1.7 4.6 1.1 -1.4 -4.2 -2.7 2.9 -0.2   
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NFAM-1 Nfat activating molecule with ITAM motif 1, CNAIP Surface 
receptor 
NM_028728 -0.9 -1.5 -0.6 -2.5 -0.1 0.0 0.5 0.6 -0.2 2.7 1.5 1.6 0.8 0.5 0.7 2.4 1.0 1.5 
NLRP3 NLR family, pyrin domain containing 3 (Nlrp3), Cias1 Apoptosis NM_145827  0.3 -1.1 1.6 -1.0   
NOD1 nucleotide-binding oligomerization domain 1 TLR related NM_172729 -3.7 -0.9 -1.7 0.0 0.3 0.0 3.2 2.3 3.1 0.7 0.2 0.3 1.0  -0.5 
NOD2 nucleotide-binding oligomerization domain 
containing 2(Nod2), Nlrc2, Card15 
TLR related NM_145857 -2.0 -0.6 0.0 -0.8 0.7 -0.2 1.0 1.5 -0.2 1.5 -0.8 0.6 0.4 0.9 -0.1 1.0 -0.1 -0.2 
NOGGIN noggin (Nog) BMPs NM_008711 -0.8 -1.9 -2.3 0.7 -0.5 2.9 1.5 1.6 -1.9 0.4 0.3 0.3 0.4 -0.3 
NONO non-POU domain containing, octamer-binding 
(NONO) 
House 
keeping 
NM_023144 0.9 0.4 0.3 1.6 1.8 0.9 -1.0 -0.3 0.3 -1.2 0.1 0.3 -0.7 -0.1 -0.3 -1.0 -0.4 0.6 
NOS2 nitric oxide synthase 2, inducible (Nos2) Macrophage 
related 
NM_010927 0.3 -0.7  2.6 2.2 -5.1 2.4 -3.2 0.2  5.3 
Nramp1 solute carrier family 11 (proton-coupled divalent metal ion 
transporter) member1 (Slc11a1),Bcg,Ity,Lsh 
Macrophage 
related 
NM_013612 -0.9 -0.7 -0.3 1.0 0.6 -0.3 1.7 0.4 -0.9 -1.0 -1.1 -0.6 0.0 1.3 -0.2 -0.1 0.0 
Nramp2 solute carrier family 11 (proton-coupled divalent metal ion 
transporter) member2(Slc11a2),DCT1,DMT1 
Macrophage 
related 
NM_008732 -0.7  -1.3 -1.9 -0.3 1.7 2.7 2.7  2.1 
P2Y12 purinergic receptor P2Y, G-protein coupled 12, 
P2RY12 
Surface 
receptor 
NM_027571 -4.3 -0.1 2.3 2.1 0.1 -0.6 0.8 -0.1 -0.8 -0.3 -0.1 6.9 -1.3 -0.9 -0.6 -0.4 -1.0 
P2Y13 purinergic receptor P2Y, G-protein coupled 13, 
P2RY13 GPCR1, GPR94, Gpr86, P2Y13, SP174 
Surface 
receptor 
NM_028808 -1.3 -0.8 -1.4 0.3 -1.0 -1.7 2.7 1.4 -0.2 0.3 0.1 0.5 0.0 -0.2  
P2Y14 P2ry14 Gpr105 P2Y14 GPR NM_133200 0.0 -0.3 0.4 0.5 -1.0 -0.7 -1.2 0.2 0.3 -0.3 0.4 0.5 -0.3 -0.2 -0.2 0.0 0.6 0.3 
p47phox neutrophil cytosolic factor 1 (Ncf1), NOXO2, Ncf-1, 
p47phox 
Macrophage 
related 
NM_010876 -0.9  0.0 -0.6 -0.2 1.4 6.4 2.2  4.3 
PCSK5 proprotein convertase subtilisin/kexin type 5, PC5 BMPs XM_129214  -0.4 -1.9 1.6 -0.9 1.9 1.3 -2.3 0.7 -0.7 -4.2 -1.2 0.2 
PCSK6 proprotein convertase subtilisin/kexin type 6, SPC4 BMPs XM_355911  0.8 0.1 -1.3 0.3 -0.2 -0.9 -0.8  1.9 
PCSK7 proprotein convertase subtilisin/kexin type 7, PC7 BMPs NM_008794 0.4 -5.8 1.8 -0.5 1.0 6.6 -3.1 -0.1 -4.2 1.6 6.7 -1.6 -1.7  
PF4 CXCL4, platelet factor 4 (Pf4) Chemokine NM_019932 -0.9 -1.7 -0.5 -2.4 0.1 -0.6 0.6 0.3 -0.2 2.6 1.4 2.0 0.8 0.3 0.4 2.3 1.1 1.9 
PGF placental growth factor (Pgf) Cytokine NM_008827 -0.7  2.0 2.8 -8.2   
PGK1 phosphoglycerate kinase 1 (PGK1) House 
keeping 
NM_008828 1.1 0.1 0.2 -0.4 -0.3 -1.1 0.0 -0.3 0.2 0.3 -0.1 0.6 -0.4 -0.5 0.1 0.4 0.5 0.7 
PILR-a paired immunoglobin-like type2 receptor alpha, 
PILRA 
Surface 
rec ptor 
NM_153510 0.4 -0.3 0.4 0.7 -0.7 -1.4 0.3 0.7 0.4 0.0 0.4 0.6 0.0 -0.1 0.3 0.0 0.4 0.5 
PIM1 proviral integration site 1 (Pim1) Signalling NM_008842 0.5 1.4  0.5 0.8 0.3 0.0 -1.7 0.1 -0.2 -1.8 0.6 -0.1 -0.7 1.0 
PIR-A1 paired-Ig-like receptor A1 (Pira1) Surface 
receptor 
NM_011087 -0.6  -1.9 -0.6 2.0 -0.9 -2.2 2.1 -2.2 -1.3 -1.3 -0.2 0.9 -0.4 
PIR-A2 paired-Ig-like receptor A2 (Pira2) Surface 
receptor 
NM_011089 -0.7 -0.4 0.2 0.5 -0.4 -0.3 0.8 0.2 -0.3 -0.1 0.4 1.0 0.7 0.7 -0.3 0.0 0.0 0.5 
PIR-B leukocyte immunoglobulin-like receptor, subfamily B, 
member 1, CD85, ILT2, LIR1, MIR7, CD85J, LIR-1 
Surface 
receptor 
NM_011095 1.3 -0.3  2.3 -1.0 -2.1 1.5 0.1 -1.4 0.1 1.5 2.7 0.6 -1.5 -0.1 0.8 
PIR-B paired immunoglobulin-like receptor B (PirB) Surface 
receptor 
AF148880 2.3 -0.8  1.1 0.1 2.7 2.2 0.9 -0.7 3.1 0.0 1.3 -1.4  -3.3 
PLAUR plasminogen activator, urokinase receptor (Plaur) Surface 
receptor 
NM_011113 0.3 -0.1 1.0 2.0 0.2 0.9 0.0 0.0 -1.8 0.0 -0.9 0.2 -0.5 -0.5 -2.1 -0.7 -1.1 
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PLD2 phospholipase D2, PLD2 Phospholipa
se 
NM_008876 -3.1  4.4 1.0 -5.5 0.3 -1.3   
PLD3 phospholipase D family, member 3, PLD3 Phospholipa
se 
NM_011116 -0.7 -0.2 0.0 0.1 0.3 -0.3 0.4 0.0 -0.7 -0.2 -1.2 0.6 -0.4 0.6 -0.5 0.2 0.8 0.6 
PLD4 phospholipase D family, member 4, PLD4 Phospholipa
se 
NM_178911 -2.0 -0.7 -1.4 0.0 -4.1 -2.0 0.5 2.9 2.3 -0.8 3.4 -0.2 2.1 0.7 
PPARa peroxisome proliferator-activated receptor alpha  PPAR NM_011144 -1.7 0.7 -0.4 0.0 -2.0 1.8 1.6 -0.3 1.4 0.8 -1.6 -0.1  1.2 
PPARb/d peroxisome proliferator-activated receptor delta  PPAR NM_011145 0.6 0.7 0.4 -0.2 -0.4 -0.1 0.0 -0.4 -1.0 0.5 -1.9 0.7  -0.4 
PPARg peroxisome proliferator-activated receptor gamma PPAR NM_0011273
30 
-0.7 2.3  2.0 0.4 2.4 4.3 0.7 -0.4 0.8 -1.5 3.6 0.3 -0.7   
PPIA peptidylprolyl isomerase A (cyclophilin A) (PPIA) House 
keeping 
NM_008907 0.1 -0.2 0.1 0.9 1.5 0.5 0.7 -0.6 -0.1 -0.6 -0.7 0.9 -0.2 0.2 -0.4 -0.7 0.0 0.6 
PTGES(2) prostaglandin E synthase 2 (Ptges2) Cytokine NM_133783 -0.7 -1.0 -0.3 -2.2 0.3 -0.1 0.6 1.0 0.3 2.7 -0.5 0.4 0.2 1.2 0.6 2.8 -0.7 -0.3 
PTX3 pentraxin related gene (Ptx3), TSG-14 Chemokine 
receptor 
NM_008987 -2.8  -1.2 -5.9 -0.1 4.2 1.5 4.0 1.1 1.4  0.4 
PU.1 proviral integration oncogene spi1  Signalling NM_011355 -1.5 -1.4 -1.4 -1.3 -0.8 0.7 0.8 -4.3 0.2 -0.1 0.5 -0.5 1.0 1.5 -0.1 0.3 
RANK TNF receptor superfamily member 11a (Tnfrsf11a)  Cytokine NM_009399 -2.0  0.6 -1.5 4.9 0.4 2.0 2.4 3.6  1.0 
RANKL ODF, OPG, OPGL, RANKL, Ly109l, Trance, tumor 
necrosis factor (ligand) superfamily, member 11 
Surface 
receptor 
NM_011613 -1.0 -0.2 -0.7 -0.5 -0.6 -0.4 0.8 0.2 0.0 1.6 -0.3 0.8 0.9 1.2 -0.2 1.9 0.1 -0.2 
RANTES CCL5 Chemokine NM_013653 -1.0 0.6  -0.1 -0.6 0.1 -0.3 0.8 -1.7 0.6  0.7 
RARa retinoic acid receptor, alpha (Rara) Signalling NM_009024 -2.3  2.0 1.8 1.0 2.7 0.5 -3.9 -0.8 -4.5 2.8 -3.7 -1.4 
RelA v-rel reticuloendotheliosis viral oncogene homolog A  Signalling NM_009045 -0.9 -0.2 0.3 -1.9 -2.5 1.1 -1.8 0.7 0.3 1.2 -1.6   
RelB reticuloendotheliosis viral (v-rel) oncogene related B Signalling NM_009046 -0.2 0.4 -0.4 -2.2 -0.8 -0.5 0.5 0.5 0.9 2.6 0.0 0.9 0.6 0.5 1.3 2.6 -0.4 0.5 
Resistin resistin (Retn) Macrophage 
related 
NM_022984 -1.5 -0.2  1.7 0.8 1.9 5.0 -3.0 -0.1   
RGMA Repulsive Guidance Molecule A BMPs NM_177740 0.4 0.4 -0.4 0.0 0.2 -0.3 0.0 0.0 -0.2 0.2 -0.2 -0.3 0.1 0.7 0.1 0.5 -0.1 -0.2 
RGMB Repulsive Guidance Molecule B, Dragon BMPs NM_178615 0.7 0.6 1.8 -0.7 1.6 -1.3 0.6 -2.7 0.8 1.0 -0.8  0.3 
RGMC (Hfe2) Repulsive Guidance Molecule C BMPs NM_027126 5.0 0.1  1.8 0.1 4.3 1.9 2.4 -3.4 0.1 3.0 0.7 2.6  -0.7 
RIG-I DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 (Ddx58) TLR related NM_172689 0.3 -2.2 1.7 1.1 -0.6 1.4 -1.0 2.0 2.5 1.4 1.0 -1.0 2.7 1.8 
RPL11 ribosomal protein L11 (RPL11) House 
keeping 
NM_025919 0.0 0.0 -0.2 -0.6 0.5 0.0 0.5 -0.6 -0.1 0.7 -0.1 0.8 -0.2 -0.2 0.1 0.6 0.1 0.6 
RPL13A ribosomal protein L13a (RPL13A) House 
keeping 
NM_009438 -0.6 0.0 -0.4 -0.5 0.7 -0.7 0.7 -0.4 -0.1 1.1 -0.9 0.6 0.4 0.2 0.8 1.0 -0.9 0.9 
RPL19 ribosomal protein L19 (RPL19) House 
keeping 
NM_009078 0.1 0.2 0.1 -0.6 1.1 -0.3 -0.3 -1.0 -0.7 0.8 -0.6 0.2 -0.2 -0.2 0.1 0.8 -0.8 0.7 
RPL32 ribosomal protein L32 (RPL32) House 
keeping 
NM_172086 0.2 -0.5 0.8 1.1 0.4 -0.1 0.1 -0.2 0.5 -1.2 0.3 0.3 -0.6 0.3 0.1 -0.7 -0.9 0.8 
RPS18 ribosomal protein S18 (RPS18) House 
keeping 
NM_011296 0.3 -0.4 0.3 1.4 0.1 -0.9 0.0 -0.8 0.1 -1.6 0.2 0.3 -0.1 -0.1 -0.2 -1.1 -0.6 0.8 
RPS27A ribosomal protein S27a (RPS27A) House 
keeping 
NM_024277 0.2 -0.5 0.4 0.5 0.6 0.1 0.1 -0.6 -0.1 -0.2 0.3 0.9 -0.5 0.2 -0.1 -0.4 -0.4 1.0 
RSK1 ribosomal protein S6 kinase polypeptide 1 (Rps6ka1) Signalling NM_009097 -3.7 -0.6 -4.6 2.5 2.6 -1.7 2.2 2.2 -8.7 -3.6 0.8 3.1  2.1 
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RSK2 ribosomal proteinS6k polypeptide3 (Rps6ka3 ) MPK-9 Signalling NM_148945  -3.5 -1.7 -3.2 -2.5 -3.1 -1.2 -0.1  1.0 
RSK3 Rps6ka2  Rsk3 p90rsk pp90rsk Signalling NM_011299 -0.7  0.6 3.6 1.8 2.5 -0.9 1.5 -3.0 -3.0 -1.1 1.3 -0.1   
Runx-1 Runx1, CBFA2 BMPs NM_0011110
21 
0.7 -0.3 0.2 -0.2 -1.1 -1.5 -1.0 0.0 0.6 0.4 -0.2 1.2 -0.5 0.2 0.5 0.7 -0.3 0.9 
RXRg retinoid X receptor gamma (Rxrg) Signalling NM_009107 -1.6 -0.3 -0.5 -2.2 -0.7 -0.7 1.3 0.8 -0.5 2.9 -0.2 0.7 0.8 0.9 0.6 3.1 -0.4 0.0 
SCARF2 scavenger receptor class F, member 2 (Scarf2) Macrophage 
related 
NM_153790 -0.6  1.1 0.3 2.4 1.9 -2.1 -0.2 -0.3 -0.3 
SDF1a/b CXCL12 Chemokine NM_021704 -0.3 -0.1  0.5 -1.8 -0.6 0.4 0.9 0.3 2.0 0.7 0.0 -0.5 0.7 0.0 1.0 
SDHA succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp) (SDHA) 
House 
keeping 
NM_023281 0.7 0.3 -0.5 -0.6 -1.8 -1.0 -0.1 0.4 0.4 1.4 0.5 -0.1 -0.6 0.8 0.5 1.4 0.3 
Siglec-1 sialic acid binding Ig-like lectin1, sialoadhesin CD169 Lectin NM_011426 -1.9 0.0 1.8 -0.6 3.2 0.3 1.4 -2.0 1.1 0.9 -3.0 0.1 
Siglec-5 sialic acid binding Ig-like lectin 5, siglec-F, mSiglec-F Lectin NM_145581 0.3  -3.1 1.3 -0.7 -0.4 -0.7   
siglec-e Cd170, Siglec5, Siglec9, Siglecl1, mSiglec-E Lectin NM_031181 0.3 0.0  1.2 1.1 1.3 -2.7 -1.0 1.7 -2.2   
Siglec-g sialic acid binding Ig-like lectinG, Siglec10,mSiglec-G Lectin NM_172900 -0.8  0.2 0.0 2.8 -0.4 -0.1 0.9 -0.6 -0.5 
Siglec-H sialic acid binding Ig-like lectin H (Siglech) Lectin NM_178706 0.4 -1.2  0.7 0.6 2.5 1.8 -0.3 -0.8 0.0 0.5 -0.7  -1.2 
SIGNR1 CD209b, SIGNR1, mSIGNR1 Macrophage 
related 
NM_026972 -3.1 -1.3 -4.5 1.4 -0.3 -4.0 2.3 -3.0 5.1 0.3  2.5 
SIRPa signal-regulatory protein alpha (SIRPA) Surface 
receptor 
NM_007547 0.6 -3.5 0.5 -0.6 2.7 0.5 0.5 1.2 3.3 -1.7 0.4 
SLC CCL21 Chemokine NM_011124 -0.4 -0.6 1.2 0.4 0.0 -2.5 0.7 0.2 -0.1 -0.3 2.4 -1.4 0.0 -0.5 0.0 -0.6 2.1 
SMAD1 MAD homolog 1 BMPs NM_008539 -0.2 -1.3 1.5 1.2 -3.3 0.9 -0.4 0.6 -0.6 0.4 -0.1 -0.5 -0.2  
SMAD4 MAD homolog 4 (Drosophila) (Smad4) Signalling NM_008540 -3.5 -2.1  3.2 2.4 1.6  2.5 
SMAD5 MAD homolog 5 BMPs NM_008541 -0.1 0.9 -3.4 0.2 -1.7 -2.3 0.7 0.0 1.8 -0.4 -0.5 -1.0 -0.7 3.3 0.3 0.5 0.2 
SMAD6 MAD homolog 6 (Drosophila) (Smad6) Signalling NM_008542 0.1 -0.1 -0.1 -0.1 -2.2 0.0 0.7 0.7 -0.4 1.7 0.1 1.0 -0.3   
SMAD7 MAD (mothers against decapentaplegic, Drosophila) 
homolog 7 
BMPs NM_0010426
60 
-1.4  2.2 5.0 -1.1 6.3 3.5   
SNX10 sorting nexin 10, SNX10 Other 
(nexin) 
NM_028035 1.6 -0.2 1.0 2.4 -1.1 -0.8 0.5 -0.3 -2.5 0.9 0.3 -1.0 -2.9 0.5 -2.5 0.6 0.5 
SOCS1 suppressor of cytokine signaling 1 (Socs1) Signalling NM_009896 0.6 0.7 0.1 -0.7 -1.0 -1.3 -0.4 -0.3 0.2 0.8 -0.3 1.2 -0.7 0.2 0.5 0.9 -0.3 0.8 
SOCS2 suppressor of cytokine signaling 2 (Socs2) Signalling NM_007706 0.3 0.9 4.3 1.7 -0.1 -1.7 -3.1 0.6 0.0 -1.2 -1.7 0.5 -0.9 0.3 -0.8 -1.8  
SOCS3 suppressor of cytokine signaling 3 (Socs3) Signalling NM_007707 -0.8 0.6 -1.0 -2.2 -0.4 -0.6 0.7 0.2 -0.2 2.6 -1.0 0.9 0.4 0.5 1.3 2.8 -0.9 0.5 
SOD2 superoxide dismutase 2, mitochondrial (Sod2) Macrophage 
related 
NM_013671 0.3 0.0 0.1 -0.7 -1.4 -1.7 0.2 -0.4 0.2 0.2 0.9 1.6 -0.4 -0.1 0.7 0.5 0.5 1.3 
SOSTDC1 sclerostin domain containing1,Ectodin,USAG-1,DCR5 BMPs NM_025312 -0.8 -0.6 -1.9 1.6 1.0 1.6 -0.1 3.1 -1.4 0.4 -0.6 0.1 -4.1 0.3 
Sox-4 SRY-box containing gene 4 (Sox4) BMPs NM_009238 1.5 -0.9 2.6 0.7 1.3 -4.2 -0.2 0.6 -1.4  0.6 
SP1 trans-acting transcription factor 1 (Sp1) Signalling NM_013672 0.4 -2.0 -0.4 0.2 0.7 0.7 0.4 -1.3 -1.7 -0.3 1.2 2.5   
SR1 macrophage scavenger receptor 1, SR-A,CD204, phSR1, 
phSR2, SCARA1 
Macrophage 
related 
NM_031195 -1.1 -0.6  -0.3 -0.3 -0.4 0.9 0.9 0.7 0.3 0.2 -0.6 0.5 0.1 0.2 
ST3Gal1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1   
(St3gal1) 
Sialyltransfe
rase 
NM_009177 0.2 -0.4 0.3 -1.7 0.4 -0.6 -0.1 0.1 -0.6 2.3 -0.7 1.2 -0.1 0.3 0.3 2.0 -0.5 0.8 
ST3Gal2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2  
(St3gal2) 
Sialyltransfe
rase 
NM_009179 -0.5 -5.6  -4.4 5.5 6.5 0.9  2.6 
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ST3Gal3 ST3 beta-galactoside alpha-2,3-sialyltransferase 3 (St3gal3) Sialyltransfe
rase 
NM_009176  -0.4 -0.9 -1.1 -1.2 -2.8  0.5 
ST3Gal4 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 (St3gal4) Sialyltransfe
rase 
NM_009178 -2.6 -1.5  1.8 -2.5 -1.3 1.1 1.4 0.6 -0.5 1.5 0.4 -0.5 1.1 0.7 -0.5 2.3 0.2 
ST3Gal5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5  
(St3gal5) 
Sialyltransfe
rase 
NM_0010352
28 
-0.9 -0.7 1.0 -0.1 -1.5 -0.4 1.3 -0.4 0.3 1.1 -1.9 -0.5 -2.0 -0.2 0.2 0.4 -0.3 
ST6Gal1 beta galactoside alpha 2,6 sialyltransferase 1 (St6gal1) Sialyltransfe
rase 
NM_145933 0.9  -2.5 2.3 -2.3 0.8 -2.8 -6.4 2.2 
ST6Gal2 beta galactoside alpha 2,6 sialyltransferase 2  (St6gal2) Sialyltransfe
rase 
NM_172829 -0.2 -0.7 0.4 0.8 -0.7 -0.9 0.6 -1.8 -1.0 0.2 1.1 1.5 -0.3 0.1 0.7 -0.2 1.1 
ST6Galnac1 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,   3)-
N-acetylgalactosaminide alpha-2,6-sialyltransferase1 
(St6galnac1) 
Sialyltransfe
rase 
NM_011371 -1.4   -1.8 2.8 4.1 3.6   
ST6Galnac2 ST6(alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1, 3)-
N-acetylgalactosaminide alpha-2,6-sialyltransferase 
2(St6galnac2) 
Sialyltransfe
rase 
NM_009180 2.5 0.2 -0.6 0.0 -0.2 -0.5 0.4 -2.6 0.5 -1.9 2.2 -0.3 
ST6Galnac3 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1, 3)-
N-acetylgalactosaminide-2,6-sialyltransferase3 
Sialyltransfe
rase 
NM_011372 2.6 -3.1 -1.7 0.4 0.9 -1.6 -0.1 -2.5   
ST6Galnac4 ST6(alphaNacetyl-neuraminyl2,3betagalactosyl1)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 4  
Sialyltransfe
rase 
NM_011373 -2.7  1.7 -1.0 1.7   
ST6Galnac5 ST6(alpha-Nacetyl-neuraminy2,3-beta-galactosyl-1,3)-
Nacetylgalactosaminidealph-2,6sialyltransferase5 
Sialyltransfe
rase 
NM_012028 -3.5 1.2 -1.4 -0.3 -1.7 1.5 0.5 -1.8 -2.9 0.9 -2.2 -2.2 1.1 
ST6Galnac6 ST6(alpha-N-acetyl-neuraminyl2,3beta-galactosyl1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase6 
Sialyltransfe
rase 
NM_0010253
11 
-0.7 -0.4  -2.2 -2.4 0.8 0.7 1.6 0.5 -0.5 -0.1 2.9 
ST8Sia1 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 1 (St8sia1) 
Sialyltransfe
rase 
NM_011374 0.4  -4.5 -1.3 2.5 -0.9 3.3 2.4 -3.2 0.9 1.9 1.8 2.6 -3.0 0.5 
ST8Sia2 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 2 (St8sia2) 
Sialyltransfe
rase 
NM_009181 1.4  0.0 -1.2 1.0 0.3 0.6 0.6  0.9 
ST8Sia3 ST8 alpha-N-acetyl-neuraminidealpha-2,8-sialyltransferase 
3 (St8sia3) 
Sialyltransfe
rase 
NM_009182 -0.8 -0.4 -0.7 -0.3 -1.0 -1.0 0.7 0.2 0.0 1.4 -0.6 1.5 0.8 1.2 -0.1 1.7 -0.2 0.6 
ST8Sia4 ST8 alpha-N-acetyl-neuraminide  alpha-2,8-
sialyltransferase 4 (St8sia4) 
Sialyltransfe
rase 
NM_009183 0.3  2.2 1.4 -4.7 -0.7 2.0   
ST8Sia5 ST8 alpha-N-acetyl-neuraminide  alpha-2,8-
sialyltransferase 5 (St8sia5) 
Sialyltransfe
rase 
NM_153124 -0.5  0.4 1.2 1.2 2.1 -1.5  
ST8Sia6 ST8 alpha-N-acetyl-neuraminide  alpha-2,8-
sialyltransferase 6 (St8sia6) 
Sialyltransfe
rase 
NM_145838  -2.8 4.4 2.8 2.8 2.2 -3.5 -0.4 1.6 0.2 1.4  -0.5 
STAT1 signal transducer and activator of transcription 1   Signalling NM_009283   1.1 0.0 2.7 -4.6 5.4   
STAT2 signal transducer and activator of transcription 2  Signalling NM_019963 -0.2  -2.0 2.0 -0.9 3.8 4.7 -1.1 -2.9 0.7 
STAT3 signal transducer and activator of transcription 3  Signalling NM_213659 -1.4 0.6 0 1.3 0.2 -6.6 -0.9 2.0 6.3 3.1 -0.6 5.3 3.5 7.4 2.5  6.8 
STAT4 signal transducer and activator of transcription 4 Signalling NM_011487 -1.7 -4.7 -5.0 4.2 6.2 -1.9 -4.0 0.2   
STAT5A signal transducer and activator of transcription 5a  Signalling NM_011488 0.4 -1.6  0.4 1.2 -0.6 -0.3 2.9 0.4 -1.7 2.2 -0.4 -0.3 0.8 -2.5 3.5 
STAT5B signal transducer and activator of transcription 5b Signalling NM_011489 0.5  1.6 -0.2 -2.1 0.6 0.7 -2.2 0.5 6.7 -0.4 0.6 -5.7 -0.1 
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STAT5B(2) signal transducer and activator of transcription 5B2  Signalling NM_0011135
63 
0.2 -0.6 2.9 0.7 0.4 -0.1 -1.2 -2.5 -0.1 
STAT6 signal transducer and activator of transcription 6  Signalling NM_009284 -0.2 0.2  1.2 1.1 1.4 0.0 -1.4 -0.2 1.2   
Syk spleen tyrosine kinase (Syk) Signalling NM_011518 -2.7 0.6 -1.3 0.5 0.3 -0.7 2.2 -2.5 -1.7 -1.3 0.0 3.4 0.4 -4.3 -0.2 
TARC CCL17 Chemokine NM_011332 -1.8 -0.6 -0.5 7.8 2.8 3.3 -0.9 3.9 -1.0 2.2 2.3 0.2  
TBP1 TATA box binding protein 1 (TBP1) House 
keeping 
NM_011603 -1.1 1.0  1.3 -3.7 -1.9 -2.8 -1.6  -0.2 
TECK CCL25 Chemokine NM_009138 -1.9  -1.7 -2.2 -0.5 3.3 -0.4 1.2 2.5   
TFRC transferrin receptor (p90, CD71) (TFRC) House 
keeping 
NM_011638 2.4 -0.8 -1.6 0.1 1.9 -1.7 3.2 2.3 0.8 1.1 -2.8 -0.4 1.0 0.7 -4.4 -2.8 1.1 
TGFb1 transforming growth factor, beta 1 (TGFB1) Cytokine NM_011577 -0.2 -0.3 2.9 1.4 -7.0 -5.0 1.0 -5.2 -1.1 3.1 -0.4 0.4 -1.0 0.3 -0.8 2.6  
TGFb2 transforming growth factor, beta 2 (TGFB2) Cytokine NM_009367 0.4 0.9 -1.5 0.6 1.3 0.8 0.2 0.6 0.3 -0.9 -0.9 1.3 0.0 -0.9 0.9 -0.4 1.2 0.3 
TGFb3 transforming growth factor, beta 3 (TGFB3) Cytokine NM_009368 -1.5 0.7 0.6 1.7 0.4 0.0 1.0 1.0 -0.1 -0.2 -0.3 1.0 -0.1 0.7 -0.1 0.3 0.4 0.4 
TGFbR1 transforming growth factor, beta receptor I (TGFBR1) Cytokine 
receptor 
NM_009370 0.3 -1.9 -0.5 3.0 2.0 3.3 0.3 -2.6 3.3 1.6 1.1 -4.1 2.0 -2.9 
TGFbR2 transforming growth factor, beta receptor II 
(TGFBR2) 
Cytokine 
receptor 
NM_009371 -0.8 0.6 0.5 -0.3 -0.6 -1.1 0.1 0.8 -0.7 -0.7 0.2 0.3 -0.4 0.1 -0.1 0.2 0.6 
TGFbR3 transforming growth factor, beta receptor III 
(TGFBR3) 
Cytokine 
receptor 
NM_011578  0.9 0.0 0.3 -0.6 0.2 1.7 0.0 0.4 2.7 2.2 0.1 
TICAM2 toll-like receptor adaptor molecule 2 (Ticam2) TRAM TLR related NM_173394  -3.3 1.2 3.1 0.5 -0.5 3.3 -1.6  
TIMP1 tissue inhibitor of metalloproteinase 1 (Timp1) MMP/TIMP NM_0010443
84 
1.0 0.4 0.3 0.3 -3.0 -0.6 -0.9 -0.3 -0.3 -0.6 2.6 0.7 0.4 -1.3 0.6 -0.9 0.7 1.4 
TIMP2 tissue inhibitor of metalloproteinase 2 (Timp2) MMP/TIMP NM_011594 0.2 -0.7 1.3 -1.7 0.4 0.4 -0.9 0.7 0.2 2.5 1.9 0.7 0.0 0.4 -1.3 2.4 -0.1 0.5 
TIMP3 tissue inhibitor of metalloproteinase 3 (Timp3) MMP/TIMP NM_011595 -0.2 1.1 0.8 2.9 2.6 1.8 -1.2 0.6 0.1 -1.0 0.1 2.4 1.3 -1.3 
TIMP4 tissue inhibitor of metalloproteinase 4 (Timp4) MMP/TIMP NM_080639 5.2 -1.9  -1.0 -2.6 3.8 -0.1 0.6 -0.9 -1.0 1.0   
TIRAP toll-interleukin 1 receptor (TIR) domain-containing  
adaptor protein (Tirap), Mal, wyatt, Tlr4ap 
TLR related NM_054096 -1.8 -1.2  4.8 -3.1 -1.0 1.5 0.7 -1.0 2.5 0.0 -0.2 -0.5 1.6 -0.8 0.7 1.6 
TLR1 TLR1 TLR related NM_030682 -1.0 -0.3 0.2 -2.0 1.2 0.9 0.6 0.8 -0.2 2.6 -0.8 0.5 0.4 1.0 -1.2 2.4 -0.4 0.1 
TLR11 tlr11 TLR related NM_205819 1.0 -0.7 0.9 4.9 3.0 1.1 0.0 -4.4 -0.4 2.8 1.1  -3.5 
TLR12 tlr12 TLR related NM_205823 -0.3 -0.6 2.2 1.8 -1.2 0.9 0.2 0.3 0.9 0.3 -0.9 0.8 -1.1  0.2 
TLR13 tlr13 TLR related NM_205820 -0.6 -0.7 1.5 5.3 -0.2 -1.1 1.0 -0.2 -1.1 -1.0 0.3 -3.1 -3.2 -0.5 -1.3 -0.9 -0.7 
TLR2 toll-like receptor 2 TLR related NM_011905 -1.2 -2.5 -0.7 3.2 0.9 3.0 -1.0 1.2 0.7  -2.6 
TLR3 TLR3 TLR related NM_126166 -0.3 0.4  3.3 -3.7 -1.6 1.3 1.2 -1.1 3.3 1.0 -0.3 2.0 -2.6 3.2 -0.5 
TLR4 Toll-like receptor 4 TLR related NM_021297 -0.2 -1.8 0.2 -0.3 0.1 -0.8 1.1 0.0 0.9 -0.2 0.3 1.1 -0.1 0.0 1.1 -0.2 0.1 
TLR5 TLR5 TLR related NM_016928 0.3 -2.1 0.6 0.5 -0.4 -1.0 1.1 0.1 -0.8 -0.2 0.3 0.4 0.0 -0.9 -0.3 -0.5 0.6 
TLR6 TLR6 TLR related NM_011604 -0.5 -1.5 -0.8 1.3 -4.5 -4.4 -0.8 1.5 1.0 0.5 0.9 0.7 0.5 0.0 1.3 0.4 0.8 0.3 
TLR7 toll-like receptor 7 TLR related NM_133211 -0.6 0.9 1.0 1.7 2.8 2.1 -1.7 -2.4 0.2  -3.7 
TLR8 TLR8 TLR related NM_133212 0.1 -2.2 0.3 0.2 -1.2 -0.4 -1.4 0.5 0.4 -0.3 0.7 0.1 -0.3 0.1 -0.3 -0.2 1.1 0.0 
TLR9 TLR9 TLR related NM_031178 0.4 0.1 -0.4 -1.0 0.0 -0.7 -0.1 -0.3 -0.2 0.7 -1.7 0.8 -0.5 0.6 -0.4 1.3 -1.8 0.5 
TNF tumor necrosis factor (TNF superfamily, member 2) Cytokine NM_013693 0.2 0.0 -0.8 -1.6 -1.9 -0.6 -1.6 -0.2 -0.3 1.1 0.2 1.1 -0.3 0.2 0.7 1.1 0.3 0.7 
TNFR1 tumor necrosis factor receptor superfamily, member 
1A, TNFR1 
Cytokine 
receptor 
NM_011609 0.1 0.8 -0.6 -0.4 0.1 -0.3 0.4 -0.2 -0.1 0.5 -0.4 1.1 0.0 0.2 1.1 0.9 -0.7 0.5 
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TNFR2p75 tumor necrosis factor receptor superfamily, member 
1b, p75,TNFR2, CD120b 
Cytokine 
receptor 
NM_011610 -0.1 -0.1 -0.4 -1.1 0.5 -0.1 0.5 0.1 0.3 0.7 -0.1 0.5 0.6 0.4 0.7 1.6 -0.9 0.3 
TNFRSF14 TNF receptor superfamily, member 14 (herpesvirus entry 
mediator), HVEM, ATAR, TR2, LIGHTR, HVEA 
Cytokine 
receptor 
NM_178931 0.1  -0.2 1.3 1.6 1.3 -0.6 1.8 0.0  
tnfsf10 tumor necrosis factor superfamily, member 10, TL2, 
APO2L, CD253, TRAIL 
Surface 
receptor 
NM_009425 -3.4 -1.1 -0.1 0.2 4.3 3.6 0.3 -1.2 3.4 -0.4 -2.8 -0.1  
TOLLIP toll interacting protein (Tollip) TLR related NM_023764 -2.7 -0.3  4.7 5.0 2.6 -3.5 -2.1 4.2 -0.5 3.4 0.2 0.4 -2.2 5.3 0.2 
TRADD TNFRSF1A-associated via death domain (Tradd) Apoptosis NM_0010331
61 
-0.2  3.4 -3.3 1.3 2.2 -3.3 1.2 -0.7 -2.1  0.4 
TRIF TLR adaptor molecule1,PRVTIRB,TICAM-1 TLR related NM_174989 -0.2 0.4 0.7 -0.3 5.3 3.4 1.4 0.1 -0.6 0.3 4.5 0.6 0.8 -0.9 -0.7 -0.8 
TRIM14 tripartite motif-containing 14 (Trim14) TRIM Family NM_029077 -3.4 1.0  3.4 -2.4 2.3 5.0 -0.8 3.1 5.3 0.8 1.4 1.4 -3.2 
TRIM20 Mediterranean fever (Mefv) pyrin  TRIM20 TRIM Family NM_019453 -1.7 2.2 0.8 4.9 0.0 -0.1 -1.1 1.6 0.0 -1.5   
TRIM21 tripartite motif-containing 21 (Trim21) TRIM Family NM_009277 2.3  0.9 0.5 -0.5 0.8 -0.6 0.4 -0.9 0.2 -0.4 -0.8 -0.4 
TRIM25 tripartite motif-containing 25 (Trim25) TRIM Family NM_009546 -0.6 0.1 -0.8 -1.5 0.6 0.0 1.2 -0.3 -1.0 1.0 -0.7 0.5 -0.1 0.1 0.8 1.1 -0.2 0.2 
TRIM27 tripartite motif-containing 27 (Trim27) TRIM Family NM_009054 0.1 -0.5 0.0 1.5 0.4 -0.5 0.6 0.0 0.2 -1.4 -0.7 0.3 -0.5 0.5 -0.2 -1.5 0.1 0.1 
TRIM3 tripartite motif-containing 3 (Trim3) TRIM Family NM_018880 -2.0 -0.3  0.1 0.4 0.7 0.7 1.4 -0.1 0.6 0.2 1.6 0.0 0.0 0.1 0.6 
TRIM30 tripartite motif-containing 30 (Trim30) TRIM Family NM_009099 0.1 -0.2 -0.1 -1.3 1.0 -0.1 -1.2 0.5 -1.0 1.6 -0.3 0.2 0.4 0.9 0.7 1.4 -0.2 0.0 
TRIM34 tripartite motif-containing 34 (Trim34) TRIM Family NM_030684 0.1 -0.4  2.0 -1.2 0.4 1.6 1.9 -1.0 -0.4 0.7  
TRIM35 tripartite motif-containing 35 (Trim35) TRIM Family NM_029979 0.3 0.2 -0.4 -1.1 -0.7 -1.1 0.2 -0.6 -0.1 0.6 0.6 1.3 -0.5 -0.2 0.9 1.0 0.1 1.1 
TRIM6 tripartite motif-containing 6 (Trim6) TRIM Family NM_0010136
16 
-0.6 0.0 -0.9 -0.6 0.0 -1.2 0.0 -0.9 0.6 -1.7 0.7 -2.1 0.0 1.0 0.6 0.0 0.1 
TRIM8 tripartite motif protein 8 (Trim8) TRIM Family NM_053100 2.4 -0.7  2.6 1.3 -3.3 -0.4 3.0 2.5  
TUBB3 tubulin, beta 3 (TUBB3) House 
keeping 
NM_023279 0.1 -0.2 0.1 1.4 2.0 0.7 -1.3 -0.1 0.8 -1.5 0.1 0.8 -0.4 -0.4 -0.1 -0.8 0.1 0.3 
TUBB4 tubulin, beta 4 (TUBB4) House 
keeping 
NM_009451   -1.8 -2.5 0.7 4.8 0.2  
TWSG1 Twisted Gastrulation, tsg BMPs NM_023053 0.8 -0.3 -0.1 -0.8 0.0 -0.4 -0.3 -0.6 0.1 0.7 -0.4 1.1 -0.2 0.2 0.4 0.8 -0.6 0.6 
TYK2 tyrosine kinase 2 (Tyk2) Signalling NM_018793 -1.1 0.3 -1.6 1.7 1.8 0.3 -1.5 2.0 -1.3 -2.2 4.1 0.2 0.0 -2.7  0.8 
UBC ubiquitin C (UBC)s House 
keeping 
XM_0014716
99 
0.6 0.1 -0.3 -0.5 -1.2 -1.0 0.0 -0.4 -0.3 0.3 -0.6 1.1 -0.6 0.6 -0.5 0.8 -0.7 0.7 
VDR vitamin D receptor, VDR Surface 
receptor 
NM_009504 0.4 -0.1 0.7 1.9 1.2 1.0 -5.2 1.4 -1.2 -1.4 -0.9 0.6 0.4 -0.5 -1.5 -0.2 -0.1 
VEGFa vascular endothelial growth factor A (Vegfa) Cytokine NM_0010252
50 
-5.3  0.2 0.6 -0.6 8.2 2.4 -0.8 0.6 2.4  -0.2 
VEGFb vascular endothelial growth factor B (Vegfb) Cytokine NM_011697 0.4 1.4  -2.9 -3.2 2.1 0.6 0.5 0.4 0.1 1.2 -4.9 -0.1 1.3 -0.3 
VEGFc vascular endothelial growth factor C (Vegfc) Cytokine NM_009506 -0.1 0.0 0.2 0.7 -0.2 -0.1 0.4 0.3 -0.2 0.5 1.4 -0.1 -0.2 -0.4 0.4 1.2 
Wnt5a wingless-related MMTV integration site 5A (Wnt5a) Signalling NM_009524 -1.3  -3.1 -1.6 1.7 -7.1 -4.1 1.3 4.1 -1.6 -2.2 -1.6 0.5 
Wnt7b wingless-type MMTV integration site, member 7B Signalling NM_009528 0.3 -0.5 0.7 1.3 -1.6 -0.4 1.3 0.3 0.0 1.3 -0.7 2.0 -0.1 0.4 1.7 -1.7 
YM1 chitinase 3-like 3 (Chi3l3) Ym1  ECF-L  eosinophil 
chemotactic factor-L 
Macrophage 
related 
NM_009892 -1.0 0.0 -1.2 -1.3 0.0 -1.3 1.0 0.0 -0.7 1.3 -1.6 0.8 0.0 0.0 1.3 1.3 0.0 0.2 
 
